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Abstract
AAA+ ATPase enzymes couple ATP hydrolysis to the exertion of conformational change
on a substrate. TorsinA is one of the few AAA+ ATPases that resides within the lumen of
the mammalian endoplasmic reticulum (ER). A glutamic acid deletion (ΔE) in the
catalytic domain of torsinA causes DYT1 dystonia, but torsinA’s function and the basis
for disease remain unclear. I show that torsinA is dynamically targeted from the bulk ER
to nuclear envelope (NE) upon coexpression with a cofactor protein, LULL1, and that
torsinA’s movement into the NE is concomitant with displacement of select linker of the
nucleoskeleton and cytoskeleton (LINC) complex proteins. These effects suggest a role
for torsinA in modulating nuclear positioning via the LINC proteins. ΔE-torsinA also
responds to LULL1, but only weakly displaces LINC proteins. These findings identify a
possible mechanism for regulating torsinA localization and activity via LULL1, and
suggest that activity at the NE is perturbed by the disease-causative ΔE mutation. An Nterminal hydrophobic domain (NTD) in torsinA is required for NE targeting. Surprisingly,
deletion of this domain also abolishes retention of torsinA within the ER. I demonstrate
that the NTD mediates stable monotopic association with the lumenal leaflet of the ER,
which in turn controls ER retention. Membrane domains from certain other ER resident
proteins are thought to control targeting by selective partitioning within the membrane. I
propose that this lipid-based sorting mechanism extends to monotopic membrane
proteins, and identify a group of proteins that may share torsinA’s topology and ER
retention mechanism. Returning to the interaction between torsinA and LULL1, I identify
distinct regions of LULL1 that are responsible for torsinA binding and re-targeting to the
NE. A conserved helix at the extreme C terminus of LULL1 mediates its interaction with
torsinA, while the extreme N terminus of LULL1 must be present in order for torsinA to
be targeted to the NE. Importantly, the N terminus of LULL1 is cytosolic, while the C-
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terminal torsinA-binding domain is lumenal, raising the intriguing possibility that control
of torsinA localization involves communication between the cytosol and the ER lumen.
The work in this thesis provides new insight to torsinA’s cellular function and dysfunction
in disease and defines novel mechanisms of controlling localization of membrane
proteins.
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Chapter 1

Introduction
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1.1 TorsinA is the causative gene in DYT1 dystonia
TorsinA was identified as the protein product of the human DYT1 locus, which is
located on chromosome 9q34 and is linked to early onset (DYT1) torsion dystonia [1].
Dystonia is a dominantly inherited, rare movement disorder that manifests as
uncontrollable twisting movements of the torso, neck, and limbs [2, 3]. Approximately
30% of carriers develop symptoms in adolescence. Understanding of the disease’s
etiology has been limited by the fact that no defined neural pathology or degeneration
correlates with disease symptoms. Both the absence of pathology and the
developmental timing of onset have led to the proposal that the disease arises from
abnormal development of neural circuits rather than the death of neurons. In carriers of
the DYT1 mutation, brain imaging analyses find regions of increased metabolic activity
[4] and evidence for abnormal neurotransmission in the basal ganglia [5] and cerebellum
[6]. Recent functional MRI studies have identified specific differences amongst the brain
activity patterns of carriers that correlate with clinical disease penetrance [7, 8]. It has
been proposed that the sporadic appearance of secondary, presumably compensatory,
alterations in brain circuitry underlies the low penetrance of dystonia [6, 7].

1.2 TorsinA is a member of the torsin subfamily of AAA+ ATPases
TorsinA is a member of the AAA+ ATPase superfamily of enzymes [1]. Deletion
of a glutamic acid codon (ΔGAG) at position 302 or 303 within torsinA’s AAA domain is
the most common mutation found in early onset torsion dystonia. TorsinA is an essential
gene in mice, and the ΔGAG mutant cannot compensate for torsinA ablation, suggesting
that the disease-causative mutation lacks the enzyme’s normal function [9]. TorsinA is
expressed in most tissues, with particularly high expression in certain tissues and
developmental timepoints [10, 11]. However, the disease that results from mutation to
the enzyme is neurological, and over-expression of torsinA in mice can also cause
2

neuronal abnormalities [12, 13], suggesting a particular sensitivity of neurons to changes
in torsinA function.
TorsinA is one of four AAA+ ATPases that are targeted to the mammalian
secretory pathway, which comprise the torsin subfamily [1, 14]; the other family
members are torsinB and the torsin-related proteins torp2A and torp3A. The torsinB
gene is adjacent to torsinA on human chromosome 9q34, and is much more closely
related to torsinA than are torp2A and torp3A. TorsinB is the only other family member
that shares the pair of glutamic acids in the AAA domain that are mutated in dystonia [1],
but no mutations in torsinB were found to be linked to dystonia [14]. Importantly, torsinB
is highly expressed in most tissues of the body, but expression is relatively low in
neurons [10] and during neural development [15]. Recent work suggests that torsinB
protein may compensate for torsinA’s function in non-neuronal tissues [13, 16].
Since it was first identified as linked to dystonia, torsinA homologs have been
identified in metazoans including mouse, rat, nematode, fruit fly, and zebrafish [14]. No
torsin homologues were found in lower eukaryotes. Deletion of torsinA is lethal in mice
[9]. Mutation to the C. elegans torsinA homolog OOC-5 causes a nuclear rotation defect
early in embryonic development [17, 18]. Targeted down-regulation of the D.
melanogaster homologue of torsina, torp4A, causes retinal degeneration [19].

1.3 The AAA+ superfamily of nucleotide hydrolases
AAA+ ATPase enzymes couple ATP hydrolysis to the exertion of conformational
changes on substrates. This large enzyme family has members in all domains of life.
AAA+ ATPases function as molecular chaperones, using their nucleotide hydrolase
activity to exert changes on the folded state of their nucleic acid or protein substrates.
This reaction may involve unwinding DNA, as in the case of helicases, or completely
unfolding a protein into a polypeptide chain, such as in the case of substrate unfolding
3

by the 19S proteasome subunit. Other family members function to disassemble a stable
protein complex into its individual folded protein components, as in the case of NSF
disassembling SNARE complexes after vesicle fusion. In this latter case, the complex
subunits remain functional and are recycled for further rounds of fusion [20].
AAA+ domains can occur in tandem (NSF, ClpB) or alone (spastin, torsinA) [21].
The AAA+ domain can be divided into two distinct subdomains: an N-terminal α/β
Rossman fold and a C-terminal helical domain (Figure 1-1B). ATP binds in the interface
between these subdomains, and key ATP-interacting motifs can be found in both
regions. The relative positioning of these subdomains is dynamic through the ATP
hydrolysis cycle [22]. In the α/β domain, Walker-A and Walker-B motifs fall in loops
between secondary structure elements, and are features shared by P-loop NTPases and
AAA+ enzymes [20, 23]. A conserved lysine residue in the Walker-A motif
(GxxxxGK[T/S]) interacts with the β and γ phosphates of ATP, and the following
threonine or serine coordinates Mg2+ ions. The Walker-B motif (hhhhDE) consists of
several hydrophobic residues followed by a conserved DE pair. The conserved
glutamate residue participates in ATP hydrolysis by nucleophilic attack on the γ
phosphate of ATP. It has been shown for various AAA+s that mutations to the Walker-A
motif abolish ATP binding [24, 25] while mutations to the Walker-B motif inhibit ATP
hydrolysis but not binding [26, 27]. Since interaction with substrates and cofactors often
occurs after ATP binding, mutation to either of these two motifs is a useful diagnostic
tool in evaluating enzyme function.
Sensor I and II motifs are unique to AAA+ ATPases. These motifs are located in
the C terminal portion of the α/β domain and in the helical domain, respectively, and
interact with the γ-phosphate of ATP. Sensor I contains a polar residue that is closely
apposed to the Walker-A and –B motifs; mutations to Sensor I impair ATP hydrolysis
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[28, 29]. Sensor II contains a conserved GAR sequence, with the arginine being key for
ATP hydrolysis and in some cases, binding [30].
AAA+ ATPases generally assemble into hexamers with a flat ring structure [22,
31]. The oligomer is thought to be the catalytically active state, as ATP binding sites are
positioned at subunit interfaces with ‘arginine finger’ residues from neighboring subunits
contributing to binding and hydrolysis [22, 30]. AAA+ ATPases with two AAA+ domains
in tandem, such as NSF, are often stable oligomers; those with only one AAA+ cassette
tend to assemble transiently. The center of the oligomeric ring forms a pore through
which substrates are translocated in many cases. Conserved aromatic, hydrophobic,
and charged residues have been identified as key substrate contacts within the pore of
various family members [21].

1.4 Features of the AAA+ domain in torsin subfamily members
The torsins contain a single AAA+ domain that is most homologous to the second
AAA+ domain of the Clp/Hsp100 subfamily of AAA+ ATPases [1, 32, 33]. Torsin AAA+s,
however, have some non-canonical features (Figure 1-2). The Walker-A motif diverges
from the norm, having a conserved asparagine residue in place of the typical threonine
or serine [32, 33]. Despite this difference, mutation to the Walker-A motif’s lysine (K108)
affects torsinA behavior in cells, suggesting that this motif is functional [34].
Replacement of the canonical threonine in ClpB’s Walker-A with asparagine preserves
nucleotide-stimulated oligomerization, but shifts nucleotide binding preference slightly
towards ADP versus ATP, lowering baseline ATPase activity without affecting the ability
of substrate to induce hydrolysis [35]. Similar behavior has been reported in the AAA+
family member and DNA helicase DnaC, which also contains an asparagine in its
Walker-A motif. It requires cofactors in order to hydrolyze ATP effectively, and its ATPand ADP- bound states each perform biologically important functions [36], leading to the
5

proposal that DnaC is an ATP/ADP switch. Catalysis by torsinA may have similar
features.
Torsin Sensor IIs are also divergent, having the conserved sequence GCK
instead of GAR [32] [33], yet mutation to this conserved lysine affects readouts of torsinA
activity [32, 34]. The dystonia-causative ∆GAG deletion is predicted to fall in the helix
preceding torsinA’s Sensor II loop, and could disrupt the helix and/or weaken ability to
bind ATP [32, 33]. Torsins contain six conserved cysteines that could be involved in
disulfide bonds in the oxidizing ER lumen; three of these fall in the AAA+ domain (Figure
1-1, 1-2) [33]. Interestingly, one of these cysteines directly precedes the conserved
lysine in Sensor II. Analysis of the redox state of the nematode homolog OOC-5
indicates that there may be a conformational transition linked to the redox status of the
Sensor II cysteine [33], making redox regulation of the torsins a possibility. A final
distinctive characteristic of torsin AAA+s is the presence of two glycosylation sites in a
loop between β2 and α2 [32]. Modification of both of these glycosylation sites has been
confirmed [16, 37], and the presence of bulky sugar groups should be taken into account
when considering the structure and conformational flexibility of these enzymes.
A structure of a torsin enzyme has not been solved, but weak ATP hydrolysis by
a fragment of human torsinA has been observed [38], and the AAA+ domain of the
nematode homolog OOC-5 is stabilized by nucleotide, suggesting that torsin proteins at
least bind ATP [33]. Co-immunoprecipitation experiments [39, 40] support the idea that
torsinA oligomerizes.

1.5 AAA+ ATPases use N terminal domains to engage adaptors and substrates
The combination of AAA+ domains with regulatory domains allows this
superfamily of enzymes to function in diverse contexts. AAA+ cassettes have been
reported joined to various protein-protein interaction domains, metal binding domains,
6

other catalytic domains, and DNA-binding motifs [23]. These domains may serve to
recruit an AAA+ to a particular organelle or promote direct interaction with a substrate.
The torsin enzymes have relatively minimal sequence outside of their AAA+ domain;
human torsinA has a 67-residue N terminal domain preceding the AAA+ cassette (Figure
1-1A) [32]. This domain is mostly unstructured, but contains a few features of interest,
including a hydrophobic region and three of torsinA’s six conserved cysteines. Cellular
fractionation indicates that the hydrophobic region associates with membranes [41, 42].
TorsinA may thus be thought of as a membrane-targeted AAA+ ATPase.

1.6 TorsinA and the endoplasmic reticulum
TorsinA and its three homologs, torsinB, torp2A, and torp3A, are residents of the
mammalian endoplasmic reticulum lumen [16, 37, 43]. The endoplasmic reticulum (ER)
is the site of synthesis for the cell’s secretory and membrane proteins, as well as some
of the cell’s lipids. The ER thus contains the machinery necessary for translocation of
nascent polypeptides, assisted folding of polypeptides into functional proteins,
degradation of misfolded proteins, and the sorting and packaging of secreted proteins for
forward transport. In addition, the ER functions as an intracellular calcium store. This
organelle has several distinct subdomains, including smooth ER (lipid synthesis,
hormone synthesis, detoxification), rough ER (protein synthesis), transitional ER
(anterograde protein transport), the nuclear envelope (see below), and contacts with
other organelles, including the plasma membrane, mitochondria, peroxisomes, and lipid
droplets. The ER membrane network comprises over 10% of the cell volume [44].
Amazingly, this network is disassembled, divided, and reassembled in daughter cells
during each cell division.
The nuclear envelope (NE) is a double bilayered membrane that is contiguous
with the bulk ER and defines the border of the nucleus. The NE appears to function as
7

an extension of the ER; ribosomes and COPII coat components have been observed on
the outer nuclear membrane [45, 46]. In addition to the general ER functions defined
above, the NE has some specialized features. For instance, the NE is the site where
nuclear pore complexes (NPCs) regulate transport between the cytosol and nucleus.
The inner surface of the nuclear membrane abuts the nuclear lamina, a cytoskeletal
network that surrounds the nuclear volume. The lamina and inner nuclear membrane
interact with and scaffold the cellular genome, influencing gene expression [47]. Proteins
of the nuclear envelope connect the nuclear lamina to the cytoskeleton, allowing
controlled positioning of the nucleus within the cell [48].
What essential function might torsinA perform in the ER? As an AAA+ ATPase, it
is likely that torsinA modulates the folded state of ER resident protein substrate(s).
TorsinA is unlikely to function as a general folding chaperone, as it is not upregulated
when ER stress is induced [49]. Contradictory findings on torsinA’s ability to alter
readouts of unfolded protein stress have been reported [40, 50, 51], but overexpression
of torsinA does appear to promote the folding of some proteins [52-54]. It is possible that
torsinA could exert a chaperone-like activity on a small number of substrates in a
specific paradigm, rather than in the global cellular response to stress [55].

1.7 TorsinA binds to LAP1 and LULL1
Identification of torsinA binding partners has provided few clues to the enzyme’s
cellular function. Lamina-associated polypeptide 1 (LAP1) was first identified as a
torsinA binding protein in a microscopy-based screen for interacting proteins [56].
Lumenal domain like LAP1 (LULL1) was then identified as an additional torsinA binding
partner that shares the lumenal torsinA-binding domain first found in LAP1 [56].
Immunoprecipitation of torsinA and proteomic identification of co-precipitating bands [34]
indicated that LAP1 and LULL1 are the major binding partners of torsinA in cultured
8

cells. Neither of these proteins has a well understood function other than binding to
torsinA.
LAP1 and LULL1 are each type II single-pass transmembrane proteins of the
ER/NE membrane system. The LAP1 and LULL1 genes are adjacent on human
chromosome 1 [56], and based on the high homology of their lumenal domains, it is
likely that a gene duplication event was involved in their genesis. The extralumenal
domains of these proteins diverge from one another dramatically and may confer unique
functions on the proteins. Despite low conservation of the extralumenal domains
amongst LAP1 sequences or LULL1 sequences, one conserved feature of these
domains is the basic pI in the case of LAP1 (pI ~9) and the acidic pI in the case of
LULL1 (pI ~4) [34]. Perhaps because of its basic character, LAP1 is retained at the inner
nuclear membrane by direct interaction of its extralumenal domain with the nuclear
lamina [57]. LULL1’s extralumenal domain does not interact with the lamina, and LULL1
is localized to the bulk ER.
As is the case for the interaction of many AAA+ ATPases with their substrates
and cofactors [20], torsinA’s binding to LAP1 and LULL1 appears to be linked to the
nucleotide hydrolysis cycle. Stable interaction between torsinA and LAP1/LULL1 can be
best detected when ATP hydrolysis is prevented by mutations to the catalytic domain
[34, 56] or incubation with ATPγS. The ΔGAG mutation does not stabilize interaction with
LAP1 and LULL1 [34]. Rather, ΔGAG weakens the interaction of ATP-trapped mutant
torsinA with LAP1 and LULL1 [34], providing further evidence that this disease-causative
mutation destabilizes the enzyme.
Conditions for interaction of torsinA with LAP1 can be screened by the ability of
overexpressed LAP1 to shift some wild type torsinA or a large proportion of ATP-trapped
torsinA into the NE [56]. Application of this analysis to other torsin family members
indicated that only torsinB responded significantly to LAP1 overexpression [16]. These
9

data would suggest that torsinB but not torp2A or torp3A may share some or all of
torsinA’s binding partners.

1.8 Evidence for a function for torsinA at the nuclear envelope
Several lines of evidence suggest that torsinA may function specifically at the
nuclear envelope (NE), despite being localized throughout the ER. Firstly, neurons
lacking torsinA or homozygous for the dystonia-causative ΔGAG mutation exhibited
ultrastructural abnormalities at the nuclear envelope, consisting of vesicular structures in
the perinuclear space [9]. The NE is the favored binding site for hydrolysis deficient
“substrate trap” torsinA mutants [58, 59] as well as ΔGAG-torsinA [58, 59], suggesting
that the enzyme may have substrate(s) there. Mutation of the C elegans homolog of
torsinA, OOC-5, results in a nuclear rotation defect in the embryo [17]. The ooc-5 mutant
shares some phenotypic similarities to nematodes lacking the NE-localized Sun or
nesprin proteins [60, 61]. These proteins interact in the perinuclear space to form linker
of nucleoskeleton and cytoskeleton (LINC) complexes, which tether the nucleus to the
cytoskeleton and are important for processes involving nuclear movement [48].
Interestingly, nesprin-3 is abnormally distributed in fibroblasts from torsinA knockout
mice, and these cells move slower than controls in a polarized cell migration assay [62].
Since nuclear movement is central to neuronal migration [63, 64], it is possible that
torsinA’s dysfunction at the NE in dystonia could cause subtle changes to the
establishment of neural circuits, leading in some cases to disease. Altogether, these
data provide a compelling argument that torsinA may have an important function at the
NE, but do not exclude the possibility of other function(s) in the bulk ER.

10

1.9 Summary of the thesis
When I first began my thesis work, I was intrigued by preliminary findings
indicating that torsinA could be enriched in the nuclear envelope (NE) in the presence of
a binding partner, LULL1. This was the first demonstration of the enzyme being targeted
specifically to the NE, where other studies have suggested it may function.
I show that torsinA is dynamically targeted from ER to NE upon coexpression
with LULL1, and that torsinA’s movement into the NE is concomitant with displacement
of NE resident transmembrane proteins including Sun2, nesprin-2, and nesprin-3.
Because Sun and nesprin proteins cooperate to anchor the nucleus to the cytoskeleton,
these effects suggest a role for torsinA in modulating nuclear positioning. ΔGAG-torsinA
can also be further enriched in the NE by LULL1, but is inefficient at displacing Sun2.
Knockdown of LULL1 reduces the baseline level of ΔGAG-torsinA in the NE, suggesting
a general role for LULL1 in controlling the distribution of torsinA within subdomains of the
ER. These findings identify a possible mechanism for regulating torsinA localization and
activity via LULL1, and suggest that activity at the NE is perturbed by the diseasecausative ΔGAG mutation [65] (Chapter 2). We also determine that a rare second
dystonia-causative mutation, R288Q [66], has a similar cellular phenotype to ΔGAG
(Chapter 5), strengthening the argument that dysfunction of torsinA at the NE causes
disease.
By analyzing the features of torsinA required for response to LULL1, we
determined that an N-terminal hydrophobic domain (NTD) is required for NE targeting.
Surprisingly, deletion of this domain also abolishes retention of torsinA within the ER.
Although the NTD is physicochemically similar to a transmembrane domain (TMD), the
NTD does not traverse the membrane, but mediates stable monotopic association with
the lumenal leaflet of the ER. This association in turn controls ER retention. It has been
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shown that TMDs from some ER resident proteins control targeting by selective
partitioning among different domains of the membrane bilayer. I propose that this lipidbased sorting mechanism extends to monotopic membrane proteins, and identify a
group of proteins that may share torsinA’s topology and ER retention mechanism. This
group includes the pharmacologically important prostaglandin synthetic enzyme COX1
(Chapter 3). This study has several exciting implications. Firstly, it identifies a previously
unknown way for lumenal membrane proteins to escape “bulk flow” secretion out of the
ER without the intervention of recycling receptors or vesicular coat proteins. Secondly,
many monotopic membrane domains have been shown to sense membrane curvature;
torsinA’s NTD could preferentially partition into relatively flat membranes, and thus
contribute to torsinA’s targeting to the NE by LULL1. Finally, homology models suggest
that the NTD could place torsinA’s central catalytic pore proximal to the membrane,
which could have consequences for engagement with transmembrane protein
substrates.
Returning to the interaction between torsinA and LULL1, I identify nonoverlapping regions of LULL1 that are responsible for (a) torsinA binding and (b) torsinA
re-targeting to the NE. Specifically, a conserved helix at the extreme C terminus of
LULL1 mediates its interaction with torsinA, while residues at the extreme N terminus of
LULL1 must be present in order for torsinA to be effectively targeted to the NE.
Importantly, the N terminus of LULL1 is cytosolic, while the C-terminal torsinA-binding
domain is lumenal, raising the intriguing possibility that control of torsinA localization
involves communication between the cytosol and the ER lumen (Chapter 4). Separately,
conserved cysteines in LULL1’s lumenal domain must be present in order for LULL1 to
re-target torsinA, which might suggest that regulation of torsinA by LULL1 involves a
redox component.
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The work in this thesis provides new insights into aspects of torsinA’s cellular
function and dysfunction in disease, as well as the sorting mechanisms that lumenal
membrane proteins, including torsinA, use to achieve ER localization.
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Figure Legends

Figure 1-1. Domain organization of torsinA and AAA+ domain structure. (A) TorsinA
consists of an N-terminal signal peptide (black), a hydrophobic domain (gray), an
unstructured linker region (white), and a single AAA+ cassette (yellow). The position of
the dystonia-causative glutamic acid deletion is indicated (E302/303); the positions of
torsinA’s 6 conserved cysteines are indicated in red. (B) 3D model of the D2 AAA+
domain of T. thermophilus ClpB, a close homolog to torsinA. Predicted positions of
relevant residues in torsinA are superimposed, including ATP-interacting sensor I and II
motifs and the ∆GAG deletion. Adapted from [32].

Figure 1-2. Alignment of torsinA’s AAA+ domain to the D2 domain of T. thermophilus
ClpB. Helices and sheets from ClpB are numbered and colored correspondingly to the
3D model in (1-1B). Key conserved motifs for AAA+ function are shaded. The two
sequences are 21% identical and 40% similar. Adapted from [32].
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Figure 1-2

Walker A
TorsinA (61) LQKDLDDNLFGQHLAKKIILNAVFGFINNPK-PKKPL-TLSLHGWTGTGK
ClpB D2 (552) LEEELHKRVVGQDEAIRAVADAIRRARAGLKDPNRPIGSFLFLGPTGVGK
TorsinA (109)NFVSKIIAENIYEGGLNSDYVHLFVATLHFPHASNITLYKDQLQLWIRGN
ClpB D2 (602) TELAKTLAATLFDTEEAMIRIDMTEYMEKHAVSRLIGAPPGYVGYEEGGQ
Walker B
TorsinA (159) VSACAR----SIFIFDEMDKMHAGLIDAIKPFLDYYDLVDG----VSYQK
ClpB D2 (652) LTEAVRRRPYSVILFDEIEKAHPDVFNILLQILDDGRLTDSHGRTVDFRN
Sensor 1
TorsinA (201) AMFIFLSNAGAERITDVALDFWRSGKQREDIKLKDIEHALSVSVFNNKNS
ClpB D2 (702) TVIILTSNLGSPLILEGLQKGW-------------PYERIRDEVFKVLQQ
TorsinA (251) GFWHSSLIDRNLIDYFVPFLPLEYKHLKMCIRVEMQSRGYE-IDEDIVSR
ClpB D2 (739) HFR-PEFLNR--LDEIVVFRPLTKEQIRQIVEIQLSYLRARLAEKRISLE
Sensor 2
**
TorsinA (300) VAEEMTFFPKEERVFSDKGCKTVFTKLDYYYDD
ClpB D2 (786) LTEAAKDFLAERGYDPVFGARPLRRVIQRELETPLAQKILAGEVKEGDRV

ClpB D2 (836)QVDVG------PAGLVFAVPARVEA—
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Chapter 2

LULL1 retargets torsinA to the nuclear envelope revealing an activity
that is impaired by the DYT1 dystonia mutation
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Abstract
TorsinA is an AAA+ ATPase in the endoplasmic reticulum (ER) lumen that is mutated in
early onset DYT1 dystonia. TorsinA is an essential protein in mice, and is thought to
function in the nuclear envelope (NE) despite localizing throughout the ER. Here, we
report that transient interaction of torsinA with the ER membrane protein LULL1 targets
torsinA to the NE. Fluorescence recovery after photobleaching and Blue Native PAGE
indicate that torsinA is a stable, slowly diffusing oligomer in either the absence or
presence of LULL1. Increasing LULL1 expression redistributes both wild-type and
disease-mutant torsinA to the NE, while decreasing LULL1 with shRNAs eliminates
intrinsic enrichment of disease-mutant torsinA in the NE. When concentrated in the NE,
torsinA displaces the nuclear membrane proteins Sun2, nesprin-2G and nesprin-3 while
leaving nuclear pores and Sun1 unchanged. Wild-type torsinA also induces changes in
NE membrane structure. Since SUN proteins interact with nesprins to connect nucleus
and cytoskeleton, these effects suggest a new role for torsinA in modulating complexes
that traverse the NE. Importantly, once concentrated in the NE, disease-mutant torsinA
displaces Sun2 with reduced efficiency and does not change NE membrane structure.
Together, our data suggest that LULL1 regulates the distribution and activity of torsinA
within the ER and NE lumen and reveal functional defects in the mutant protein
responsible for DYT1 dystonia.
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Introduction
Early-onset (DYT1) torsion dystonia is a neurological movement disorder characterized
by twisting movements of the limbs and an absence of neuropathology or
neurodegeneration [1, 2]. The disease is caused by autosomal dominant inheritance of a
glutamic acid deletion in the protein torsinA, frequently referred to as the ΔGAG mutation
because of the deleted codon [3]. Although torsinA is expressed ubiquitously [4], the
only abnormalities described so far in animals lacking this essential protein are in
neurons [5]. The failure of ΔGAG-mutant torsinA to rescue torsinA knock-out animals
from perinatal lethality suggests that the ΔGAG mutant lacks whatever essential activity
torsinA normally provides [5, 6].
The specific cellular functions ascribed to torsinA vary widely despite the fact that
it has been a decade since the protein was first described and linked to dystonia [2].
TorsinA resides in the lumen of the endoplasmic reticulum (ER) [7-9]. Based on its
membership in the AAA+ (ATPases associated with a variety of cellular activities) family
of ATPases [3, 10], it is likely that torsinA disassembles or changes the conformation of
a protein or protein complex within the ER or nuclear envelope (NE) lumen. While
typically found throughout the ER, several things point to a function for torsinA in the NE.
Reducing torsinA activity by gene knock-out in mice [5] or expressing a dominant
negative form of the enzyme in cultured cells [11] selectively perturbs NE structure. The
NE is the favored binding site for hydrolysis deficient “substrate trap” torsinA mutants
[11-13]. Finally, the outer nuclear membrane protein nesprin-3 [14] is abnormally
distributed in fibroblasts from torsinA knock-out mice, and these cells move slower than
controls in a polarized cell migration assay [15]. Since nesprin-3 participates in linker of
the nucleoskeleton and cytoskeleton (LINC) complexes [14, 16-19] these data suggest
that torsinA activity may help regulate NE structure and connections between nucleus
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and cytoskeleton.
Previously identified binding partners for torsinA include the transmembrane
proteins LAP1 (also known as TOR1AIP1) in the NE and LULL1 (also known as
TOR1AIP2 or NET9) in the ER, which control the distribution of hydrolysis deficient
“substrate trap” torsinA between NE and ER in direct proportion to their relative
abundance [20]. Here, we describe the surprising finding that increasing expression of
LULL1 induces torsinA to redistribute from throughout the ER into the NE while
decreasing it reverses concentration there. Once in the NE, torsinA displaces a subset of
LINC complex components and gradually promotes structural changes in the NE. The
disease-associated ΔGAG mutant is less efficient at enacting these changes. We
conclude that LULL1 dynamically tunes the distribution of torsinA between the ER and
NE and is thereby likely to regulate its function.
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Methods
Plasmids
GFP in previously described torsinA-GFP plasmids [11] was changed to monomeric
GFP (mGFP) by site-directed mutagenesis of L221K in GFP [22]. TorsinA-TagRFP was
made by transferring torsinA mutants excised with XhoI and EcoRI from EGFP-N1 into a
RFP-N1 vector containing TagRFP [44].The torsinA Δ26-43 deletion was created by
QuikChange mutagenesis (Stratagene). LULL1-myc was made by amplifying LULL1
(NM_145034, NP_659471) from human cDNA with primers containing HindIII and EcoRI
restriction sites and ligating it into pcDNA4/TO/MycHis B (Invitrogen). LULL1-mCherry
was made by excising LULL1 from EGFP-N1 using HindIII and EcoRI restriction sites
and ligating into pmCherry-N1 (Clontech). ER-RFP was from [30]. Sun2-GFP is from
[32]. Nesprin-3α-GFP is from [17]. The sequences of all constructs were verified by
nucleotide sequencing.

Cell Culture and cell line generation
U2OS cells were grown in DMEM supplemented with 10% FBS and L-glutamine.
Transient transfections were performed with Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. Clonal LULL1-myc tetracycline-inducible U2OS cell
lines were made as described previously [45], with selection in hygromycin (50 µg/mL)
and zeocin (100 µg/mL). LULL1-myc/Sun2-GFP dual-expressing cells were made by
transfecting Sun2-GFP into LULL1-myc cells and selecting with 400 µg/mL G418. LULL1
was depleted by lentiviral transduction of shRNAs directed against human LULL1
(Sigma Mission shRNA, RefSeq # NM_145034). Lentiviruses were produced by
cotransfecting hairpins in pLKO with the pCMV 8.2 ΔR packaging plasmid into 293T
cells. U2OS cells were then transduced with viral particles according to manufacturer’s
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instructions. Cells depleted of LULL1 were enriched for by selecting transduced cells
with puromycin (10 µg/ml).

Immunofluorescence
Cells were fixed with 3% paraformaldehyde in PBS for 10 min, followed by
permeabilization in 0.2% Triton-X-100 for 10 min. Coverslips were blocked in 2% goat
serum in PBS for 1 hour before incubation with primary and Alexa Fluor-conjugated
secondary antibodies. For epifluorescence imaging, coverslips were mounted in Mowiol
(Calbiochem) and imaged with a Leica Diaplan microscope using a 63 x 1.4 N.A.
objective and a Zeiss AxioCam MRm camera. Brightness and contrast were adjusted in
Adobe Photoshop (Adobe Systems). For confocal imaging, coverslips were mounted in
VectaShield (Vector Labs), sealed with nail polish, and imaged with a Bio-Rad Radiance
2000 microscope with a 63x/1.4 NA oil objective, using the 488- and 543-nm laser lines.
Confocal z-series were acquired with a pinhole of 1.7 at 0.3 µm spacing. All confocal
images were processed using the smooth function in Image J (v1.4, NIH), which
replaces each pixel with the average in its 3 x 3 neighborhood. Maximum intensity
projections of confocal z-series were made in ImageJ. Composite figures were prepared
using Photoshop and Illustrator software (Adobe).

NE/ER Ratio Analysis
U2OS or LULL1 knock-down cells were transiently transfected with TorsinA-mGFP and
ER-RFP as indicated. Confocal images were acquired as above. Fluorescence intensity
was quantified using Metamorph 6.0 software (Universal Imaging). For each image,
average intensities in the GFP and RFP channels were quantified in four regions each of
the ER (~400 square pixels each) and NE (~200 square pixels each). Regions of interest
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were delineated as boxes for ER and as hand-drawn outlines for NE and any
overlapping perinuclear ER. These four values were averaged for each cell’s ER and NE
and then used to compute the NE/ER ratio for each channel. The data shown represent
the average of >20 cells per condition.

Live imaging
For experiments involving co-expression of LULL1 and torsinA, LULL1-myc expression
was induced with tetracycline (1 µg/mL) 6 hrs prior to adding Lipofectamine
2000/torsinA-mGFP mixtures to initiate transfection. 1-2 hours later, coverslips were
transferred to Bioptechs Delta T imaging dishes (Bioptechs Inc) and overlaid with
phenol-red-free media containing 1% FBS. The dishes were placed on an enclosed
stage (custom made by A. Czirok, Dept of Biological Physics, Eotvos University,
Budapest, Hungary) attached to a CO2 pump to maintain 5% CO2 and to a temperature
control device set to 37°C. Images were obtained with a 20 x 0.4 NA objective on an
inverted epifluorescence/DIC microscope (Leica DMI6000B, Leica Microsystems).
Images (696 by 520 pixels, 12-bit intensity resolution) were recorded with a QImaging
Retiga Exi camera (QImaging) using 2 x 2 binning and pre-determined 1-2 sec
exposures. Image acquisition and microscope settings were controlled by software
based on [46]. Briefly, up to 16 pre-selected fields were visited in each scanning cycle,
and epifluorescence images were taken in one or two channels. For each field and
channel, 5 images were acquired in z positions centered around the chosen focal plane.
Cells were imaged every 15 minutes for the duration of the experiment. Images were
processed using software based on [46]. For each time point, the software chooses the
most in-focus image of the “z-stack” for each 64 by 64 pixel block of the image. These
best-focused pixel blocks are then collapsed into a single image. The software also
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corrects for small shifts in x position. The resulting images were further processed using
“Subtract Background” and “Enhance Contrast” tools in ImageJ. Time-lapse imaging
(TiLa) code was created by the Computational Imaging Group at the University of
Kansas Medical Center, under the direction of Drs. C. Little, B. Rongish, and A. Czirok.
Dr. Czirok devised the original code for image acquisition and processing, which has
been further developed and modified by Alan Petersen, Michael Filla, and Dr. Evan
Zamir. A current version of this open source code is available from the Computational
Imaging Group upon request (clittle@kumc.edu).

FRAP analyses
Cells were grown in 8-well Labtek chambers (Nunc) and imaged in phenol red-free RPMI
supplemented with 10mM Hepes and 10% fetal bovine serum. Live cells were imaged
on a 37°C environmentally controlled chamber of a confocal microscope system
(Duoscan; Carl Zeiss MicroImaging, Inc.) with a 63X/1.4 NA oil objective and a 489-nm
100mW diode laser with a 500-550 nm bandpass filter for GFP. FRAP experiments were
performed by photobleaching a region of interest at full laser power of the 489nm line
and monitoring fluorescence recovery by scanning the whole cell at low laser power. No
photobleaching of the cell or adjacent cells during fluorescence recovery was observed.
Diffusion (D) measurements were calculated as described previously [23, 47].
Composite figures were prepared using Photoshop CS2 and Illustrator CS software
(Adobe). Plotting of diffusion coefficients was performed with Prism 4.0c.

Immunoblotting
Western blots were developed as described [45]. For quantitative analysis using the
Odyssey system (LiCOR Biosciences), samples were separated, blocked, and blotted
according to manufacturer’s instructions. Secondary antibodies conjugated to IRDye-680
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or -800 were used.

Antibodies
The following antibodies were used: mouse anti-myc (9E10, Developmental Studies
Hybridoma Bank, Univ. of Iowa), rabbit anti-Sun1 (Sigma), rabbit anti-Sun2 [32], chicken
anti-nesprin2-Giant (Brian Burke, University of Florida, Gainesville), mouse anti-NPCs
(mAb414, Babco), rabbit anti-calreticulin (Stressgen), mouse anti-torsinA DM2A8
[8],mouse anti-α-tubulin (Sigma), and rabbit anti-Sec61β (Joe Bass, Northwestern
University). We generated an affinity-purified rabbit antibody against residues 1-217 of
human LULL1 fused to GST. Protein purified from Escherichia coli was sent to Sigma
Genosys for injection into rabbits. The resulting sera were depleted of GST-reactive
antibodies by incubation with GST protein, and subsequently affinity purified on
immobilized antigen. Secondary goat anti-mouse, goat anti-rabbit, and goat anti-chicken
antibodies conjugated to Alexa 488, 555, or 595 were purchased from Molecular Probes.
Goat anti-mouse and goat anti-rabbit antibodies conjugated to HRP were purchased
from Bio-Rad.

Triton X-114 phase separation
Cells from a 6 cm plate of U2OS cells transfected with the indicated construct were
collected and resuspended in 250 µl buffer containing 2% Triton X-114 and 200 mM
NaCl. Samples were incubated at 4°C for 30 min and then centrifuged for 10 min at
10,000 x g to remove insoluble material. The soluble extract was incubated at 37° C for
10 min followed by centrifugation at 1,000 x g for 10 min at room temperature to
separate phases. The top “aqueous” phase was transferred to a new tube, and the
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bottom “detergent” phase brought to the same volume as the aqueous phase. Equal
volumes were boiled and analyzed by SDS-PAGE and immunoblotting.

Blue native PAGE
10 cm plates of U2OS cells or U2OS cells with tetracycline-inducible LULL1-myc were
induced with tetracycline and/or transfected with constructs as indicated. Cells were
resuspended in sample buffer (50 mM imidazole, 50 mM NaCl, 2 mM EDTA, 2 mM ATP,
2 mM aminocaproic acid, 4 mM MgCl2 , PMSF, protease inhibitors, and
dodecylmaltoside or digitonin detergent at indicated concentrations). The samples were
incubated at 4°C for 15 minutes with agitation, then centrifuged for 30 minutes at 60,000
rpm at 4°C, followed by 15 minutes at 60,000 rpm at 4°C in fresh tubes. The protein
concentration of the supernatant was determined by Bradford assay, and equivalent
amounts of protein (~20 µg per sample) were supplemented with Coomassie G-250 at
0.125% w/v final concentration and glycerol to 5% final concentration. Samples were
then loaded onto 7.5% BN-PAGE gels, run, and transferred to PVDF for Western blot
detection. Samples were run alongside a native PAGE molecular weight marker (High
Molecular Weight Calibration Kit for native electrophoresis, Amersham). BN-PAGE gels,
buffer, and PAGE protocols were as previously described (Wittig et al., 2006).

FACS isolation of a LULL1, torsinA-mGFP positive cell population
15 cm plates of U2OS cells with tetracycline-inducible LULL1-myc were induced with
tetracycline 6 hours before transfection of torsinA-mGFP. Either 12 or 22 hours later
cells were trypsinized, washed in PBS, and resuspended in phenol red-free DMEM plus
1% FBS and 0.1 mM EDTA at 4°C. Cells were diluted to a concentration of 5-10 x 106
cells/mL for sorting. Cells were collected by GFP fluorescence to obtain cells exclusively
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expressing LULL1-myc- and torsinA-mGFP. FACS was performed at a WUSM core
facility on a FACS Vantage Sorter (Becton Dickinson).

Immunoprecipitation
U2OS-LULL1 myc cells in 6 cm plates were induced to express LULL1-His6myc by
adding 1 mg/ml tetracycline 6 hrs before adding Lipofectamine 2000 and the indicated
torsinA-mGFP plasmid. On the following day, cells were collected and solubilized in 20
mM Hepes pH 7.2, 25 mM NaCl, 2 mM Mg2+ATP, 0.5% CHAPS, and complete protease
inhibitor cocktail. LULL1-His6myc was then immunoprecipitated with 9E10 anti-myc
monoclonal antibody and protein G Sepharose. Samples were resolved by SDS-PAGE
and the distribution of mGFP tagged torsinA proteins monitored by immunoblotting with
a GFP antibody.
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Results
Dynamic regulation of torsinA distribution by LULL1
In an effort to understand how and when torsinA functions within the NE, we
studied the subcellular localization of torsinA with monomeric GFP fused to its Cterminus in transfected U2OS cells. As expected, torsinA-mGFP is distributed evenly
throughout the ER (Figure 2-1A, left). The dystonia-causative mutant, ΔGAG-torsinA,
also localizes to the ER but is enriched in the contiguous NE as expected based on
earlier studies (Figure 2-1A, middle) [11, 12, 21]. TorsinA’s binding partner LULL1-myc
is also found throughout the ER (Figure 2-1A, right).
To our surprise, however, expressing torsinA-mGFP together with LULL1-myc
shifted torsinA-mGFP almost entirely into the NE, where it displayed patterns ranging
from concentration in a portion of the NE (Figure 2-1B, left hand cell) to coverage of the
entire nucleus (Figure 2-1B, right hand cell). In the latter cells, the torsinA-mGFP
containing NE was often distorted (Figure 2-1B’’). A confocal slice from the z-stack used
to generate the projected image in Figure 1B confirms that torsinA-mGFP concentrates
at the nuclear periphery, and that the LULL1-myc containing ER appears generally
normal (Figure 2-1B’). Overall, 65% of cells (n >150) expressing both proteins for 18
hours had torsinA-mGFP concentrated in the NE. A smaller, more variable proportion of
LULL1-myc also relocalized to the NE (compare Figure 2-1A to 2-1B), leading us to
hypothesize that LULL1 changes the subcellular targeting of torsinA rather than vice
versa. ΔGAG-torsinA-mGFP similarly responded to coexpressed LULL1-myc by further
concentrating in the NE (Figure 2-1C).
To assess the specificity of this phenomenon, we asked whether overexpressing
LULL1 would cause another ER protein to redistribute, and conversely, whether
introducing another ER protein would change the localization of torsinA. For this
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analysis, we used Sec61γ tagged with GFP, which, similarly to LULL1, is a mobile
single-pass transmembrane protein of the ER [22]. We found that expressing LULL1myc did not change the distribution of mGFP-Sec61γ between bulk ER and NE (Figure
2-1D), and that introducing mGFP-Sec61γ did not cause torsinA to redistribute to the NE
(Figure 2-1E). To ensure that the effect of LULL1 on torsinA is not tag-dependent, we
examined different forms of the proteins and found that untagged torsinA and torsinATAG-RFP responded to LULL1-myc, and that LULL1-mGFP caused torsinA-myc to
redistribute (Supplemental Figure 2-S1). To determine how much LULL1 is required to
have this effect on torsinA, we induced LULL1 expression with 100-fold less (10 ng/ml)
or 1000-fold less (1 ng/ml) tetracycline; 1 ng/ml tetracycline induced expression of
LULL1 to ~5 times endogenous levels (Figure 2-S2D) and was also capable of moving
torsinA-mGFP into the NE (Figure 2-S2A).
The variable distribution of wild-type torsinA in fixed LULL1- and torsinAexpressing cells suggested a dynamic process that we further explored in living cells.
Shortly after transfecting torsinA-mGFP into LULL1-expressing cells, we transferred
coverslips to an imaging chamber and collected pictures every 15 min for up to 24 hours.
A typical field of cells is shown 2 hours after transfection of torsinA-mGFP and again 5
hours later (Figure 2-2A). These images demonstrate that as torsinA-mGFP expression
begins, it is predominantly localized to the ER, recognizable at low magnification as a
crescent of fluorescence surrounding a comparatively dark nucleus (Figure 2-2A, upper
panel). Over time, torsinA-mGFP shifts to the NE in many of the expressing cells (Figure
2-2A, lower panel). A pair of cells viewed at higher magnification in Figure 2-2B show
the typical manner in which torsinA redistributes. TorsinA starts to concentrate in the NE
at one or a few points and proceeds to surround the whole nucleus in an average of 45
min (Figure 2-2B). This confirms that partially covered nuclei in fixed cells represent

37

intermediates in the redistribution of torsinA into the entire NE. In most cells, torsinA
remained concentrated in the NE for the duration of the experiment (Figure 2-2B, righthand cell). Rarely, it later returned to the ER demonstrating that the redistribution is
reversible and implying that NE-localized torsinA is still responsive to changes in its
environment (Figure 2-2B, left-hand cell). Mitosis was occasionally observed,
demonstrating that NE breakdown and reformation remain possible in the presence of
NE-localized torsinA (data not shown). Initiation of torsinA’s redistribution to the NE
occurred randomly with respect to time of observation and position in the viewing field,
suggesting that the redistribution is a cell-autonomous process initiated by factor(s) that
could include a threshold amount of LULL1, torsinA, or something else. Imaging of
∆GAG-torsinA-mGFP in LULL1-myc-expressing cells showed that it too enriched in the
NE with time, as expected based on the immunofluorescence of fixed cells
(Supplemental Figure 2-S3A). However, the mutant enzyme never progressed with
polarity into the NE (and we never saw partially covered nuclei in fixed samples). To be
sure that LULL1 was responsible for the enhanced enrichment of ∆GAG-torsinA-mGFP
in the NE, we also imaged it in U2OS cells with only endogenous levels of LULL1. In this
case, its partitioning between NE and ER did not change over time (Supplemental Figure
2-S3B).
We next asked whether the LULL1-dependent shift of torsinA into the NE could
be explained by selective immobilization there, analogous to the behavior of NE resident
proteins such as the lamin B receptor (Ellenberg, 1997). To address this, we carried out
quantitative FRAP (fluorescence recovery after photobleaching) experiments [23]. We
found that expressed individually, torsinA-mGFP recovered slowly from photobleaching
(Figure 2-2D, 2-2F) while LULL1-mGFP recovered an order of magnitude more quickly
(Figure 2-2C, 2-2F). Coexpressing torsinA-mGFP with LULL1-mCherry did not change
the slow mobility of torsinA in either the NE or ER (Figure 2-2E, 2-2F). Conversely,
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coexpression with torsinA-mGFP did not change LULL1-mCherry diffusion (Figure 2-2E’,
2-2F). Notably, torsinA-mGFP is readily solubilized by mild detergents (data not shown,
but see Figure 2-3 below), indicating that its slow diffusion and localization to the NE are
not consequences of aggregation.
The diffusive behavior of torsinA suggested that it participates in a large protein
complex in the ER and NE. Furthermore, AAA+ proteins typically function as higher
order oligomers, typically either hexamers or dodecamers [10]. However, previous
analyses of torsinA’s oligomeric state had not identified any such large assemblies [24],
although torsinA can self-associate as judged by co-immunoprecipitation [21, 25]. To
reconcile these two lines of data, we hypothesized that torsinA oligomers might be
disrupted by the detergents used to prepare previous samples for analysis. We turned to
Blue Native polyacrylamide gel electrophoresis (BN-PAGE), which separates native
membrane proteins by size and shape in the presence of mild detergent and the protein
binding dye Coomassie Brilliant Blue [26]. BN-PAGE of dodecylmaltoside (DDM)solubilized torsinA reveals the presence of an oligomeric species of approximately
hexameric size in samples containing 0.25% w/v DDM (Figure 2-3A, left lane). This
oligomer is destabilized by higher concentrations of DDM (Figure 2-3A), indicating that it
represents a complex of folded proteins rather than an aggregate. A comparable
oligomer is detected in samples solubilized with 0.5% w/v digitonin (Figure 2-3B, upper
panel). Further, the oligomeric species is completely dispersed on a second-dimension
denaturing SDS-PAGE gel (Figure 2-3B, lower panel), where all immunoreactivity
corresponds to the size of monomeric torsinA (~38 kDa). This suggests that torsinA
forms a hexameric unit similar to other AAA+ ATPases [10], and together with earlier
suggestions that torsinA is peripherally associated with the ER lumenal membrane (Liu
et al., 2003; Callan et al., 2007) provides a likely explanation for its slow mobility in the
FRAP experiments described above. Slow diffusion may explain why it takes an average
39

of 45 min (Figure 2-2B) for torsinA-mGFP to relocalize from ER to NE. Finally, torsinA is
a stable oligomeric species of approximately hexameric size regardless of whether or
not LULL1 is coexpressed (Figure 2-3C). The fact that LULL1 changes neither the
oligomeric state nor the apparent mobility of torsinA suggests that LULL1 changes the
enzyme’s targeting but not its fundamental organization.

Features of TorsinA involved in its redistribution to the NE
LULL1-promoted redistribution of torsinA to the NE was unexpected based on
the earlier finding that hydrolysis deficient “substrate trap” mutant torsinA (containing a
Walker B motif E171Q mutation) accumulates together with LULL1 in the peripheral ER
and efficiently co-immunoprecipitates with it [20]. Because wild-type torsinA only
inefficiently co-immunoprecipitates with LULL1 [20], we hypothesized that a transient,
ATP-dependent interaction between active enzyme and LULL1 changes something,
most likely in torsinA, that in turn targets it to the NE. To learn more about how torsinA
responds to LULL1, we explored the effects of mutations in defined motifs within torsinA.
Under conditions in which wild-type enzyme efficiently relocalizes to the NE, we found
that, as expected (Goodchild and Dauer, 2005), torsinA(E171Q) remained distributed
throughout the ER (Figure 2-4B). Interestingly, torsinA with a mutation in its Walker A
ATP-binding motif (K108A) also did not redistribute into the NE (Figure 2-4B),
establishing that torsinA needs to be able to engage ATP to move in response to LULL1.
We next wondered whether peripheral association of torsinA with the lumenal
membrane is important for its targeting to the NE. We deleted the hydrophobic
sequence (Δ26-43) implicated in membrane association [27, 28] and confirmed that
torsinA no longer behaved as a hydrophobic protein in Triton X-114 phase partitioning
experiments (Figure 2-4D). Interestingly, this hydrophilic torsinA did not move into the
NE in cells expressing LULL1 (Figure 2-4B). Because deleting the hydrophobic
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sequence does not affect binding of “substrate trap” E171Q mutant torsinA to LULL1
(Figure 2-4E), this mutant’s failure to redistribute suggests that the N-terminus of torsinA
plays an essential role in LULL1-dependent NE targeting.

Removing LULL1 reduces enrichment of ΔGAG-TorsinA in the nuclear envelope
The above experiments indicate that overexpressing LULL1 shifts a large
proportion of torsinA into the NE. This, together with the fact that ΔGAG-torsinA (and in
some cell types, also wild-type torsinA) is known to be intrinsically enriched in the NE
(Figure 2-1A) [11, 12, 29], led us to hypothesize that distribution of torsinA between ER
and NE may normally be controlled by interaction with endogenous LULL1. To explore
this possibility, we used RNAi to deplete LULL1 (Figure 2-4A) and compared the
localization of ΔGAG-torsinA-mGFP to that of a cotransfected ER lumenal marker
consisting of a prolactin signal sequence and a KDEL ER-retrieval sequence fused to
mRFP (ER-RFP) [30]. Representative confocal sections show that ∆GAG-torsinA-mGFP
is more concentrated around the nucleus than is ER-RFP in U2OS cells (Figure 2-4B),
but not in LULL1 knock-down cells (Figure 4C). Wild type torsinA, meanwhile, is
distributed similarly to ER-RFP in both cell types (images not shown, Figure 2-4D).
Quantitative analysis (Figure 2-4D and Materials and Methods) confirms that wild type
torsinA has no preference for the NE and/or perinuclear ER in U2OS cells. ∆GAGtorsinA-mGFP, in contrast, is enriched in the perinuclear region in U2OS cells but not in
cells depleted of LULL1 (p = 0.003). The distribution of ∆GAG-torsinA-mGFP in the
absence of LULL1 was indistinguishable from that of ER-RFP (p >0.05). Analysis of
∆GAG-torsinA-mGFP in the presence of another RNA hairpin directed against LULL1
showed the same effect (data not shown). This demonstrates that enrichment of ∆GAGtorsinA-mGFP in the NE requires LULL1. Together with the finding that high levels of
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LULL1 shift torsinA into the NE, these experiments suggest that LULL1 has a general
role in regulating localization of both wild-type and disease-mutant torsinA.

Redistributed torsinA displaces a subset of LINC complex components from the NE
To explore torsinA’s effects on the NE, we examined specific NE components by
immunostaining. In cells containing NE-localized torsinA, the distribution and staining of
nuclear pores did not change indicating that the overall integrity of the NE is maintained
in these cells (Figure 2-6A). We next examined torsinA’s effects on the inner nuclear
membrane proteins Sun1 and Sun2. While Sun1 was not affected by redistributed
torsinA (Figure 2-6B), Sun2 immunostaining was notably diminished in regions of the NE
where torsinA was concentrated suggesting that torsinA might displace Sun2 as it
moves into the NE (Figure 2-6C). Orthogonal views of confocal z-series confirmed that
Sun1 remains at the nuclear periphery in cells with torsinA in the NE (Figure 2-6B’) while
Sun2 is decreased (Figure 2-6C’). The normal distribution of nuclear pores, known to
colocalize with Sun1 but not Sun2 [31], could explain a selective effect of torsinA on
Sun2. A survey of Sun2 immunoreactivity in cells containing LULL1-redistributed torsinAmGFP indicated that changes in Sun2 were widespread; 60% of these cells lacked a
clearly delineated nuclear rim of Sun2 compared to only 4% of untransfected cells (n >
110 for each). To rule out the alternative possibility that redistributed torsinA masked the
lumenal Sun2 antibody epitope [32], we made a tetracycline inducible LULL1-myc cell
line that also constitutively expressed Sun2-GFP and assessed the effect of introducing
TorsinA fused to TagRFP (Merzlyak et al., 2007). Direct examination of protein
fluorescence showed that Sun2-GFP was displaced by torsinA-TagRFP (Figure 2-6D),
paralleling the effect of torsinA on endogenous Sun2. Importantly, despite being
somewhat concentrated in the NE, E171Q-torsinA and ΔGAG-torsinA expressed
individually in U2OS cells had little or no effect on Sun2 (Supplemental Figure 2-S5).
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Further, expression of wild type torsinA on its own had no detectable effect. Sun2 in the
NE thus appears to decrease specifically in response to LULL1-redistributed torsinA.
The overall decrease in Sun2 intensity in cells with redistributed torsinA in the NE
suggests that displaced Sun2 may be unstable and possibly degraded. Western blot
analysis of Sun2 in such cells confirms a decrease in the overall level of Sun2 but not
nucleoporins or a general ER marker (Figure 2-7). Increased degradation of INM
proteins has been reported when lamin anchors are absent [33]; it is possible that
torsinA could similarly destabilize Sun2 as a consequence of altering its association with
the nuclear lamina.
SUN proteins participate in NE-spanning LINC complexes [34], which consist of
SUN proteins in the inner nuclear membrane (INM) and nesprins in the outer nuclear
membrane (ONM) [19]. Conserved domains of these proteins interact in the perinuclear
space to physically connect the nucleus to the cytoskeleton [18, 19]. We therefore next
asked whether redistributed torsinA affects the ONM-localized nesprins. Cells
expressing LULL1-myc and torsinA-mGFP were stained with an antibody for nesprin2Giant, revealing that it too was missing from the NE when torsinA was concentrated
there (Figure 2-6E). This displacement occurred in 56% of cells expressing LULL1-myc
and torsinA-mGFP compared to only 1% of untransfected cells (n > 35 for each).
Similarly, transiently transfected nesprin3a-GFP was absent from regions of the NE
containing torsinA-TagRFP (Figure 2-6F). These findings demonstrate that torsinA
changes the behavior of a subset of LINC complex components, including Sun2 in the
INM and nesprin2-Giant and nesprin-3 in the ONM. Indeed, some of the changes in NE
membranes caused by redistributed wild-type torsinA (Figure 2-1B’, see also
subsequent Figure 2-8A) are reminiscent of changes induced by manipulating
components of LINC complexes [34]. A recent report of interaction between torsinA and
nesprin-3 suggests that these effects could be direct [15], but further studies are needed
43

to understand the molecular changes involved. Since live imaging analysis (Figure 2-2B)
indicated that torsinA moves across the NE within an hour, the coincident patterns of
Sun2 and nesprin-3 imply that their displacement is temporally related to the arrival of
torsinA in the NE and that they could be its direct targets.

The DYT1 ΔGAG mutation impairs the effects of torsinA on the NE
∆GAG-torsinA has consistently been found to be more enriched in the NE than is
wild-type torsinA [11, 12, 21, 29], leading to the hypothesis that mislocalization to the NE
might contribute to the development of dystonia [12]. At the same time, ΔGAG-torsinA is
thought to be less functional and less stable than wild-type torsinA such that loss of
normal enzyme function could underlie the disease [5, 21, 35]. As shown in Figure 2-1
and Supplemental Figure 2-S3, coexpressing LULL1 with ∆GAG-torsinA-mGFP caused
it to enrich further in the NE, albeit without the distinctive polarity that characterized the
shift of wild type protein. We therefore compared the behavior of ΔGAG- and wild-type
torsinA in more detail. Maximum intensity projections of nuclei in cells in which these
proteins were concentrated for up to 18 hours revealed that wild-type torsinA distorted
NE membranes into both the nucleus and the cytoplasm (Figure 2-8A, 2-8A’, left) in 68%
of cells with NE-localized torsinA (n =136). In contrast, ΔGAG-torsinA-mGFP left the NE
largely unchanged (Figure 2-8A, 2-8A’, right), causing NE distortions in only 7% of cells
containing NE-localized protein (n = 74). These differences suggest that ∆GAG-torsinA
interacts differently than wild-type enzyme with components of the NE.
To determine how redistributed ΔGAG-torsinA affects specific NE components,
we looked for changes in Sun2. In cells expressing LULL1-myc and ∆GAG-torsinAmGFP Sun2 was diminished (Figure 2-8D, 2-8D’). However, a difference between
mutant and wild-type enzyme became apparent when we used time-lapse imaging to
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compare the effects of wild-type or ΔGAG torsinA-TagRFP on Sun2-GFP.
Representative sequential images show that transiently transfected wild-type torsinATagRFP displaces Sun2-GFP as it appears in the NE (Figure 2-8E). In the cells shown,
Sun2-GFP decreases at one end of the nucleus while torsinA-TagRFP is too dim to see,
but as torsinA-TagRFP becomes visible it is apparent that the boundary between
increasing torsinA-TagRFP and decreasing Sun2-GFP remains closely apposed (see
especially 90 min and 120 min frames of Figure 2-8E). In contrast, time lapse imaging of
∆GAG-torsinA-TagRFP revealed a much slower effect of ΔGAG-torsinA on Sun2-GFP
(Figure 2-8F). Whereas Sun2-GFP started to decrease within 15 min of when wild-type
torsinA began to concentrate in the NE, it took ~7 hrs for this to happen in cells
expressing ∆GAG-torsinA. Together with the lack of structural abnormalities in the NE of
cells expressing ΔGAG-torsinA, this suggests that ∆GAG-torsinA is less efficient than
wild-type torsinA at changing NE components.
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Discussion
Controlling the localization of enzymes within the cell is an important general
mechanism for regulating their activity. Post-translational modifications and
conformational changes are known to retarget many cytoplasmic enzymes from one
place to another, but dynamic changes in the distribution of enzymes within the ER
lumen are less well characterized. We find that the torsinA binding partner LULL1 – an
ER transmembrane protein – drives redistribution of this lumenal AAA+ ATPase from
throughout the ER network specifically into the NE (Figure 2-9), where previous in vitro
and in vivo studies have suggested a function[5, 11, 12]. The idea that regulated
distribution between the ER and NE might control torsinA’s activity toward spatially
restricted substrate(s) arose initially from studies showing that so-called “substrate
trapped” torsinA mutants accumulated in the NE [11, 12, 36]. The wild-type enzyme, in
contrast, is diffusely distributed throughout the ER except in a few cell types [21] and
after certain pharmacological manipulations [8, 15, 37]. We hypothesized that additional
factor(s), which perhaps are more abundant in cell types where torsinA exhibits NE
preference [21], were therefore likely to control the targeting and activity of wild-type
torsinA. Extrapolating between the extremes of LULL1 overexpression (Figures 2-1, 2-2,
& 2-6) and LULL1 silencing (Figure 2-5) leads us to propose that transient interaction
with LULL1 positively regulates the targeting and activity of torsinA in the NE. The
abundance of LULL1 thus emerges as a critical regulator of torsinA activity. Future
studies will address whether variations in endogenous LULL1 levels explain previously
described cell-type specific differences in torsinA distribution [21] and whether there are
peaks in the expression or stabilization of LULL1 that correlate with important events in
neuronal development or plasticity.
LULL1 is a ~70 kDa single-pass transmembrane protein with no defined
functional motifs and no known binding partners other than torsinA [20]. Several features
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suggest that LULL1 may be regulated at both the transcriptional and post-translational
levels, making it an attractive potential regulatory protein. There are significant variations
in the level of LULL1 message in different cells and tissues [20, 38] and over the course
of in vitro muscle cell differentiation [38]. Further, the extralumenal domain of LULL1 has
a preponderance of charged residues and a dearth of hydrophobic residues, both of
which are likely to predispose it to rapid and potentially regulated turnover [39].
Consistently, secondary structure prediction algorithms indicate a lack of stably folded
structures in this region, and the PESTfind algorithm
(http://www.at.embnet.org/toolbox/pestfind) finds two high scoring sequences that may
correlate with rapid protein turnover [40]. Finally, as a transmembrane protein, LULL1
provides a way to directly or indirectly transmit signals across the ER membrane to
torsinA.
Using LULL1 overexpression to concentrate torsinA in the NE, we were able
uncover molecular and structural changes that are likely to represent torsinA’s normal
activity, including alterations in a subset of NE proteins that participate in NE-bridging
LINC complexes (Figures 2-6 & 2-7). LINC complexes are formed when INM-localized
Sun proteins and ONM-localized nesprin proteins interact within the NE lumen, and have
recently attracted attention as important connectors between the cytoskeleton, NE
membranes, and elements within the nucleus including the lamina and telomeres [19].
While much remains to be learned about the cell biology of LINC complexes, it is clear
that they have important roles in such diverse processes as nuclear anchorage, cell
migration, and regulating gene expression [16, 41]. Our data showing that some LINC
complex proteins – Sun2, nesprin-2G, and nesprin-3 – are destabilized by torsinA as it
accumulates in the NE suggest possible roles for torsinA in these same processes. In
support of this, a recent study showed that fibroblasts from torsinA knock-out mice
migrate more slowly than controls in a polarized cell migration assay [15].
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Although LINC complex proteins may help recruit torsinA to the NE, the subset
that torsinA displaces (i.e. at least Sun2, nesprin-2G, and nesprin-3) seem unlikely to be
directly responsible for retaining it there since torsinA remains in the NE even after these
proteins are gone. Future work will need to explore possible roles for other NE proteins
in this process, perhaps especially remaining LINC complex proteins such as Sun1 and
the known torsinA binding partner LAP1.
The mechanism by which LULL1 induces torsinA retargeting is an area of
ongoing interest. Here, we present several observations about torsinA that constrain the
possible explanations. Using BN-PAGE (Figure 2-3) and FRAP (Figure 2-2), we
established that torsinA assembles into a large, membrane associated oligomer –
probably a hexamer – within the ER lumen. The oligomeric state of torsinA did not
change following interaction with LULL1, and LULL1 remained highly mobile whether or
not it was transiently engaging and affecting torsinA. These results are the first
demonstration that torsinA indeed assembles into the kind of oligomer expected of an
AAA+ protein, and establish that LULL1 changes torsinA targeting without affecting its
fundamental structure. Our mutagenesis experiments indicate that an N-terminal
hydrophobic sequence distinct from torsinA’s core AAA+ domain [13, 42] is required for
this retargeting (Figure 2-4). It is therefore attractive to hypothesize that interaction with
LULL1 causes a conformational change involving this N-terminal domain, enhancing
torsinA’s affinity for something within the NE. Future work will focus on defining these
states and further delineating the mechanism(s) responsible for controlling the transition
between the ER-distributed and NE-enriched forms of torsinA.
Importantly, we found that DYT1-associated ΔGAG-torsinA is also redirected to
the NE by LULL1 (Figures 2-1 & 2-8), but once there it is less effective at enacting
changes in NE structure and protein composition (Figure 2-8). These results suggest a
molecular loss-of-function that may correlate with the previously described inability of
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ΔGAG-torsinA to rescue the lethality of torsinA knock-out in the mouse [5, 6]. These
functional deficiencies could ultimately contribute to the development of DYT1 dystonia.
The fact that torsinA is now established to be an oligomeric enzyme (Figure 2-3)
supports the possibility that mixed oligomers containing wild-type and mutant subunits
could turn a loss-of-function mutation into a dominantly inherited trait. Separately, data
from other groups have shown that overexpressing ΔGAG-torsinA can have toxic effects
on the function of the secretory pathway [43], raising the possibility that a combination of
the loss-of-function shown here and gain-of-function shown elsewhere might explain the
dominant inheritance of DYT1 dystonia. The discovery that LULL1 regulates the
distribution and activity of torsinA within the ER and the NE paves the way for future
exploration of how changes in its activity correlate with the development of disease.
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Figure Legends
Figure 2-1. LULL1 promotes relocalization of TorsinA to the NE.
(A) Distribution of torsinA-mGFP, ΔGAG-torsinA-mGFP and LULL1-myc expressed
individually in U2OS cells. (B) Distribution of co-expressed torsinA-mGFP and LULL1myc, shown in maximum intensity projections (B, B’’) and a confocal slice (B’). (C)
Distribution of co-expressed ΔGAG-torsinA-mGFP and LULL1-myc. (D) Distribution of
co-expressed Sec61γ-mGFP and LULL1-myc. (E) Distribution of co-expressed Sec61γmGFP and torsinA-myc. (A-C, E) are all maximum intensity projections of confocal zseries. (D) is an epifluorescence image. Scale bars, 10 µm.

Figure 2-2. Live imaging and FRAP analysis of LULL1-directed torsinA relocalization to
the NE. (A) Selected images from time-lapse observation of torsinA-mGFP in cells
expressing unlabelled LULL1-myc. (B) Selected images from zoomed-in portion of a field
similar to (A). TorsinA-mGFP fills the NE over an average time of 45 minutes (+/- 26 min,
n = 52 cells). (C) Time series showing FRAP of LULL1-mGFP in U2OS cells. (D)
Comparable time series showing FRAP of torsinA-mGFP in U2OS cells. (E) Time series
showing FRAP of torsinA-mGFP in a cell coexpressing LULL1-mCherry. (E’)
Corresponding time series showing FRAP of LULL1-mCherry in a cell expressing
torsinA-mGFP. (F) Diffusion coefficient values for LULL1 and torsinA –mGFP,
determined as described in [23, 47] from recovery curves such as those shown in
Supplemental Figure S3. LULL1’s diffusion coefficient averages ~0.4 µm2/s in U2OS
cells and in cells coexpressing torsinA-mGFP, while torsinA’s diffusion coefficient ranges
between 0.09 and 0.13 µm2/s in both U2OS and LULL1-mCherry-expressing cells. For
comparison, luminal ER-GFP has a Deff of ~10 um2/s [23], an ER-localized
transmembrane protein has a Deff of ~0.4 um2/s [23], and a polysome-associated
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translocon has a Deff of ~0.05 um2/s [48].
Scale bars, 10 µm.

Figure 2-3. Blue Native PAGE separation of torsinA oligomers. (A) BN-PAGE separation
of untagged TorsinA expressed in U2OS cells. TorsinA is detectable as a species of
approximately hexameric size in 0.25% w/v DDM; this species is decreased in
abundance in the presence of higher concentrations of DDM. (B) 2D PAGE of untagged
torsinA expressed in U2OS cells. TorsinA was solubilized in 0.5% w/v digitonin, run on
1st dimension Blue Native PAGE, then separated in a second dimension by SDS-PAGE.
(C) Blue Native PAGE separation of untagged torsinA expressed alone or with LULL1myc, solubilized in 1% w/v digitonin.

Figure 2-4. Structural requirements for LULL1-directed torsinA redistribution.
(A) Schematic of torsinA structure. (B) Representative epifluorescence images of
torsinA-mGFP containing indicated mutation in LULL1-myc (not shown) expressing
U2OS cells. Scale bars, 10 µm. (C) Quantitation of redistribution. n>150 cells for each
mutant. (D) Immunoblots of equal fractions of aqueous and hydrophobic phases from a
Triton-X114 phase partitioning assay show that wild type torsinA partitions with the
hydrophobic phase, but shifts to the aqueous phase after deleting the protein’s Nterminal hydrophobic domain (amino acids 26-43). (E) E171Q-torsinA-mGFP
immunoprecipitates efficiently with LULL1-myc, and deletion of the N-terminal
hydrophobic domain (amino acids 26-43) does not abolish binding.

Figure 2-5. Removing LULL1 by RNAi reverses enrichment of ΔGAG-torsinA in NE. (A)
Immunoblot of lysates from cells transduced with the indicated shRNA probed for
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LULL1. (B and C) Representative confocal images of ΔGAG-torsinA-mGFP and ER-RFP
coexpressed in control U2OS cells (B) vs. in U2OS cells transduced with shRNA #2088
(C). (D) Relative fluorescence intensity of ER-RFP, wt-torsinA-mGFP, and ΔGAGtorsinA-mGFP in NE vs. ER. ∆GAG-torsinA-mGFP has a significantly higher NE/ER ratio
in U2OS cells than in LULL1 knockdown cells (p = 0.003). The NE/ER ratio of ∆GAGtorsinA-mGFP is not significantly different from that of ER-RFP in LULL1 knockdown
cells (p = 0.19). n > 21 cells for each condition. Scale bars, 10 µm.

Figure 2-6. Redistributed torsinA displaces LINC complex components from the NE. (A)
Nuclear pore components stained with mAb414 in cells expressing LULL1-myc (not
shown) and torsinA-mGFP, epifluorescence image. (B) Emerin in cells expressing
LULL1-myc (not shown) and torsinA-mGFP, epifluorescence image. (C) Sun1 in cells
expressing LULL1-myc (not shown) and torsinA-mGFP. Shown are maximum intensity
projections of a confocal z-series. (C’) XZ orthogonal view: top, torsinA-mGFP; bottom,
Sun1. Approximate position of xz slice is marked by asterisk in (C). (D) Sun2
immunostaining in the same cells. 60% of cells containing torsinA-mGFP in the NE lack
a nuclear rim of Sun2, compared to 4% of untransfected cells (n > 110 for each). (D’) XZ
orthogonal view: top, torsinA-mGFP; bottom, Sun2. Approximate position of xz slice is
marked by asterisk in (D). (E) Sun2-GFP and torsinA-TagRFP in cells also expressing
LULL1-myc, projected z-series. (F) Nesprin2-Giant and torsinA-mGFP in cells also
expressing LULL1-myc (not shown), imaged by epifluorescence microscopy. 56% of
cells containing torsinA-mGFP in the NE lack NE-localized nesprin2-Giant, compared to
1% of untransfected cells (n >35 for each). (G) Transfected nesprin3α-GFP in cells also
expressing torsinA-TagRFP and LULL1-myc (not shown), projected z-series. Scale bars,
10 µm.
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Figure 2-7. Sun2 protein levels are decreased as a consequence of LULL1-directed NE
localization of torsinA. Western blot analysis of cells coexpressing LULL1-myc and
torsinA-mGFP for 12 or 22 hours and sorted by GFP fluorescence indicates that Sun2
protein levels decrease, while NPCs (mAb 414) and a representative ER protein
(Sec61β) are not affected.

Figure 2-8. Comparison of wild-type and ΔGAG-torsinA-mGFP effects on the NE. (A)
Comparison of NE in cells expressing LULL1-myc (not shown) with redistributed wildtype torsinA-mGFP (left) and ΔGAG-torsinA-mGFP (right). NE membrane distortions
occur in 68% of cells with NE-localized wild-type torsinA (n = 136) and in 7% of cells with
NE-localized ΔGAG-torsinA (n = 74). Shown are maximum intensity projections of
confocal z-series, with orthogonal xz views in (A’). Approximate position of xz orthogonal
slice marked by asterisk in (A). (B) Effect of LULL1-redistributed ΔGAG-torsinA-mGFP
on Sun2. Projected z-series, with orthogonal views of ΔGAG-torsinA (top) and Sun2
(bottom) in (B’). Approximate position of xz slice is marked by asterisk in (B). (C) Timelapse imaging of Sun2-GFP and torsinA-TagRFP in LULL1-myc expressing cells. (D)
Time-lapse imaging of Sun2-GFP and ΔGAG-torsinA-TagRFP in LULL1-myc expressing
cells. The median delay between the onset of torsinA-TagRFP redistribution and
initiation of Sun2-GFP loss was <15 min (between consecutive frames) for wild type (+/20 min, n = 32 cells) and 420 min for ΔGAG-TorsinA (+/-378 min, n = 33 cells). Scale
bars, 10 µm.

Figure 2-9. Model of LULL1-dependent torsinA function at the NE. LULL1 interacts with
the torsinA hexamer in the peripheral ER, which promotes an activating change in
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torsinA that requires catalytic residues and association with the membrane. TorsinA then
moves into the NE, where it displaces components of LINC complexes, including Sun2,
nesprin2-Giant, and nesprin3. This gives torsinA the ability to alter contacts between the
nuclear lamina (or nuclear contents), the nuclear envelope membranes, and the
cytoskeleton.

Supplemental Figure Legends
Figure 2-S1. Differently tagged torsinAs can redistribute to the NE, and differently
tagged LULL1s can target TorsinA to the NE. (A) Untagged, myc-tagged, and TagRFPtagged versions of torsinA all redistribute to the NE when coexpressed with LULL1-myc.
(B) LULL1-mGFP also sends torsinA-myc to the NE. Scale bars, 10 µm.

Figure 2-S2. A wide expression range of LULL1 is capable of inducing redistribution of
transiently transfected torsinA. (A-C) LULL1-myc is expressed in a tetracyclineresponsive manner over a wide range of tetracycline dosage. Low (A, 1 ng/mL tet),
intermediate (B, 10 ng/mL tet) and high (C, 1 µg/mL tet) levels of LULL1 expression are
all capable of causing redistribution of coexpressed torsinA-mGFO to the NE. (D)
Western blot comparison of overexpressed myc-tagged LULL1 (upper band) to
endogenous LULL1 (lower band) expression in U2OS cells. LULL1 is expressed at low
levels in U2OS cells; induction of LULL1-myc to ~5 times endogenous expression levels
(with 1 ng/mL tet) is capable of inducing torsinA redistribution to the NE.

Figure 2-S3. ΔGAG-torsinA-mGFP enriches in the NE over time when coexpressed with
LULL1-myc, but not when expressed alone in U2OS cells. (A) Time lapse live imaging of
ΔGAG-torsinA-mGFP coexpressed with LULL1-myc and (B) imaging of ΔGAG-torsinA-
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mGFP expressed alone. In both, fluorescent protein signal increases over the imaging
period, but partitioning into the NE increases over time in (A) but not in (B). Thus, ΔGAGtorsinA-mGFP responds to the presence of LULL1 with a time-dependent enrichment in
the NE.

Figure 2-S4. FRAP parameters for LULL1-mGFP and torsinA-mGFP. (A)
Representative fluorescence recovery curves for LULL1-mGFP in U2OS cells (“LULL”),
torsinA-mGFP in U2OS cells (“torsinA”), and torsinA-mGFP in LULL1-mCherryexpressing cells (“torsinA+LULL”). TorsinA recovers to a much lesser extent than LULL1.

Figure 2-S5. Sun2 is only displaced from the NE by coexpressed LULL1 and torsinA.
(A-C) Sun2’s NE localization is not changed by torsinA-myc expression (A), E171QtorsinA-myc expression (B), or ΔGAG-torsinA-myc expression (C). Compare to
displacement of Sun2 caused by LULL1-myc and torsinA-mGFP in Figure 5.
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/3
02
Δ3

71
E1

K1

08

A

Δ26-43

Q

03

A.

1

332
21 70
signal sequence
hydrophobic domain
AAA+ domain

B.
C.

x5

un

d

E.

IP

Aq
u

eo

us
Hy
dr
op
ho

bi

c

D.

bo

Δ26-43

un

K108A

at
e

E171Q

lys

wtA

IB: E171Q-TorA-mGFP

TorA mGFP

IB: E171Q/Δ26-43-TorA-mGFP

Δ26-43 TorA mGFP

IP: LULL1-myc

64

Figure 2-5
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Chapter 3

Static retention of the lumenal monotopic membrane
protein torsinA in the endoplasmic reticulum
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Abstract
TorsinA is a membrane-associated enzyme in the endoplasmic reticulum (ER) lumen
that is mutated in DYT1 dystonia. How it remains in the ER has been unclear. We report
that a hydrophobic N terminal domain (NTD) directs static retention of torsinA within the
ER by excluding it from ER exit sites, as has been previously reported for short
transmembrane domains (TMDs). We show that despite the NTD’s physicochemical
similarity to TMDs, it does not traverse the membrane, defining torsinA as a lumenal
monotopic membrane protein and requiring a new paradigm to explain retention. ER
retention and membrane association are perturbed by a subset of non-conservative
mutations to the NTD, suggesting that a helical structure with defined orientation in the
membrane is required. TorsinA preferentially enriches in ER sheets, as might be
expected for a lumenal monotopic membrane protein. We propose that the principle of
membrane-based protein sorting extends to monotopic membrane proteins, and identify
other proteins including the monotopic lumenal enzyme cyclooxygenase 1
(prostaglandin H synthase 1) that share this mechanism of retention with torsinA.
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Introduction
Early-onset (DYT1) torsion dystonia is a neurological movement disorder [1] caused by a
glutamic acid deletion (ΔE) in the catalytic domain of torsinA [2]. TorsinA is an AAA+
ATPase of the endoplasmic reticulum (ER) and contiguous nuclear envelope (NE). The
specific cellular functions ascribed to torsinA vary widely despite the fact that it has been
a decade since the protein was first described and linked to dystonia [3]. Based on its
membership in the AAA+ family of ATPases [2, 4], it is likely that torsinA disassembles
or changes the conformation of a protein or protein complex in the ER or NE. The ΔE
mutation is thought to compromise this function [5, 6].
TorsinA is targeted to the ER lumen by an N-terminal signal peptide. Analyses of
torsinA’s subcellular localization, processing, and glycosylation show that the signal
peptide is cleaved and the mature protein resides in the lumen of the ER [7-9] where it is
a stable protein [10] [11]. TorsinA’s binding partners include the transmembrane proteins
LULL1 in the ER and LAP1 in the NE [12] [13]. Abnormalities in NE structure [6, 14] and
effects on NE-localized LINC complex proteins [15] when torsinA levels are perturbed
suggest an important function for this enzyme specifically at the NE. Other studies point
to additional functions elsewhere in the ER [16].
The steady state localization of torsinA in the ER and NE demands that it
escapes forward flux out of the ER into the secretory pathway. This is a significant issue
for all ER resident proteins, and the underlying mechanisms are what define the
composition of the ER. Proteins intended for efficient secretion are concentrated in
nascent COPII vesicles at ER exit sites (ERES) by specific interactions with subunits of
the COPII coat or, in the case of lumenal proteins, with transmembrane receptors that in
turn interact with COPII subunits [17]. However, proteins without specific export signals
also leave the ER in COPII vesicles at a rate referred to as bulk flow. For soluble
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proteins in the ER lumen, recent quantitative measurements indicate that bulk flow
empties the equivalent of half of the lumenal volume every 40 minutes [18]. Proteins that
leave the ER by bulk flow may return to the ER in COPI vesicles if they are recognized
by a recycling receptor. The prototype for this is the KDEL receptor that recycles lumenal
proteins with the tetrapeptide KDEL at their C-terminus [19]. For membrane proteins
there is less quantitative information about the rate of bulk flow. There are some
membrane proteins that never leave the ER and are statically retained by their TMD [2025]. This retention is attributed to preferential partitioning of short TMDs into the thinner
and less ordered membrane of the ER, and the best characterized of these TMDs has
been shown to partition differentially among subdomains of the ER [24]. However, that
there is a bulk flow of membrane proteins is clear from the need for the TMD-specific
recycling receptor, Rer1 [26], and from studies showing that small increases in the
hydrophobicity of ER-retained TMDs allow their escape from the ER [22-25].
How does torsinA achieve its localization to the ER? An early study indicated that
a hydrophobic domain at the N terminus of the protein was required for ER localization
of human torsinA in heterologous cells [8]. However, the mechanism underlying
localization was unclear as neither the N-terminal domain nor other regions of the
torsinA sequence contain any canonical targeting motifs. A subsequent proposal was
that torsinA remains in the ER lumen because of protein-protein interactions with other
resident proteins [27]. The facts that the N terminus is not involved in interactions with
known abundant binding partners including LULL1 in the ER and LAP1 in the NE [28],
and that even highly overexpressed torsinA remains in the ER [7], suggest that this is
unlikely. These discrepancies raise the question of whether a previously unknown
mechanism might be responsible for keeping torsinA and similar proteins in the ER. In
this study, we provide evidence that torsinA’s N-terminal domain is a monotopic
membrane associating domain that is directly responsible for static retention in the ER
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lumen. Further, we identify other membrane proteins that appear to behave similarly,
providing new insight into protein sorting in the early secretory pathway.
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Methods
Plasmids
TorsinA-mGFP and Δ26-43-torsinA-mGFP are as described previously [28]. (1-67), (143), and (1-25) torsinA-mGFP were made by PCR amplification of the indicated
sequences with primers containing XhoI and EcoRI sites, followed by ligation into the
mGFP-containing pEGFP-N1 vector. All NTD substitution and insertion mutations were
introduced by QuikChange mutagenesis. MBP-(21-43) and MBP-(21-67) were made by
PCR amplification of the corresponding sequence with primers containing EcoRI and
BamH1 restriction sites, followed by ligation into pMAL-c (NEB). The Lep reporter vector,
Lep 13A/6L, and 18A/1L constructs were generously provided by Gunnar von Heijne
(Stockholm University). The NTD was inserted into the Lep reporter vector as described
[29]: oligonucleotides encoding residues 21-43 of human torsinA in forward (Nlum-Ccyto
orientation) or reverse (Ncyto-Clum orientation) sequence were annealed together and
ligated into Lep vector that had been digested with SpeI and KpnI. The COX-1
expression vector was provided by Robert J. Kulmacz (University of Texas, Houston).
VSVG-(ts045)-GFP [30] and NPY-GFP [31] were as described.

Reagents
A peptide consisting of residues 21-43 of human torsinA, an aminohexanoic acid linker
and a biotin tag was synthesized and verified by mass spectrometry by the W.M. Keck
Foundation Biotechnology Resource Laboratory (Yale University). 7-methyl diguanosine
triphosphate cap structure analog and amylose resin were from NEB (Ipswich, MA).
Rabbit reticulocyte lysate, canine rough microsomes, and NTPs were from Promega
(Madison, WI). Complete protease inhibitor cocktail was from Boehringer (Ridgefield,
CT). Protein G Sepharose was from GE/Amersham (Piscataway, NJ). Antibodies used
include: mouse monoclonal anti-bCOP (clone maD, Sigma), mouse monoclonal anti79

Sec31A (BD Biosciences, San Jose, CA), mouse monoclonal anti-GFP (clone B-2,
Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-GFP [32], rabbit polyclonal antiHis (Cell Signaling, Beverley, MA), mouse monoclonal ERGIC-53 (Alexis Biochemicals,
San Diego, CA), and rabbit polyclonal anti-COX-1 (Cayman Chemical, Ann Arbor, MI).
All other chemicals were from Sigma (St. Louis, MO).

Cell culture
U2OS cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS) and
L-glutamine. Transient transfections were performed with Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.

Immunofluorescence
For temperature block experiments, coverslips were transferred to HEPES-buffered
media supplemented with 10% FBS and L-glutamine, and incubated for 2 h in a water
bath set to 10°C or 15°C. For BFA treatment, cells were transfected approximately 16 h
before adding 1 mM BFA to the medium for 4 h. Cells were washed in PBS and then
fixed with 4% paraformaldehyde in PBS for 10 min, followed by permeabilization in 0.2%
Triton-X-100 for 10 min. Coverslips were blocked in 2% goat serum in PBS for 1 h
before incubation with primary and Alexa Fluor-conjugated secondary antibodies. For
selective permeabilization with digitonin, cells were washed once in PBS before transfer
to 0.0025% digitonin in PBS for 5 min at 4°C. Cells were then fixed, blocked, and stained
as described above. Coverslips were mounted in Mowiol (Calbiochem, San Diego, CA).
Epifluorescence imaging was performed with a Diaplan microscope (Leica
Microsystems, Bannockburn, IL) using a 63 x 1.4 NA objective and a Zeiss MRm camera
(Thornwood, NY). Confocal imaging was performed on an Olympus FV500 microscope
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using a 60 x 1.4 NA objective. Brightness and contrast were adjusted with Adobe
Photoshop (Adobe Systems, San Jose, CA) and composite figures were prepared in
Adobe Illustrator.

Quantifying colocalization
To monitor localization of candidate cargo proteins to ER exit sites, cells expressing the
indicated candidate proteins were costained for Sec31A and viewed by confocal
microscopy. Colocalization analysis was restricted to ERES as described [33]. Briefly, a
binary mask of the Sec31A signal was created, manually thresholded, and added as an
additional channel in the RGB image. Colocalization was then quantified in the regions
defined by the mask, and expressed as Pearson’s correlation coefficient. Colocalization
was analyzed in >20 cells for each condition reported. Statistical comparison of data sets
was performed by t-test.

Immunoprecipitation from culture medium
60-mm plates of U2OS cells were transiently transfected with the indicated plasmids and
incubated for ~16 h. For experiments involving BFA treatment, fresh media was added
with or without 1 mM BFA and cells were incubated for an additional 6 h. The media was
then collected, placed on ice, and supplemented with 1 mM PMSF, 1x complete
protease inhibitors, and 5 mM EDTA. The media was centrifuged at 4000 rpm for 10 min
at 4°C to remove cell debris. Protein-G-sepharose beads covalently conjugated to
affinity purified rabbit anti-GFP antibody were then added to the supernatant and
incubated 2h at 4°C. The beads were then pelleted and washed 3 x in PBS/0.5% TritonX-100 with PMSF and protease inhibitors, then boiled in 50 uL SDS-PAGE sample buffer
for analysis. The cells, meanwhile, were scraped and pelleted in PBS and solubilized in
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~300 ul PBS/0.5% Triton-X-100 with PMSF and protease inhibitors for 30 min at 4°C.
The insoluble material was pelleted at 15,000 x g for 10 min at 4°C. An aliquot of the
supernatant was boiled in SDS-PAGE sample buffer. 15 ul each of the cell lysate and
immunoprecipitate were separated on SDS-PAGE and analyzed by immunoblotting.

Far UV circular dichroism
Far UV CD spectra were recorded using a 0.2 mm pathlength cuvette in a Jasco J715
spectropolarimeter at ambient temperature, scanning from 260 to 190 nm in 0.2 nm
steps at 100 nm/min, averaging 5 spectra per condition. Peptide was diluted to 1 mg/ml
in 10 mM sodium phosphate buffer, pH 7.0 supplemented with trifluoroethanol (Sigma)
or SDS as indicated. Solvent spectra gave negligible signal and were subtracted from
sample spectra. Data shown are expressed as mean residue ellipticity (deg cm2/dmol).
The percentage of α-helix was estimated from the molar ellipticity at 222 nm (θ222) using
the equation fh = (θ222/θ222a) + (iκ/N) where fh is the fraction in the α-helical form, θ222 is
the mean residue ellipticity at 222 nm, θ222a is the molar ellipticity at 222 nm for an
infinitely long α-helix (-39,500 deg cm2/dmol), i is the number of helices (assumed to be
one), κ is a wavelength specific constant (2.6 at 222 nm), and N is the number of peptide
bonds in the peptide (defined as 26 for the 23 residues of torsinA plus aminohexanoic
acid linker and biotin) [34].

Purification of MBP fusion proteins
BL21(DE3) Escherichia coli transformed with MBP, MBP-21-43, or MBP-21-67 were
grown in 0.5 liters of Terrific Broth and induced to express protein by addition of
isopropyl 1-thio-β-D-galactopyranoside and shaking for 3 hours at room temperature.
After pelleting, bacteria were lysed in 20 mM Tris pH 7.4, 200 mM NaCl, 1 mM EDTA,
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5% glycerol, 1 mM PMSF by sonication. N-octyl glucoside was added to 1% w/v and
samples were incubated for 30 min at 4°C, followed by centrifugation at 9000 x g for 20
min at 4°C. Amylose resin was added to the supernatant and incubated overnight at 4°C.
Unbound material was removed by washing in lysis buffer, and proteins were eluted in
lysis buffer supplemented with 10 mM maltose. MBP-21-67 was incubated sequentially
with 10 mM DTT (30 min at room temperature) and 50 mM NEM (30 min at room
temperature) to reduce and alkylate cysteines. For use in proteoliposome preparations,
proteins were dialyzed into 10 mM sodium phosphate pH 7.0, 150 mM NaCl, 30 mM noctyl glucoside overnight at 4°C. Proteins were clarified by centrifugation at 200,000 x g
for 1 hr at 4°C before use in proteoliposome preparations. Protein concentrations were
quantitated by Bradford assay with BSA as standard and snap frozen.

Proteoliposome preparation and characterization
1,2-dioleoyl-sn-glycerol-3-phosphocholine (DOPC) was purchased from Avanti Polar
Lipids (Alabaster, AL). 60 µg of DOPC in chloroform was dried under a stream of
nitrogen and then under vacuum for several hours. The lipid film was resuspended in 1
mL of 10 mM sodium phosphate, pH 7.0, 150 mM NaCl, and 30 mM n-octyl glucoside,
followed by addition of MBP fusion proteins for a final protein:lipid ratio of 2:1 by weight.
Liposomes were generated by removing detergent by dialysis at 37°C in 2000 Da
molecular weight cutoff dialysis cassettes (Pierce) against 3 x 1 L changes of buffer
lacking detergent for 48 hours. To determine how much protein was associated with
liposomes, samples were loaded on the bottom of a sucrose cushion and centrifuged to
separate liposomes from unincorporated protein by flotation. A 150 µL aliquot of the
proteoliposome preparation was mixed with 100 µL 2.2 M sucrose/10 mM sodium
phosphate pH 7.0/150 mM NaCl in a polycarbonate centrifuge tube. This mixture was
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overlaid with a 200 µL cushion of 0.75 M sucrose/10 mM sodium phosphate pH 7.0/150
mM NaCl, then with a 50 µL layer of buffer lacking sucrose. The step gradients were
centrifuged for 80 min at 240,000 g (55,000 rpm) in a Beckman TLS 55 rotor. Three
fractions were collected from the bottom using a syringe (250 µL, 150 µL, and 100 µL).
Aliquots of each fraction were analyzed by SDS-PAGE and Coomassie stain.

In vitro translation
Template was generated by amplifying the coding region of interest using a 5’ primer
that contains the T7 promoter sequence and a 3’ primer that anneals just beyond the
stop codon. The resulting product was purified using the Qiagen PCR purification kit and
eluted in 50 µL water. 2 µL of the product was then mixed with 0.2 µL T7 RNA
Polymerase (Promega), 0.2 µL water, and 7.6 µL T1 mix (final concentration 40 mM
HEPES, pH 7.6, 6 mM MgCl2, 2 mM spermidine, 10 mM DTT, 500 µM ATP, 500 µM
UTP, 500 µM CTP, 100 µM GTP, and 500 µM 7-methyl diguanosine triphosphate). This
transcription mix was incubated for 1 h at 37°C, then RNA was precipitated by adding
1.5 µL 5 M NaCl and 24 µL of 100% ethanol and incubating at -20°C overnight. The
RNA was pelleted at 15,000 x g for 30 min at 4°C and resuspended in 10 µL of
nuclease-free water. In vitro translation reactions were then set up as follows: 12.5 µL
rabbit reticulocyte lysate, 0.5 µL TnT reaction buffer (Promega), 0.5 µL amino acids –
Met (Promega), 1 µL 35S-methionine (Perkin Elmer), 5 µL of the freshly prepared
transcript, 2 µl canine rough microsomes, and water to a 25 µL final reaction volume.
Translation reactions were incubated for 1 h at 30°C. The reaction was stopped by
boiling in SDS-PAGE sample buffer; samples were then separated by SDSPAGE and
detected by autoradiography.
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Sorting proteomics data
[35] identified 1430 proteins of the secretory pathway proteome by mass spectrometry
analysis of rat liver rough microsome (RM), smooth microsome (SM), Golgi, and COPI
vesicle fractions. To identify ER resident proteins similar to torsinA, these 1430 proteins
were sorted using the following criteria: (1) presence of a predicted cleavable signal
peptide (Gilchrist et al Table S1C); (2) similar biochemical behavior to torsinA in salt
extraction and Triton X-114 partitioning experiments (Gilchrist et al Table S3B); and (3)
enrichment in rough microsomal and smooth microsomal fractions over Golgi and COPI
fractions (Gilchrist et al Table S3D). Approximately 150 proteins including torsinA
matched these criteria. Literature and database searches were then used to eliminate
proteins known to be localized to different compartments and identify proteins for which
the cell biological data are consistent with a lumenal orientation in the ER, and for which
other established ER retention or retrieval mechanisms either do not exist or do not fully
explain sorting behavior. Selected proteins of interest from this set are highlighted in
Table 1.

Transmembrane segment prediction
To explore the potential for hydrophobic sequences in torsinA to adopt a TMD
configuration, the full sequence of human torsinA was analyzed in the MPEx program
(http://blanco.biomol.uci.edu/mpex/) [36] in biological hydrophobicity scale mode
(“translocon TM analysis”). The predicted ΔG for membrane insertion (ΔGpred) was
calculated for the MPEx-identified protein sequence and mutants to that region using the
dGpred prediction algorithm (http://dgpred.cbr.su.se/) [37]; these values are reported in
Figure 5A.
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Triton-X-114 phase separation and Fluorescence recovery after photobleaching
(FRAP) were performed as described in [28]. SDS-PAGE and Immunoblotting were
performed as described [32].

Linescan analysis
To analyze ER subdomain preference, cells expressing the indicated proteins were fixed
and costained for CRT as a bulk ER marker. The distribution of red and green
fluorescence was analyzed by linescan in Metamorph. Two lines per cell were drawn
from the nuclear periphery to the cell edge, and a line in a cell-free region of the
coverslip was drawn for background measurement. The average background intensities
were subtracted and the intensities normalized to 1 before replotting the data in
Microsoft Excel.
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Results
TorsinA is a life-long ER resident
While all transmembrane and secreted proteins are transiently found in the ER, proteins
that reside in the ER either never leave and are said to be statically retained or are
retrieved from the ER-to-Golgi intermediate compartment (ERGIC) by COPI-mediated
retrograde transport. Both are commonly referred to as ER retention mechanisms. To
determine how torsinA remains in the ER, we incubated cells expressing mGFP-tagged
torsinA or cargo proteins at temperatures that selectively block different trafficking steps.
At 15°C, COPII-mediated transport from the ER proceeds but recycling and forward
transport from the ERGIC do not, causing all proteins that leave the ER to accumulate in
the ERGIC [38] while statically retained ER proteins are unchanged. At 10°C, COPII
components assemble together with cargo at ER exit sites (ERES) but do not generate
free vesicles [39-41]. VSVG-(ts045)-mGFP, a plasma membrane-targeted
transmembrane protein that directly interacts with COPII, accumulated dramatically with
the COPI component βCOP in the ERGIC (Figure 3-1A). TorsinA-mGFP, in contrast,
remained distributed throughout the ER and was absent from the ERGIC after incubation
at 15° C (Figure 3-1B). After incubation at 10°C, GFP fusions of VSVG-(ts045), the
secreted neuropeptide Y (NPY), and ER-GFP appeared at ERES marked by the COPII
component Sec31A, but torsinA-mGFP did not (Figure 3-2A-D). Quantitating
colocalization confirmed that VSVG-(ts045), NPY, and ER-GFP are present in ERES at
10°C, while torsinA is not (Figure 3-2E). Notably, the large increase in colocalization of
VSVG-(ts045) with Sec31A at 10°C vs. 39.5°C is because VSVG-(ts045) is a
temperature sensitive mutant protein that misfolds at 39.5°C and interacts with folding
chaperones that keep it away from ERES; once folded at a permissive temperature its
diacidic COPII interacting motif promotes rapid accumulation at ERES [40]. The fact that
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torsinA avoids ERES to an extent comparable to misfolded VSVG, while ER-GFP is
readily detectable in ERES despite the lack of a forward transport signal, suggests
specific exclusion of torsinA from ERES. This exclusion is similar to that previously
described for short TMD-containing proteins (Ronchi et al., 2008). Finally,
overexpressed torsinA-mGFP is efficiently retained in the ER at physiological
temperature (Figure 3-1B) and is completely EndoH sensitive [7], implying that torsinA
rarely leaves the ER. Altogether, these data indicate that torsinA is statically retained in
the ER.

An N-terminal domain (NTD) directs ER retention
Mature torsinA consists of a hydrophobic N-terminal domain (NTD), a short linker region,
and the AAA+ domain (Figure 3-3A). Building on an earlier report showing that deleting
the NTD led to secretion of human torsinA from Drosophila S2 cells [8], we deleted
residues 26-43 from human torsinA and found that the mutant protein appeared in the
Golgi (Figure 3-3B) and in the cell medium (Figure 3-3C) when expressed in human
U2OS cells. Both changes were blocked by brefeldin A (BFA), indicating that without its
NTD, torsinA traffics through the classical secretory pathway. Deletion of the N terminus
allows torsinA to access ERES to an extent comparable to the lumenal marker ER-GFP
(Figure 3-4), consistent with truncated torsinA exiting the ER by bulk flow transport.
While the deletion led to secretion of all torsinA variants analyzed (Figure 3-3C),
changes in intracellular distribution were most apparent in cells expressing the Δ26-43
deletion in combination with an E171Q mutation in the AAA+ domain. A likely
explanation for this difference is that the E171Q mutant is trapped in its ATP-bound state
[14] and may therefore be more conformationally stable than the wild-type enzyme,
which can cycle through different nucleotide states. In support of this, OOC-5, the C.
elegans ortholog of torsinA, is more thermostable in the presence of nucleotide [42] and
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protein stability often correlates with the efficiency of secretion [43].
To determine whether the NTD is sufficient for ER retention or whether the AAA+
domain is also required, we attached torsinA’s signal sequence (1-25), the signal
sequence plus the NTD (1-43), or the entire pre-AAA sequence (1-67) to mGFP. (1-43)mGFP and (1-67)-mGFP localized to the ER while (1-25)-mGFP was present in the
Golgi (Figure 3-3D). Furthermore, only (1-25)-mGFP was detectable in the cell medium
(Figure 3-3E). The NTD is thus both necessary and sufficient for ER retention, and
determining why it stays in the ER should delineate the mechanism controlling torsinA
localization.

Physical properties of the NTD
The NTD contains a pattern of hydrophobic and nonpolar residues that is well conserved
among torsinA orthologs (Figure 3-5A), suggestive of a membrane-associating domain.
As previously shown, torsinA partitions almost completely into the hydrophobic phase in
Triton X-114 phase separation experiments; this is reversed by deleting the NTD (Figure
3-5B) [8, 28]. The NTD alone controls this partitioning (Figure 3-5B) providing
hydrophobic behavior typical of a transmembrane domain (TMD) [44]. To determine
whether cellular factors or modifications contribute to this hydrophobicity, we purified the
NTD fused to maltose binding protein from E. coli. Residues 21-43 or 21-67 of torsinA
shifted a fraction of this 45 kDa soluble protein into the hydrophobic phase (Figure 35C), confirming that hydrophobicity is intrinsic to the NTD and is not the result of posttranslational modification or binding to another protein.
Since α-helices are the predominant secondary structure found in membraneassociating domains [45], we analyzed the secondary structure of torsinA’s NTD. Far UV
circular dichroism shows that a synthetic peptide corresponding to residues 21-43 of
torsinA is unstructured in aqueous buffer, but becomes partially helical as
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trifluoroethanol (TFE) is added (Figure 3-5E). To test whether helicity also increases in a
membranous environment, we added detergent. In the presence of 20 mM SDS, the
NTD peptide became as helical as in 50% TFE (Figure 3-5E). This stabilization of NTD
structure in detergent micelles implies that the peptide may also be helical in the lipid
bilayer [46].

The NTD associates directly and stably with membranes
To study the behavior of the NTD in cellular membranes, we analyzed the diffusion of an
NTD-mGFP fusion protein by fluorescence recovery after photobleaching (FRAP) [47].
While free GFP in the ER lumen has a diffusion coefficient (Deff) of 7.67 +/- 0.44
µm2/sec, (1-67)-mGFP diffuses at least an order of magnitude slower (0.69 +/- 0.07
µm2/sec) (Figure 3-5D). Single-pass TMD proteins of the ER have a similar Deff [47]. The
NTD’s behavior in cellular membranes is thus most comparable to that of a membrane
protein.
To determine whether the NTD associates directly with membranes, we asked
whether residues 21-67 of torsinA fused to MBP could be co-reconstituted into
proteoliposomes with phosphatidylcholine, which is a major component of the ER
membrane [48]. We combined protein with 1,2-dioleoyl-sn-glycerol-3-phosphocholine
(DOPC) lipid in the presence of n-octyl glucoside, then generated liposomes by dialyzing
away the detergent. Liposomes were separated from soluble protein by flotation through
a sucrose step gradient. The MBP-NTD fusion protein floated to the top of a sucrose
gradient with the lipids, while the MBP protein remained at the bottom (Figure 3-5F).
This experiment shows that the NTD associates directly with membranes in the absence
of other proteins or modifications, and thus has the ability to mediate stable and direct
association with the ER membrane.
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The NTD is a monotopic membrane interacting domain
Proteins known to be statically retained in the ER appear to rely on preferential
partitioning of short and/or polar TMDs into the thinner and less ordered ER bilayer [2325]. We have established that torsinA’s NTD is necessary and sufficient for ER retention
and associates directly with membranes. We do not, however, know how the NTD is
positioned in the membrane. While originally thought to be a transmembrane protein [8,
49], torsinA has more recently been termed a peripheral membrane protein based on
partial extraction from membranes by alkaline wash and modification of a glycosylation
site inserted into the NTD [27]. However, bona fide TMD proteins can be sensitive to
alkaline extraction [50] and inserting an Asn residue could itself perturb handling of a
TMD by the translocon [37]. Indeed, based on a biologically based TMD prediction
algorithm [36], torsinA’s NTD contains a 23-residue sequence (Ile24 - Phe46) that might
traverse the bilayer (Figure 3-7A below). Because both torsinA’s ER retention (Figure 33) and LULL1-dependent NE targeting [28] rely on the NTD, we set out to definitively
assess its membrane topology.
The bulk of torsinA’s sequence is in the lumen of the ER, as demonstrated by its
protection from protease digestion [7, 9]. Importantly, if the NTD were to function as a
stop-transfer sequence, the protein’s C terminus would be in the cytosol, the reverse of
what is seen in cells. However, the unusually close apposition of torsinA’s signal peptide
and NTD could influence topogenesis in more complex ways [51]. In addition, there are
examples of post-translational insertion of hydrophobic domains across the membrane,
particularly when that domain falls at a protein terminus [52]. We therefore wanted to
directly test whether torsinA’s N terminus is exposed to the cytosol. To do this, we asked
whether a polyhistidine tag inserted between the signal peptide and the NTD (Figure 36A) is accessible from the cytosol. We verified that the epitope tag did not disrupt
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lumenal targeting (Figure 3-6B) and confirmed that selective permeabilization with
digitonin allows detection of the cytosolic Sec31A epitope (Figure 3-6C) but not of the
lumenal PDI epitope (Figure 3-6D). We found that the His tag was accessible to antibody
when membranes were fully permeabilized with Triton-X-100 (Figure 3-6E), but was
inaccessible when only the plasma membrane was permeabilized with digitonin (Figure
3-6F). To test whether the NTD is read as a TMD when not adjacent to torsinA’s signal
peptide, we inserted residues 21-43 of torsinA into a TMD reporter construct [53] and
assessed whether the NTD integrates into the membrane or translocates into the lumen
by monitoring glycosylation after in vitro translation (Figure 3-S1). Comparing the
behavior of the NTD to test segments that do (Lep 13A/6L) or do not (Lep 18A/1L) insert
into the ER membrane [29, 37] shows that the NTD is most similar to the latter segment
(Figure 3-S1). These results suggest that in any context, torsinA’s NTD does not
traverse the bilayer, but rather associates with the lumenal side of the ER membrane.
Together with its direct membrane association demonstrated above, these experiments
define the NTD as a monotopic membrane interacting domain.

Mutations to the NTD have distinct effects on topology and ER retention
Given that the NTD is not behaving as a TMD, we wondered what distinguishes it from a
TMD and as a TMD, how it would be sorted within the secretory pathway. Energetic
predictions suggest that small changes to the sequence will decrease the energy barrier
to membrane insertion (Figure 3-7A); we increased hydrophobicity either by inserting the
sequence LALALA between Ala 31 and Gly 32, or by replacing polar residues in the
NTD itself with Leu. Both inserting the LALALA sequence and replacing two or more
polar residues with Leu caused the domain to be read as a stop-transfer sequence,
monitored by cytosolic exposure of the C-terminal GFP tag to antibody (Figure 3-7B-F).
This shows that the NTD is close to the edge of recognition as a type I TMD.
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Significantly, there were noticeable differences in the steady state subcellular distribution
of these hydrophobic mutant proteins. The LALALA and 5 x Leu mutants clearly
accumulated in a perinuclear region suggestive of the Golgi in many cells (Figure 3-7E,
6F). Upon closer inspection, (1-67)-LALALA-GFP, (1-67)-5 x Leu-GFP, and (1-67)-3 x
Leu-GFP all partially colocalize with the intermediate compartment marker ERGIC-53
(Figure 3-S2). In contrast, the 2 x Leu construct did not colocalize with ERGIC-53
(Figure 3-S2) despite its transmembrane orientation (Figure 3-7C). Thus, the small
increase in hydrophobicity created by two leucine substitutions promotes integration as a
TMD optimized for retention in the ER, while further hydrophobic substitution or
extension of the sequence allows the same TMD to escape to post-ER compartments.
These data indicate that both topology and sorting of torsinA is affected by changes in
NTD amino acid composition. The changes in sorting once the NTD becomes a TMD
parallel those previously reported when the hydrophobicity of other ER transmembrane
domains was increased [22-25].

A map of the orientation of the NTD in the ER bilayer
We next performed scanning mutagenesis along the NTD to explore its orientation with
respect to the membrane. Ala or Gly substitutions had no effect on targeting (Figure 3S4A) or topology (not shown) of torsinA. We therefore introduced Arg residues, which
are typically tolerated on the surface and in interfacial regions of the bilayer but not in the
hydrophobic core [37] . We analyzed the effects of these Arg substitutions on E171QtorsinA’s steady state localization, secretion, and diffusion in cellular membranes. Arg
substitutions at positions 24, 28, 29, 31, and 38 had little to no effect on ER localization
(Figure 3-8B and Figure 3-S3B), retention (Figure 3-8C and Figure 3-S5), or diffusive
behavior in cells (Figure 3-8F and not shown). In contrast, Arg substitutions at positions
26, 30, and 34 caused partial relocalization to an ERGIC-53-labeled compartment
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(Figure 3-8A and Figure 3-S4) and some secretion into the cell medium (Figure 3-8C
and Figure 3-S5). These mutations also caused an increase in diffusion as measured by
FRAP (Figure 3-8F and not shown), although not to the extent observed when the NTD
is deleted (Figure 3-8E). Altogether, these data indicate that selected mutations perturb
torsinA’s association with the membrane and retention in the ER. Importantly, the
residues most affected by single Arg substitutions would fall along one face of a helix
formed by the NTD (Figure 3-8D). This less tolerant helical face where Leu 26, 30, and
34 lie is therefore likely to be buried in the hydrophobic core of the lipid bilayer, while the
more tolerant helical surface where Ile 24, Leu 28, Ala 29 and 31, and Ile 38 lie may be
positioned in the interfacial region or on the membrane surface [37]. While the NTD is
not a strikingly amphipathic sequence, the asymmetry in distribution of its small nonpolar
residues vs. leucine residues results in a low hydrophobic moment (µH = 0.22) that may
define the orientation of the domain in the membrane. Hydrophobic residues along one
surface of this domain are necessary for retention of torsinA in the ER.

Other lumenal membrane proteins are also excluded from ER exit sites
To identify proteins that might share torsinA’s topology and sorting mechanism, we took
advantage of the proteomic analysis of secretory pathway components published a few
years ago by Bergeron and colleagues [35] (see Methods). From a group of hydrophobic
ER-enriched proteins, we selected those for which the bulk of the protein is known to be
in the ER lumen and which were either known to be monotopic lumenal membrane
proteins or had less well characterized hydrophobic domains that could be either
monotopic membrane associating domains or TMDs (Table 3-I). The mechanism(s)
underlying the ER localization of these proteins are unknown, although data in each
case pointed to a role for their association with the membrane in ER retention.
The best studied of these proteins is COX-1, a key enzyme in prostaglandin
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synthesis [54]. Structures and simulations show that it uses segments of four
amphipathic helices to associate monotopically with the lumenal bilayer leaflet [54, 55].
COX-1 was originally proposed to reside in the ER because of a KDEL-like S/P-TEL
sequence at its C terminus [56]. However, mutation or deletion of this sequence had no
effect on ER localization [57, 58]. Rather, deletion studies suggest that the membraneassociating region of COX-1 is independently retained in the ER [59], although a
mechanistic explanation for this result has been lacking. A similar situation applies to the
unrelated ER protein 11-β-hydroxysteroid dehydrogenase, which produces cortisol and
uses an amphipathic helix to associate monotopically with the lumenal bilayer leaflet [55,
60]. To test whether one of these known lumenal monotopic membrane proteins exhibits
torsinA-like ER retention, we analyzed the effects of low temperature blocks on the
localization of transfected COX-1 (Figure 3-9). Immunostained COX-1 is distributed
throughout the ER at physiological temperature. Like torsinA, COX-1 is absent from the
ERGIC after incubation at 15°C and is efficiently excluded from ERES after incubation at
10°C (Figure 3-9B,C). These data support the idea that COX-1 is statically retained in
the ER by exclusion from ERES.
We also identified a number of less well studied ER membrane proteins that may
share a similar retention mechanism, although detailed studies of their hydrophobic
membrane interacting domains are lacking (Table 3-I, Groups II and III). Mutagenesis
analyses on Group II proteins point to a role for their hydrophobic domains in ER
localization. This group includes arylacetamide deacetylase, whose N terminal
hydrophobic domain is responsible for localization in the ER and bears similarity to the
monotopic hydrophobic domain of 11-β-hydroxysteroid dehydrogenase [61]. The UDPglucuronosyltransferases (UDP-GTs) contain a lumenal hydrophobic domain that is
responsible for ER localization independently of a C-terminal TMD and dilysine motif
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[62]. Proteins in Group III are minimally studied, having confirmed ER localization and
proposed membrane-associating domains based on hydrophobicity. These include
malectin, a recently identified lectin involved in protein N-glycosylation in the ER, and the
peptidyl-prolyl cis-trans isomerase FKBP19; each has a proposed N-terminal signal
peptide and C-terminal hydrophobic domain [63, 64]. Our analysis of COX-1 indicates
that this enzyme shares features with torsinA; whether the other proteins of this group
are similarly excluded from ER exit sites will be the focus of a future study.

Preferential partitioning of lumenal monotopic membrane proteins into ER sheets
The fact that both torsinA and COX-1 are monotopically associated with the ER
membrane via short helical domains predicts preferential positioning of their membrane
interacting domains in the lumenal leaflet of the ER membrane. The ER consists of an
anastamosing network of flat sheets and curved tubules [65]. Because of the inherent
curvature of the tubules, we would expect proteins in the lumenal leaflet to distribute
preferentially into the sheets rather than the tubules. To test this prediction, we analyzed
the distribution the known sheet-preferring protein CLIMP63 or torsinA-mGFP in the
sheets and tubules of COS-7 cells (Figure 3-10) [65]. Both proteins were compared to
the distribution of calreticulin, which is a soluble lumenal protein that is present
throughout the ER. We found a striking segregation of both torsinA and CLIMP63 to the
perinuclear ER with its predominant population of sheets and away from the more
dispersed tubules of the peripheral ER, which were stained well with calreticulin (Figure
3-10A-B). Linescan analysis demonstrated preferential accumulation of torsinA-mGFP in
sheet structures (Figure 3-S4). At higher levels of expression, torsinA could in some
cases be observed in tubules while in other cases, highly expressed torsinA appeared to
promote formation of additional sheet structures, similarly to what has been described
with CLIMP-63 overexpression [65]. Importantly, sheet preference of torsinA was
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abolished when the NTD was deleted (Figure 3-10C); the ∆26-43-torsinA-mGFP signal
was superimposable on calreticulin. We also examined cells expressing COX-1 and saw
robust colocalization of it with endogenous CLIMP-63 in ER sheets (Figure 3-10D). In
many cases, COX1 overexpression also appeared to cause sheet proliferation. Overall,
this analysis indicates that the monotopic lumenal proteins torsinA and COX-1 segregate
into ER sheets, and at least in the case of torsinA, that this segregation correlates with
the presence of ER retention determinants. Notably, in a previous study of TMD-based
ER retention, a plasma membrane-targeted TMD partitioned into ER tubules before it
exited the ER, while a shorter ER-retained TMD preferred ER sheets [24]. Thus, it
appears that preference for less curved membranes decreases the likelihood of diffusing
into an ER exit site.
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Discussion
Protein flux into and out of the ER is governed by the cell’s need to create, fold,
and secrete proteins. Direct or indirect interaction of secreted proteins with the COPII
coat results in concentration into transport vesicles and efficient secretion; alternatively,
proteins may passively enter COPII vesicles and exit the ER by bulk flow. Retention and
retrieval mechanisms counter the forward flux of the secretory pathway to keep resident
proteins in the ER. Although many sorting signals have been defined, how the unique
protein and lipid composition of the ER is established and maintained remains a topic of
study and debate [18]. Here, we identify a monotopic membrane interacting domain in
the lumenal enzyme torsinA that allows it to escape bulk flow out of the ER, and is both
necessary and sufficient for static retention in the ER. Importantly, this sorting behavior
is attributable to the domain’s direct association with the membrane, and results in
exclusion of the protein from ER exit sites (ERES). We find evidence for similar behavior
in other lumenal monotopic proteins.
TorsinA has over the years been called either a transmembrane [49] [8] or a
peripheral membrane-associated protein [27]. Our data show that its NTD is hydrophobic
(Figure 3-5B,C) and interacts directly with membranes in the absence of any other
proteins (Figure 3-5F) but in a monotopic and not transmembrane configuration (Figure
3-6). Several observations indicate that the NTD controls ER retention independently of
other proteins. Firstly, retention of torsinA or the NTD alone in the ER is not readily
saturated by overexpression. Secondly, torsinA achieves ER localization by static
retention rather than by retrieval from post-ER compartments (Figure 3-1, 3-2). As has
been previously noted [24], a receptor-mediated mechanism for excluding a protein from
ER exit sites is currently considered unlikely and would both require enough statically
retained receptor protein to interact with torsinA over its entire lifetime and move the
problem of defining a retention mechanism from torsinA to the receptor. In addition,
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although the NTD controls ER retention it is not involved in interaction with the
predominant torsinA binding partners LAP1 and LULL1 [13, 28] (not shown), ruling these
out as potential retention factors. Finally, conservative substitutions along the length of
the NTD (Figure 3-S3A, Figure 3-S4B) have no effect on ER retention, which would be
unexpected if the NTD were to harbor a protein-protein interacting motif. We therefore
conclude that ER retention is mediated by physical features of the NTD.
Membrane-based sorting of proteins along the secretory pathway is a well
characterized phenomenon for transmembrane proteins, generally explained by a
matching of TMD length and composition to bilayer thickness, which in turn depends on
lipid composition [66, 67]. The ER bilayer is generally thinner, less ordered, and less
charged than post-ER membranes [48]. Based on our analysis of torsinA and COX1, we
suggest that the underlying principles of membrane organization that result in sorting of
TMDs [67] extend to monotopic membrane interacting domains (Figure 3-11). We
propose that there are two potentially complementary effects arising from association of
monotopic domains with bilayers that could contribute to ER retention. First, the
energetic cost of inserting a monotopic domain into the lumenal bilayer leaflet is likely to
be lower in the loosely packed membrane of the ER relative to the more ordered
membranes of the Golgi and later secretory pathway (Figure 3-11, box i). Second,
monotopic domains may preferentially partition into less curved bilayers because the
inner leaflet of curved ER domains, such as tubules and budding vesicles, will be
relatively contracted (Figure 3-11, box ii). Crowding of coat-associated cargo in the
membrane may amplify these effects in COPII vesicles in vivo. We propose that these
and potentially other membrane-based sorting effects may explain the retention of
torsinA and similar proteins in the ER.
While proteins that associate with the lumenal leaflet of the ER membrane have
not been extensively studied, we identified a few that share both torsinA’s topology and
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its exclusion from ER exit sites (Table 3-I, Figure 3-11). Two of these – COX1 and 11-βhydroxysteroid dehydrogenase – have been structurally characterized as lumenal
monotopic proteins. Subsequent molecular modeling of one of these proteins, COX-1, in
membranes indicates that its monotopic membrane association disorders the lumenal
leaflet [68] and affects membrane curvature [69]. Both of these effects could influence
partitioning of the domain within the lipid bilayer (as schematized in Figure 3-11) and
ultimately protein sorting. Although a structure of torsinA’s NTD in a membrane will be
important to confirm a similar relationship between it and the ER membrane, our finding
that it tolerates non-conservative mutations on only one face of the helix involved in
membrane association suggest that it adopts a defined position in the membrane,
perhaps as an in-plane helix.
The exclusion of torsinA from the ERES microenvironment and its preferential
concentration in ER sheets raises questions about the composition of ERES and the
transitional ER. This membrane domain is characterized by a lack of ribosomes and an
abundance of COPII components and cargo [70] [71]. Phosphatidylinositol 4-phosphate
is found on the cytosolic surface of ERES [72] and long-chain phosphatidylserine is
concentrated in COPII vesicles relative to the bulk ER [73], suggesting that the
transitional ER may also be a distinct lipid environment. Notably, the transitional ER is a
stable ER subdomain that is marked throughout the cell cycle by Sec16 [74]. A recent
study formalized the idea that rough and smooth ER correspond approximately to sheets
and tubules, respectively, in mammalian cells [65]. Further studies will be needed to
delineate the relationships between ER subdomains with differing composition,
membrane curvature, and membrane protein sorting.
As is typical for AAA+ family members [4], torsinA is an oligomeric enzyme [28]
held together by interactions among its AAA+ domains. It is possible that the NTD
helices on such an oligomer will function together to perturb lipid structure and thereby
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amplify the effects of the NTD on protein distribution among different subdomains of the
ER. The topologically similar dimeric COX1 enzyme contributes four helices per subunit
to anchor itself in the membrane [54]. Thus, cooperative effects of membrane interacting
domains may amplify the partitioning of monotopic membrane proteins between
subdomains of the ER.
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Figure Legends
Figure 3-1. TorsinA is a static ER resident. (A, B, C) Epifluorescence microscopy of
U2OS cells expressing VSVG-(ts045)-GFP (at 39.5°C), ER-GFP, or torsinA-mGFP (at
37°C). (A’, B’, C’) Costaining with βCOP ( A’, C’) or ERGIC53 (B’) after 2 hr incubation at
15°C.

Figure 3-2. TorsinA is excluded from ER exit sites. (A-D) Confocal microscopy of cells
expressing VSVG-(ts045)-GFP (at 39.5°C), NPY-GFP, ER-GFP, or torsinA-mGFP (at
37°C). (A’-D’) Costaining with Sec31A after 2 hr incubation at 10°C. Scale bars, 10 µm.
(E) Quantification of colocalization of the indicated GFP-tagged proteins with Sec31A. N
> 20 cells for each condition. Bars indicate standard error of the mean. * Indicates
significant difference between conditions (p <0.05).

Figure 3-3. Residues 26-43 of torsinA’s NTD are necessary and sufficient for ER
retention. (A) Schematic view of torsinA sequence: signal peptide (1-20, black), NTD
(21-43, gray), linker region (44-70), AAA domain (71-332), ∆E mutation (*, 302/303), and
C-terminal mGFP tag. (B) Confocal microscopy of torsinA-mGFP, ∆26-43-torsinAmGFP, E171Q /∆26-43-torsinA-mGFP, and E171Q /∆26-43-torsinA-mGFP in the
presence of BFA. (C) Immunoblot of the indicated GFP fusion proteins in cell lysates or
media immunoprecipitates. (D) Confocal microscopy of torsinA’s signal sequence (1-25),
NTD (1-43), or NTD plus linker region (1-67) fused to mGFP. Scale bars, 10 µm. (E)
Immunoblot of the indicated GFP fusion proteins in cell lysates or media
immunoprecipitates.
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Figure 3-4. N-terminally deleted torsinA accesses ER exit sites. Confocal microscopy of
cells expressing ∆26-43-torsinA-mGFP or E171Q/∆26-43-torsinA-mGFP at 37°C. (F’-G’)
Costaining with Sec31A after 2 hr incubation at 10°C. Scale bars, 10 µm. (H)
Quantification of colocalization of the indicated GFP-tagged proteins with Sec31A. N >
20 cells for each condition. Bars indicate standard error of the mean.

Figure 3-5. TorsinA’s NTD is intrinsically hydrophobic, helical, and stably associates
with membranes. (A) Alignment of torsinA’s NTD (residues 21-43 of human torsinA).
Completely conserved residues are indicated in green, conserved residues in yellow,
conservative substitutions in cyan, and nonconservative substitutions in white. (B) AntiGFP Immunoblot of equal proportions of aqueous and Triton-X-114 detergent phases of
the indicated constructs. (C) Coomassie stain of equal proportions of aqueous and
Triton-X-114 detergent phases of recombinant MBP chimeras. (D) Diffusion coefficients
determined by FRAP (ER-GFP, 7.67 +/- 0.44 µm2/s, n = 10; 1-67-mGFP, 0.69 +/- 0.07
µm2/s, n = 8). (E) Far UV circular dichroism of a synthetic peptide of residues 21-43 of
human torsinA in aqueous buffer, in increasing concentrations of trifluoroethanol, and in
20 mM SDS. The 50% TFE and 20 mM SDS conditions induced 28.5% and 29.3%
helicity, respectively (see Methods for calculation). (F) Coomassie stain showing the
distribution of MBP chimeras following sucrose flotation of DOPC liposomes generated
by detergent dialysis in the presence of the indicated proteins.

Figure 3-6. TorsinA’s N terminus is not accessible from the cytosol. (A) Schematic
diagram of His-torsinA-mGFP construct. (B) His-torsinA-mGFP migrates at the same
apparent molecular weight as wild type torsinA-mGFP and is similarly sensitive to
EndoH. (C-D) Selective permeabilization with digitonin allows detection of the cytosolic
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Sec31A epitope (C) but not the lumenal PDI epitope (D). (E-F) Cells expressing HistorsinA-mGFP were treated with Triton-X-100 (E) or with digitonin under conditions that
permeabilize only the plasma membrane (F). The N-terminal His tag was detected using
anti-His antibody and gave specific signal in Triton-X-100 but not in digitonin treated
samples. Transfected cells are indicated with asterisks (*); note that background nuclear
staining by the anti-His antibody is unrelated to His-TorA-GFP expression. Scale bars,
10 µm.

Figure 3-7. TorsinA’s NTD can be converted into a transmembrane domain. (A) MPEx
predicted TM segment in torsinA and ΔGpred for membrane insertion of wild type and
mutated NTD sequences. (B-F) Epifluorescence microscopy of cells expressing the
indicated GFP fusion proteins, stained with anti-GFP antibody after either selective
permeabilization in digitonin (left panels) or complete permeabilization in Tx100 (right
panels). Scale bars, 10 µm.

Figure 3-8. ER retention correlates with membrane association. (A-B) Epifluorescence
microscopy of E171Q-torsinA-mGFP with the indicated mutations, costained with
ERGIC-53. Scale bars, 10 µm. (C) Immunoblot of cell lysates or media
immunoprecipitates from cells expressing the indicated torsinA-mGFP constructs. (D)
Helical wheel plot summarizing results of nonconservative mutations placed throughout
the NTD. Sensitive residues marked in red, insensitive residues marked in gray, and
untested residues marked in white. See Figure S3 for supporting data. Arrowhead
indicates direction of hydrophobic moment of wild type sequence (µH = 0.22). (E-F)
Diffusion coefficients of the indicated mutations in E171Q-torsinA-mGFP determined by
FRAP (E: E171Q, 0.09 +/- 0.01 µm2/s, n = 9; E171Q/∆26-43, 1.08 +/- 0.12 µm2/s, n =
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12), (F: L28R, 0.17 +/- 0.02 µm2/s, n = 12; L30R, 0.27 +/- 0.02 µm2/s, n = 12; A31R, 0.20
+/- 0.02 µm2/s, n = 12; L34R, 0.33 +/- 0.03 µm2/s, n = 12.) Means and SEMs are
indicated by lines and brackets. * indicates p <0.05; L28R vs A30R, A31R vs L34R, and
L28R vs L34R are significantly different, as determined by ANOVA followed by Tukey’s
post test.

Table 3-I. Identification of proteins with similar characteristics to torsinA from Gilchrist et
al., 2006. Hydrophobic ER-enriched proteins with experimentally confirmed ER
localization and lumenal orientation are listed. See text for details.

Figure 3-9. COX-1 is a static ER resident and is excluded from ER exit sites. (A)
Epifluorescence microscopy of cells expressing untagged COX-1 at 37°C. (A’)
Costaining with ERGIC-53 after 2 hr at 15°C. (B) Confocal microscopy of cells
expressing untagged COX-1 at 37°C. (B’) Costaining with Sec31A after 2 hr at 10°C.
Scale bars, 10 µm. (C) Quantification of colocalization of the indicated proteins with
Sec31A. N > 50 cells for each condition. Bars indicate standard error of the mean. *
Indicates significant difference between conditions (p<0.05).

Figure 3-10. Preference of torsinA and COX1 for ER sheets. (A-C) Confocal microscopy
of COS-7 cells stained for or expressing the indicated GFP-tagged proteins, zoomed in
to show a section of the perinuclear and peripheral ER. ‘N’ indicates the nucleus. (D)
Confocal microscopy of a COS-7 cell expressing untagged COX1, costained for CLIMP63. Scale bars, 10 µm.
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Figure 3-11. Model of retention of monotopic lumenal proteins within the ER. Monotopic
lumenal proteins associate with the lumenal leaflet of the ER. This membrane
association favors partitioning away from sites of ER-to-Golgi transport. This effect on
protein sorting may be achieved by monotopic domains selectively partitioning into less
ordered bilayers (box i) or less curved bilayers (box ii).

Figure 3-S1. TorsinA’s NTD does not traverse the ER bilayer in an in vitro system. (A)
Diagram of the Lep membrane insertion reporter construct with test domain in gray and
bracketing glycosylation sites in red. If the test domain is inserted as a TMD, only one
site is glycosylated (left); if it is not, both are glycosylated (right). (B) In vitro translations
of Lep reporter constructs in the absence or presence of canine rough microsomes
(RMs) with the following test domains: the model TM segments Lep13A/6L, Lep18A/1L
(Hessa et al., 2007); torsinA residues 21-43 (NTD) in Nlum-Ccyto (type I) or Ncyto-Clum (type
II) orientation. Unglycosylated, singly glycosylated, and doubly glycosylated bands are
designated 0g, 1g, and 2g, respectively. While unglycosylated bands remain prominent,
the membrane-inserted Lep13A/6L segment is also singly glycosylated, while the
translocated Lep18A/1L segment is doubly glycosylated. The torsinA segment in either
orientation was doubly glycosylated, similarly to the latter model segment, indicating that
it is translocated into the ER lumen.

Figure 3-S2. Increasing hydrophobicity of torsinA’s NTD allows ER exit. Colocalization
of the indicated TorsinA (1-67)-mGFP constructs with the intermediate compartment
marker ERGIC-53. (1-67)-GFP (A) and (1-67) 2 x Leu- GFP (B) do not appreciably
accumulate in the ERGIC-53 stained compartment. (1-67) 5 x Leu-GFP (D), (1-67)LALALA-GFP (E), and to a lesser extent (1-67) 3 x Leu-GFP (C) do colocalize partially
with ERGIC-53, indicating that these mutants are able to escape the ER. (1-67) 2 x Leu115

GFP, 3 x Leu- GFP, and LALALA-GFP traverse the ER bilayer as transmembrane
domains (Figure 5).

Figure 3-S3. Effects of scanning mutagenesis on torsinA’s ER localization I. (A) The
intracellular localization of torsinA is unaffected by conservative substitutions throughout
the NTD. (B) Nonconservative replacement of residues 24, 29, 31, or 38 with Arg has no
effect on torsinA’s ER localization. All mutations were made in ATP-stabilized E171QtorsinA-mGFP; similar results were seen with wild type torsinA-mGFP.

Figure 3-S4. Effects of scanning mutagenesis on torsinA’s ER localization II.
Epifluorescence microscopy of cells expressing the indicated mutations to E171QtorsinA-mGFP, costained for ERGIC-53. (A) Nonconservative replacement of residues
26, 30, or 34 with Arg causes partial mislocalization to the ERGIC-53 stained
intermediate compartment. (B) A conservative Ala substitution at these positions does
not have this effect. All mutations were made in ATP-stabilized E171Q-torsinA-mGFP;
similar results were seen with wild type torsinA-mGFP.

Figure 3-S5. A subset of mutations to torsinA’s NTD causes secretion.
Immunoprecipitation of NTD mutants from cell media. Mutation of residues 26, 30, or 34
to Arg leads to secretion of torsinA-mGFP into the cell medium. Conservative Ala
substitutions at these positions did not cause secretion. Mutation of residues 24, 28, 29,
31, or 38 to Arg also did not cause secretion.

Figure 3-S6. Linescan analysis of ER subdomain preference. (A-C) Representative
confocal images of COS-7 cells costained for (A) endogenous CLIMP-63 and calreticulin
(CRT); (B) torsinA-mGFP and CRT; (C) ∆26-43-torsinA-mGFP and CRT. Linescans of
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the relative intensities of the two signals are shown to the right; two linescans per image
were performed, a background linescan was subtracted, and the intensities were
normalized before plotting.
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Arylacetamide deacetylase
UDP-GT 1A1
UDP-GT 1A6
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cyclooxygenase 1 (COX1)
(Prostaglandin G/H synthase 1)
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Table 3-I. Identification of proteins with similar characteristics to TorsinA from Gilchrist et al., 2006.
GI accession
Group I
603052
78214365
Group II
8347733
695162
89276780
27545358
Group III
34872654
27664728

Abbreviations used: HD, hydrophobic domain; TMD, transmembrane domain; UDP-GT,
UDP-glucuronosyltransferase; FKBP19, FK506-binding protein of 19 kDa.
Group I: structurally characterized as monotopic lumenal membrane proteins with defined
membrane domains. Group II: deletion mutagenesis analyses indicate hydrophobic domains
that are necessary and/or sufficient for ER localization. Group III: confirmed ER localization
and proposed membrane associating domains based on hydrophobicity.
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Chapter 4

Molecular characterization of torsinA’s interaction with its
cofactor LULL1
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Abstract
TorsinA binds robustly to two cofactor proteins, LAP1 and LULL1. These are partially
homologous, but have distinct effects on torsinA behavior (Chapter 2): LULL1 activates
torsinA to displace NE resident proteins, while LAP1 does not. The goal of this chapter is
to identify conserved torsinA-binding regions and unique torsinA-activating regions.
LAP1 and LULL1 are most homologous at their C-terminus, and I determine that a Cterminal helix in LULL1 (which is conserved in LAP1) is required for binding to torsinA.
LULL1 and torsinA are each oligomeric proteins, and I find that ATP-trapped torsinA and
LULL1 are associated as a stable hetero-oligomer; this may indicate that heterooligomers assemble at some point during the cycle of interaction. Additional features in
LULL1 that are required to target torsinA to the NE include a large proportion of LULL1’s
cytosolic domain and conserved cysteines within the lumenal domain. These findings
are suggestive of (a) signaling being transduced from the cytosol to the ER lumen via
LULL1, and (b) a redox component to regulation of torsinA by LULL1. Future
experiments will determine whether either or both of these factors are mechanistically
important for LULL1 activation of torsinA.
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Introduction
TorsinA has two known binding partners, lamina-associated polypeptide 1
(LAP1) and lumenal domain like LAP1 (LULL1). These proteins were identified as
potential torsinA binding partners in a microscopy-based screen for proteins that
modulate torsinA localization [1]. Immunoprecipitation of torsinA and proteomic analysis
of co-precipitating bands indicated that LULL1 and LAP1 are the preeminent torsinA
binding partners in U2OS cells [2].
LAP1 and LULL1 are each type II single-pass transmembrane proteins of the
ER/NE membrane system. The LAP1 and LULL1 genes are adjacent on human
chromosome 1 [1], and based on the high homology of their lumenal domains, it is likely
that a gene duplication event was involved in their genesis. The extralumenal domains of
these proteins diverge from one another dramatically (Figure 4-1) and may confer
unique function on the proteins. LAP1 is specifically retained in the inner nuclear
membrane (INM) by association of its extralumenal domain with the nuclear lamina [3],
while LULL1 is present throughout the bulk ER.
TorsinA’s binding to LAP1 and LULL1 appears to be linked to torsinA’s ATP
hydrolysis cycle, as a stable interaction can be best detected when ATP hydrolysis is
prevented by various mutations to the catalytic domain [1, 2]. This transient interaction
with LAP1 and LULL1 is important for torsinA function; LULL1 levels control the amount
of torsinA present and active in the NE (Chapter 2), and LAP1 knockdown has
similarities to torsinA knockdown in mice [4]. These proteins have distinct roles in
modulating torsinA activity, however, as only LULL1 can dynamically re-target torsinA
from the bulk ER to the NE (Chapter 2). LAP1, on the other hand, can enrich torsinA in
the NE to a lesser extent, and does not induce torsinA to displace the NE resident LINC
complex proteins. Because LAP1 and LULL1 are homologous, yet LULL1 has unique
effects on torsinA, comparison of LULL1 and LAP1 sequence will allow identification of

139

conserved torsinA-binding regions (in LAP1 and LULL1) and unique torsinA re-targeting
regions (in LULL1). These analyses will provide insight into the mechanism(s) used to
restrict torsinA’s activity to the NE.
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Methods
Plasmids
TorsinA-mGFP, E171Q-torsinA-mGFP, LULL1-myc, and LAP1-myc were as described
(Vander Heyden et al 2009, Naismith et al 2009). LULL1-GFP and RFP-LULL1 were
made by amplifying the coding sequence with primers containing HindIII and EcoRI
restriction sites and ligating into eGFP-N1 and TagRFP-C1 [5], respectively. Point
mutations to LULL1 were made by Quikchange mutagenesis (Stratagene). Deletion
mutations to LAP1 and LULL1 were made by PCR amplification of the desired fragments
with primers containing HindIII and EcoRI restriction sites and ligating into
pcDNA4/TO/MycHis B (Invitrogen). The sequences of all constructs were verified by
nucleotide sequencing.

Non-reducing SDS-PAGE
35 mm dishes of U2OS cells, U2OS-derived stable cell lines, or transiently transfected
U2OS cells were grown to confluency. Cells were washed in PBS, then lysed by
incubation in buffer (PBS, 0.5% Tx100, 20 mM NEM, 1 mM PMSF, and protease
inhibitors) for 30’ at 4°C with gentle agitation. SDS-PAGE sample buffer and benzonase
enzyme were added to the lysates, and the lysates were incubated for 1 hr at room
temperature before separation on 6-8% SDS-PAGE gels. Gels were then transferred to
PVDF and immunoblotted as described.

Blue Native PAGE was performed as described in Chapter 2, with the caveat that ATP
and MgCl2 were omitted from buffers when samples were intended for analysis of
LULL1’s oligomeric state alone.
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Clear Native PAGE
Clear Native PAGE is a variant of Blue Native PAGE that uses gentle non-ionic
detergents to confer a charge shift on membrane protein complexes instead of
Coomassie dye [6]; it is often more gentle and gives improved band resolution over Blue
Native PAGE. 60 mm plates of U2OS cells, U2OS-derived stable cell lines, or transiently
transfected U2OS cells were grown to confluency. Cells were resuspended in sample
buffer (50 mM imidazole, 50 mM NaCl, 2 mM EDTA, 2 mM aminocaproic acid, 1 mM
PMSF, protease inhibitors, and dodecylmaltoside or digitonin detergent at indicated
concentrations). The samples were incubated at 4°C for 15 minutes with agitation, then
centrifuged for 30 minutes at 60,000 rpm at 4°C, followed by 15 minutes at 60,000 rpm
at 4°C in fresh tubes. 1 µL of benzonase was added to each sample, and the samples
were then incubated at 4°C overnight. Samples were supplemented with 5x CNPAGE
sample buffer (Ponceau red, 50% glycerol), then loaded onto a 7.5% Native PAGE gel.
Gels were run in buffer containing 0.01% dodecylmaltoside and 0.05% deoxycholate
(ref) and transferred to PVDF for Western blot detection. The gel and buffer formulations
were as previously described [7].

Pulse-chase analysis of protein turnover
35 mm dishes of U2OS cells inducibly expressing LULL1-myc were grown to ~90%
confluency. Expression of LULL1-myc was induced by addition of 1 µg/ml tetracycline;
cells were incubated for 4 hours. Cells were deprived of methionine and cysteine for 1
hour in medium lacking these amino acids and supplemented with 10% FBS, Lglutamine, and 1 µg/ml tetracycline. Cells were labeled in medium supplemented with
112.5 µCi of 35S-methionine/cysteine (NEN) for 10 minutes, and chased with medium
containing cold methionine and cysteine for the indicated time periods. At each time
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point, cells were collected in cold lysis buffer (150 mM NaCl, 25 mM HEPES pH 7.4, 1%
Tx100, 2 mM EDTA, 1 mM PMSF, protease inhibitors) and flash frozen in liquid N2. After
collection of all samples, LULL1-myc was immunoprecipitated with myc antibody.
Immunoprecipitates were separated on SDS-PAGE, Coomassie stained, dried, and
exposed to phosphor screen to detect radioactivity.

Immunoprecipitation, Immunoblotting, and Immunofluorescence were performed as
described in Chapter 2.
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Results
TorsinA binds to the homologous lumenal domains of LAP1 and LULL1
LAP1 and LULL1 bind to torsinA via their homologous lumenal domain, which is
approximately 250 residues long in both proteins. Comparison of the sequences of
human LAP1 and LULL1 (Figure 4-1) indicates that the C-terminal ~100 residues are the
most well conserved between the two proteins in humans (86% homology, 77% identity)
and in other species (not shown); the membrane-proximal ~130 residues and
transmembrane segments are less well conserved (70% homology, 50% identity). The
extralumenal domains of LAP1 and LULL1 are least well conserved between the two
proteins (15% identity) or amongst orthologs in different species (not shown).
The higher conservation in sequence and predicted secondary structure at the Cterminal ends of LAP1 and LULL1 suggest that a conserved torsinA-binding domain
could lie within this region. To test this prediction, the highly homologous ~100 amino
acids were deleted from LAP1 and LULL1. The resulting LAP1 1-367 and LULL 1-373
truncated mutants localized to the NE and bulk ER, respectively, as expected (Figure 42B,E). Full length LAP1 and LULL1 co-immunoprecipitate with E171Q-torsinA-mGFP
(Figure 4-2C,G), although a significant proportion of LAP1 remains insoluble because of
association of its extralumenal domain with the nuclear lamina. LAP1 1-367 and LULL1
1-373, in contrast, do not co-immunoprecipitate with E171Q-torsinA-mGFP (Figure 42C,G). When compared to overexpressed full length LAP1 and LULL1, it is apparent that
the truncated mutants do not affect the intracellular localization of wild type torsinAmGFP (Figure 4-2B,E). Overall, these data are consistent with the torsinA-binding
domain falling within the region at the C termini of LAP1 and LULL1 that is best
conserved between the two proteins. Because of LULL1’s more tractable solubility, and
because of its dramatic effects on torsinA localization and activity (Chapter 2), I chose to
further characterize torsinA’s interaction with LULL1 alone.
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LULL’s C terminal helix binds to torsinA
To more finely resolve where the torsinA-interacting domain lies in LULL1, I made
smaller deletions starting from the C-terminus. Deletion of a predicted C-terminal helix
from LULL1 (residues 440-470) abolished both torsinA-binding and torsinA-targeting
behavior (Figure 4-2F,G). The extreme C-terminus of LULL1, and probably the same
region of LAP1, is therefore important for interaction with torsinA. In LULL1, this helix
has pronounced charged and hydrophobic faces (Figure 4-3H). To determine what
surface(s) of this helix interact with torsinA, selected charged residues were replaced
with apolar residues and vice versa. Substitution of aspartate 441 or serine 444 with
alanine was tolerated; these mutants were comparable to wild type LULL1 in binding to
E171Q-torsinA-mGFP (Figure 4-4B) and redistributing wild type torsinA-mGFP from the
ER to the NE (Figure 4-3B, C, Figure 4-4A). Replacing leucine 446 with arginine had an
intermediate effect, weakening binding to E171Q-torsinA-mGFP (Figure 4-4B) and
decreasing the frequency of wild type torsinA’s movement into the NE (Figure 4-3D,
Figure 4-4A). Mutating arginine 449 to alanine, isoleucine 450 to arginine, or leucine 453
to arginine completely abolished both binding to E171Q-torsinA-mGFP (Figure 4-4B)
and NE targeting of wild type torsinA (Figure 4-3E-G, Figure 4-4A). The sensitivity of the
LULL1-torsinA interaction to these point mutations supports the proposal that LULL1’s
(and LAP1’s) extreme C terminus comprises the torsinA binding region. Attachment of
small (myc) or large (GFP) epitope tags (Figure 4-2 and not shown) to the C terminus of
LULL1 or LAP1 does not appear to affect the interaction with torsinA, suggesting that the
C termini are not buried when binding to torsinA.
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LULL1’s cytosolic domain is required for targeting torsinA to the NE
I determined that the extreme C terminal helix of LULL1 is required for binding to
torsinA. This helix falls within the region of LAP1 and LULL1 homology, corresponding in
LULL1 to residues 373-470, which independently immunoprecipitates with E171QtorsinA-mGFP (Figure 4-5B). However, this region alone cannot affect torsinA’s
intracellular localization (Figure 4-6B,G), suggesting that additional domain(s) are
involved in re-targeting torsinA from the ER to the NE. To identify these domain(s), I
generated mutants containing incrementally more of the LULL1 sequence N-terminal to
the region of homology (Figure 4-5A). The complete lumenal domain of LULL1 (residues
241-470) and a construct lacking the cytosolic N-terminal 100 residues (101-470) also
associate with E171Q-torsinA-mGFP (Figure 4-5B) but do not affect wild type torsinA’s
localization (Figure 4-6C,D,G). Attaching an RFP tag to the N terminus of LULL1 did not
affect targeting of torsinA (Figure 4-6F,G), indicating that a free N terminus is not
required. Surprisingly, a construct lacking just the N-terminal 50 residues (51-470) was
capable of targeting torsinA to the NE to an extent comparable to full length LULL1
(Figure 4-6E, G), indicating that the region containing residues 50-100 of LULL1’s
cytosolic domain is important for this function.
How might this region of LULL1 control torsinA’s localization? The cytosolic
domain of LULL1 is predicted to be unstructured; it is possible that LULL1’s cytosolic
domain could confer a short half-life on the protein [8] and thereby regulate torsinA’s
localization. However, LULL1-myc appears to be a stable protein (Figure 4-S1). One
notable feature of this region of LULL1 sequence is two conserved serine residues that
could be phosphorylated; indeed, phosphopeptides corresponding to this sequence have
been isolated in a broad-scale proteomic study [9]. However, mutating these residues to
either an aspartate residue (to simulate constitutive phosphorylation) or to an alanine
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residue (constitutively de-phosphorylated) had no effect on the ability of LULL1 to target
torsinA to the NE (not shown).
The fact that LULL1’s cytosolic domain is required for targeting torsinA to the NE
raises the intriguing possibility that LULL1 transduces a signal from the cytosol to torsinA
in the lumen of the ER. I was unable to identify any cytosolic proteins that stably interact
with LULL1’s cytosolic domain (not shown), but it remains possible that transient
interaction with a cytosolic factor could lead to modulation of LULL1 and in turn, torsinA.
A future goal will be to elucidate the precise role of LULL1’s cytosolic domain in torsinA
activation.

LULL1 and ATP-trapped torsinA coassemble
TorsinA is a hexameric enzyme (Chapter 2); to understand whether LULL1 can
co-assemble with torsinA, I performed native PAGE analysis on cell extracts expressing
exogenous untagged torsinA and LULL1-myc. This analysis demonstrated that torsinA
assembles into hexamer-sized species in the absence or presence of co-expressed
LULL1-myc (Figure 2-3C; Figure 4-7A). However, if ATP-trapped E171Q-torsinA and
LULL1-myc are co-expressed and subjected to native PAGE separation, E171Q-torsinA
and LULL1 co-assemble into a stable high molecular weight complex (Figure 4-7B). This
finding illustrates the nucleotide state dependence of the torsinA-LULL1 interaction and
suggests that a heterooligomeric complex may be an intermediate in the cyclical
interaction of hydrolysis-competent torsinA with LULL1. Separately, this analysis
indicates that LULL1-myc assembles into high molecular weight species when
expressed alone in U2OS cells (Figure 4-7B). We therefore analyzed the oligomeric
state of LULL1 in more detail.
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LULL1 multimerizes
LULL1 has three lumenal cysteines that are likely to be involved in intra- and/or
inter-molecular disulfides in the oxidizing environment of the ER lumen (Figure 4-1).
When transiently transfected into U2OS cells, LULL1-myc assembles into disulfidebonded dimers and perhaps tetramers as detected on nonreducing SDS-PAGE (Figure
4-8A). These high molecular weight species originate from disulfide bonds, as they are
completely absent when LULL1’s three lumenal cysteines are mutated (Figure 4-8A).
Under native conditions, LULL1-myc is an obligate dimer and is also detected in
hexameric and even larger species (Figure 4-8B). LULL1-myc and LULL1-GFP coimmunoprecipitate, and this interaction persists when the lumenal cysteines are mutated
(Figure 4-8C). Taken together, these analyses suggest that noncovalent interactions and
disulfide bonds cooperate to make LULL1 oligomers.
Interestingly, LULL1-myc reproducibly separated into at least three distinct bands
in the dimeric size range on non-reducing SDS-PAGE (Figure 4-8A). It is likely that these
three bands represent distinct dimeric species that have varying levels of compactness.
One explanation would be that the fastest-migrating band would have the most disulfide
bonds, while the slowest would have the least disulfide bonds. A trivial explanation
would be that combined with endogenous LULL1, LULL1-myc forms oligomers of slightly
differing molecular weights. To better understand how LULL1 assembles, I mutated
LULL1’s lumenal cysteines, expressed these mutant proteins in cells depleted of
endogenous LULL1, and compared their migration on non-reducing SDS-PAGE (Figure
4-8D). LULL1-myc’s patterning on non-reducing SDS-PAGE was unchanged by
depletion of endogenous LULL1. LULL1 C310S was present in the two more compact
dimer states, while LULL1 C382S appeared to sample all three; LULL1 C468S was
detectable only in the slowest-migrating dimer state. If these distinct disulfide-bonded
states are relevant to LULL1’s function, one may expect that their perturbation would
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impair LULL1’s effect on torsinA localization. This is indeed the case; the C310S,
C468S, and triple C/S mutations each completely abrogate the ability of LULL1 to
retarget torsinA to the nuclear envelope (Figure 4-9A, B, D-F), while the C382S
mutation, which did not detectably alter LULL1 assembly as assessed by non-reducing
SDS-PAGE (Figure 4-8D), was still active (Figure 4-9C, F). Importantly, each of these
mutations had no effect on binding to torsinA (Figure 4-9G,H). Rather, it appears that the
ability of LULL1 to sample different conformational states correlates with its ability to
affect torsinA localization.

Endogenous LULL1 is predominantly monomeric
LULL1 is expressed in U2OS cells, yet endogenous LULL1 levels are not
sufficient to redistribute torsinA from the bulk ER to the NE. I previously determined that
complete removal of LULL1 abrogated the enrichment of ∆GAG-torsinA in the NE
(Chapter 2), implying that the amount of torsinA in the NE is a direct consequence of the
expression level of LULL1. To understand how different levels of LULL1 cause a graded
effect on torsinA’s localization, I analyzed the oligomeric state of endogenous LULL1.
Surprisingly, endogenous LULL1 is predominantly monomeric on nonreducing SDSPAGE (Figure 4-10A), indicating that it is not engaged in intermolecular disulfides.
Rather, the protein migrates as a stable but non-covalent dimer under native conditions
(Figure 4-10B). This is somewhat surprising since LULL1 contains 3 lumenal cysteines
that cannot all be paired intramolecularly. It is tempting to speculate that LULL1’s
oligomerization is inducible, and that transient induction of oligomerization would
correlate with the ability of LULL1 to target torsinA to the NE. An important caveat in
analyzing these experiments, however, is that overexpression of thiol-containing proteins
in the ER (as in Figure 4-8) could in turn alter the redox equilibrium of the organelle, and
lead to generation of nonphysiological disulfides. Further experiments may be needed to
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determine which of LULL1’s cysteines are paired and unpaired in vivo, and whether
those pairings change in response to torsinA levels or other environmental stimuli.

A putative TxxC motif in LULL1
LULL1’s lumenal cysteines are key to LULL1’s effects on torsinA, yet these
cysteines are conserved in LAP1 (Figure 4-1). Two of these 3 cysteines (382 and 468)
fall within LAP1 and LULL1’s region of homology, but the region surrounding cysteine
310 is not as well conserved between the two proteins. We noticed a threonine at
position 307 that is conserved among LULL1 orthologs: a TxxC motif (Figure 4-11A).
TxxC motifs are a variant of the CxxC motif found in oxidoreductase proteins in the
thioredoxin family, including protein disulfide isomerase (PDI). TxxC motifs occur in the
peroxiredoxins, which are thioredoxin-related proteins that become disulfide-bonded in
presence of peroxide and transfer that disulfide to another protein [10].
Since this position contains an alanine or valine in LAP1 sequences (Figure 411A), I mutated LULL1’s threonine to alanine and assessed its affect on LULL1 activity.
Strikingly, torsinA was completely insensitive to LULL1 T307A (Figure 4-11C,D). While
this finding indicates functional importance for this threonine in LULL1, additional work
will be needed to address whether this putative TxxC motif is involved in an
oxidoreductase-like function. Importantly, torsinA’s sequence contains 6 conserved
cysteines, and certain combinations of mutations to these cysteines do abolish torsinA’s
response to LULL1 (T. Naismith, data not shown). Intriguingly, changes to torsinA
molecular weight and localization in response to oxidative stress have been reported
[11]. An interesting model would be that under some conditions, LULL1 would become
disulfide-bonded, and would act as an oxidoreductase on torsinA, forming or isomerizing
disulfides in torsinA. This alteration in torsinA conformation could then allow torsinA to
bind specifically to elements of the NE.
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Discussion
The data presented here indicate that the C-terminal region of homology in LAP1
and LULL1 interacts with torsinA; further analysis in LULL1 more finely maps the binding
region to a C-terminal helix. LAP1 and LULL1 are large proteins: 462 and 470 amino
acids in length, respectively. The lumenal domains alone are ~230 residues long, yet it
appears that a single helix at the C termini may be responsible for binding to torsinA.
What function(s) might the other regions of these proteins perform? We have determined
that a large portion of LULL1’s 470 amino acids is required for torsinA targeting activity.
While many AAA+ enzymes use accessory domains to recruit substrate, torsinA’s
sequence is relatively minimal outside of its AAA domain. One interesting possibility
could be that other portions of LAP1 and LULL1’s lumenal domains could function as
accessory domains to torsinA, facilitating interaction with substrate(s). In the case of
LULL1, these substrates may be the LINC complex proteins in the NE (Chapter 2).
AAA+ ATPase enzymes function as oligomeric ring structures [12]; I have
determined that torsinA assembles into a hexamer (Chapter 2). Work presented here
demonstrates that LULL1 is also capable of homo-oligomerization; it appears to be an
obligate dimer, yet can assemble into hexameric and larger species. When ATP
hydrolysis in torsinA is blocked, isolation of a stable hetero-oligomeric complex of torsinA
and LULL1 becomes possible. Altogether, these data point to hetero-oligomeric
assemblies of torsinA and LULL1 working together to achieve function.
What region of torsinA interacts with LAP1 and LULL1? While a structure of
torsinA has not been solved yet, homology models to other AAA+ ATPase family
members can provide some insight into possible structural features [13, 14]. One
interesting characteristic of the torsinA AAA+ domain is the presence of a helix-loophelix motif that is inserted between canonical structural elements of the AAA+ domain.
ClpAB subfamily members also use this motif to interact with each other [15], but
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comparatively, this region is extended in torsinA. This helix-loop-helix motif may be
surface-exposed in the holoenzyme [13] and could interact with LULL1’s C-terminal
helix, perhaps by lateral packing of the helices. Data on the implicated regions in LULL1
and torsinA could support this model. Mutations to LULL1’s C terminal helix that affect
binding cluster on one side of the helix. Separately, preliminary data suggest a role for
torsinA’s helix-loop-helix motif in binding to LULL1; deletion of the loop between the
helices does abolish binding to LULL1 (T. Naismith, data not shown). However, it is
possible that such a deletion may locally or broadly destabilize the protein fold, and
identification of point mutations in the vicinity of this loop that abolish binding will be a
next step.

Could LULL1 be a redox regulator of torsinA?
Another distinguishing feature of torsinA is the presence of six conserved
cysteines in its sequence. As a resident of the ER lumen, these cysteines would be
susceptible to oxidation. One of these cysteines falls within the Sensor II motif; the
oxidation state of this cysteine could affect the functioning of Sensor II, and thus impact
how the enzyme binds and/or hydrolyzes ATP [14]. Three of the cysteines are adjacent
to the N-terminal membrane domain (Chapter 3), and their disulfide-bonded state could
influence torsinA’s disposition in the membrane. An intriguing possibility is that LULL1
(and perhaps LAP1) could modulate torsinA’s conformational state by a redox
mechanism.
LULL1 has a TxxC motif that must be intact for the protein to target torsinA to the
NE (Figure 4-9). In peroxiredoxin TxxC motifs, the alcohol sidechain of the threonine
residue is thought to stabilize the nearby cysteine side chain as a thiolate anion,
lowering the pKa of the cysteine and increasing its reactivity [10]. This reactive cysteine,
termed the peroxidatic cysteine, then attacks a peroxide substrate to form a cysteine-
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sulfenic acid moiety. This species is resolved by attack from another cysteine on a
neighboring subunit, the resolving cysteine, to form an intersubunit disulfide. The
peroxiredoxin may then interact with a redox partner to transfer the disulfide,
analogously to disulfide bond formation by PDI.
Several features of LULL1 are comparable to peroxiredoxins. The peroxidatic
cysteine (in the TxxC motif) would be cysteine 310, and the resolving cysteine could be
the C-terminal cysteine 468. Both of these cysteines are required for torsinA-targeting
activity (Figure 4-7). Because the reaction cycle involves formation of an intersubunit
disulfide, peroxiredoxins are monomeric and oligomeric at different stages of their
reaction cycle. LULL1 can oligomerize into large assemblies (Figure 4-6) and it is
possible that this oligomerization could be inducible (Figure 4-7). Peroxiredoxin reactions
are involved in various cellular processes, including Ero1-independent protein folding in
the ER [16]; transcriptional activation [17]; and even the circadian cycle [18]. In the case
of LULL1 and torsinA, perhaps an oxidoreductase cycle involving the two proteins could
shift torsinA into a form that is targeted to the NE.
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Figure Legends
Figure 4-1. LAP1 and LULL1 are homologous in their lumenal domains. (A) Alignment of
Homo sapiens LAP1 and LULL1 protein sequences. Approximate region of
transmembrane domain is boxed. Conserved lumenal cysteines marked with asterisks.
(B) Schematic representation of LAP1 and LULL1 conservation. The C-terminal ~100
residues are best conserved in sequence and secondary structure.

Figure 4-2. LAP1 and LULL’s C terminal region of homology binds to torsinA. (A) LAP1myc overexpression causes partial enrichment of torsinA-mGFP in the NE. (B) LAP1 1367-myc localizes to the NE but has no effect on the localization of torsinA-mGFP. (C)
LAP1-myc co-immunoprecipitates with E171Q-torsinA-mGFP but LAP1 1-367-myc does
not. (D) LULL1-myc overexpression causes torsinA-mGFP to move into the NE. (E-F)
LULL1 1-373-myc and 1-439-myc localize to the bulk ER and do not affect the
localization of torsinA-mGFP. (G) LULL1-myc co-immunoprecipitates with E171QtorsinA-mGFP but LULL1 1-373-myc and LULL 1-439-myc do not. Scale bars, 10 µm.

Figure 4-3. Point mutations to LULL1’s C terminal helix abolish torsinA targeting. (A-G)
Epifluorescence microscopy of cells coexpressing the indicated LULL1-myc constructs
and torsinA-mGFP. Scale bars, 10 µm. (H) Helical wheel diagram of LULL1’s C terminal
helix with residues that have been mutated indicated by asterisks.

Figure 4-4. Point mutations to LULL1’s C terminal helix abolish torsinA binding. (A)
Quantification of the fraction of cells expressing LULL1 and torsinA that have torsinA in
the NE (representative images in Figure 4-3). N>100 cells per condition. (B) Coimmunoprecipitation of the indicated LULL1-myc mutants with E171Q-torsinA-mGFP.
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Figure 4-5. Truncated LULL1 mutants lacking N-terminal sequences bind to torsinA. (A)
Schematic of LULL1-myc deletion mutants. (B) Co-immunoprecipitation of the indicated
LULL1-myc constructs with E171Q-torsinA-mGFP.

Figure 4-6. Residues 51-100 of LULL1 are required for targeting torsinA to the NE. (A-F)
Epifluorescence microscopy of cells expressing the indicated LULL1-myc mutants with
torsinA-mGFP. Scale bars, 10 µm. (G) Quantification of the fraction of cells expressing
the indicated LULL1-myc mutants and torsinA-mGFP having torsinA in the NE. N>50
cells per condition.

Figure 4-7. ATP-trapped torsinA and LULL1 form a stable oligomeric complex. (A)
Untagged torsinA migrates as a stable hexamer on Blue Native PAGE in 0.25%
dodecylmaltoside in the absence or presence of coexpressed LULL1-myc. (B) Untagged
E171Q-torsinA also migrates partially as a hexamer; coexpression of LULL1-myc
induces the formation of a distinctly migrating complex that is reactive both for torsinA
and myc. Overexpressed LULL1-myc on its own migrates as a dimer and higher-order
species.

Figure 4-8. Analysis of LULL1-myc oligomerization. (A) Nonreducing SDS-PAGE of
exogenous LULL1-myc or LULL1 C/S-myc transiently transfected into U2OS cells. (B)
Blue Native PAGE of exogenous LULL1-myc transiently transfected into U2OS cells, in
the presence of 0.5% or 1% dodecylmaltoside. (C) Co-immunoprecipitation of LULL1myc or LULL1 with the three lumenal cysteines substituted with serines (LULL1 C/Smyc) with LULL1-GFP. (D) Nonreducing SDS-PAGE of the indicated LULL1-myc
mutants transiently transfected into cells stably depleted of endogenous LULL1.
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Distinctly migrating bands in the dimeric size range are numbered, and two distinctly
migrating monomeric species are indicated by arrows.

Figure 4-9. A subset of LULL1’s lumenal cysteines are required for re-targeting torsinA
to the NE. (A-E) Epifluorescence microscopy of the indicated LULL1-myc mutants
coexpressed with torsinA-mGFP. (F) Quantification of the fraction of doubly expressing
cells having torsinA in the NE; n>50 cells per condition. Scale bars, 10 µm. (G,H) Coimmunoprecipitation of the indicated LULL1-myc mutants with E171Q-torsinA-mGFP.

Figure 4-10. Analysis of endogenous LULL1 oligomerization. (A) Nonreducing SDSPAGE of endogenous LULL1 in U2OS cells. (B) Clear Native PAGE of endogenous
LULL1 in U2OS cells in the presence of 0.25% dodecylmaltoside (DDM).

Figure 4-11. A putative TxxC motif in LULL1 is required for re-targeting torsinA to the
NE. (A) Alignment of the region surrounding cysteine 310 in LAP1 and LULL1. Predicted
helical secondary structure (h) (PsiPred) is indicated above the alignment. (B-C)
Epifluorescence microscopy of the indicated LULL1-myc mutants coexpressed with
torsinA-mGFP. Scale bars, 10 µm. (D) Quantification of the fraction of doubly expressing
cells having torsinA in the NE; n>100 cells per condition.

Figure 4-S1. LULL1 is a stable protein. Cells inducibly expressing LULL1-myc under
control of a tetracycline-inducible promoter were labeled for 10 minutes with 150 µCi/mL
35

S-methionine/cysteine, then chased in medium for the indicated times. LULL1-myc was

immunoprecipitated with myc antibody, and 35S labeled immunoprecipitates (top) or total
cell lysate (bottom) were detected by exposure to phosphor screen.
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Abstract
This chapter contains preliminary data of interest to various aspects of torsinA
biology. We identify a conserved arginine residue that is required for torsinA’s activity at
the NE, mutation to which has been observed in a case of dystonia. This mutant is
phenotypically similar to the more common ∆GAG mutation, strengthening the argument
that dysfunction of torsinA at the NE causes dystonia. Cells depleted of LULL1, torsinA,
and LAP1 were separately generated, and the status of NE resident proteins in these
cells evaluated. LULL1 depletion reproducibly caused a decrease in the amount of Sun2
at the NE. Loss of either LULL1 or torsinA caused imbalances in nuclear pore complex
organization and number. LAP1 depletion had little to no effect on other NE residents or
on torsinA’s dynamic localization to the NE. ∆GAG-torsinA was confirmed to migrate as
a hexamer on Blue Native PAGE. Finally, the oligomeric state of torsin family members
was determined by Blue Native PAGE alone or in combination with torsinA. TorsinA,
torsin2A, and torsin3A form stable oligomers, while torsinB does not. However, torsinA is
able to coassemble into a hetero-oligomeric species with torsinB only.
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Methods

Generation of cell lines stably expressing short hairpin RNAs
To make cell lines stably lacking LULL1 expression, U2OS cells were transduced
with Sigma Mission shRNAs directed against human LULL1 (Sigma Aldrich, RefSeq #
NM_145034). Lentiviruses for transduction were produced by cotransfecting hairpins in
pLKO with the pCMV 8.2 ΔR packaging plasmid into 293T cells. U2OS cells were then
transduced with viral particles according to manufacturer’s instructions. Cells depleted of
LULL1 were enriched for by selecting transduced cells with puromycin (10 µg/ml).
To generate cell lines depleted of torsinA, U2OS cells were transfected with
shRNAs in the pLKO vector, then subjected to selection with puromycin (10 µg/ml).
Individual colonies were isolated and grown to generate clonal lines. Two cell lines were
generated with no detectable LULL1 expression (hairpins 1507 and 2088), and one cell
line was generated with ~10% of endogenous LULL1 expression (hairpin 1269). See
Figure 2-5 for a representative Western blot. Hairpins 1269 and 1507 fall within the
coding sequence of LULL1, while hairpin 2088 falls in the 3’ untranslated region of
LULL1.

Transient transfection of short interfering RNAs
To knock down LAP1, we selected a siRNA that is directed to the 3’ UTR of the LAP1
gene, which should target all LAP1 isoforms (A, B, and C). Coverslips in 6-well or 12well plates were seeded at a density of 3 x 105 or 5 x 104 cells per well, respectively, the
day before transfection with siRNA. Cells were transfected with 10-50 nM siRNA in
transfection mixtures prepared according to the manufacturer’s instructions (Thermo
Scientific). Dharmafect formulation #1 was used as the transfection reagent for U2OS
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cells. Culture medium was replaced with fresh medium ~18 hr after transfection. Cells
were collected for analysis after ~90 hr of siRNA transfection.

Analysis of NPC intensity in synchronized cells
This assay was performed essentially as described in (Doucet et al. 2010). Briefly,
U2OS cells were grown to confluency in 10-cm dishes. Cells were synchronized in
mitosis by treatment with 0.6 ug/ml nocodazole for 18 hr. Mitotic cells were harvested by
shake-off, washed twice in warm PBS, and plated on coverslips in fresh culture medium.
Coverslips were fixed in cold 4% PFA in PBS 5 hr (G1 time point) and 19 hr (G2 time
point) after replating, stained with mAb414 to visualize NPCs, and imaged by
epifluorescence microscopy. Images were obtained at the same exposure time for 5 hr
and 19 hr time points, taking care not to allow pixel saturation. NPC number is a function
of total fluorescent intensity; this value was quantified for individual nuclei in Image J.
For presentation, NPC intensity values were normalized to U2OS cells at the 5 hr
timepoint.

Blue Native PAGE, immunoprecipitations, and immunofluorescence were
performed as described in Chapter 2.
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Results and Discussion
Our data are consistent with torsinA exerting an enzymatic activity at the NE
(Chapter 2). Mutagenesis indicates that movement of torsinA into the NE depends on
the ability of the AAA domain to bind and hydrolyze ATP. Specifically, mutations that
prevent ATP binding (the Walker A motif mutant, K108A) or ATP hydrolysis (the Walker
B mutant, E171Q; the sensor II mutant, K320M) prevent LULL1-directed movement into
the NE. These mutations alter binding to LAP1 and LULL1. If LAP1 and LULL1 are
cofactors to torsinA, and NE resident LINC proteins are its substrates, it might be
possible to identify mutations that do not affect binding to LAP1 and LULL1, but alter
either targeting to the NE or activity on NE resident proteins. Identification of such
mutants would deepen our understanding of the molecular changes that torsinA
undergoes as it binds to LULL1, translocates to the NE, and displaces LINC complex
proteins. With this in mind I revisited the alignment of torsinA’s AAA domain (Figure 5-1).

Mutation to a possible pore loop blocks NE localization of torsinA
AAA+s use pore loops that protrude into the central pore of the holoenzyme to
engage substrates. In various cases, pore loops have been identified that use
hydrophobic, aromatic, or charged residues to contact substrate [1]. Mutations to these
pore loops will often hinder activity on substrates without affecting oligomerization or
ATPase activity of the enzyme; these mutations can thus be thought of as uncoupling
the nucleotide hydrolase activity from its effect on a substrate. The ClpB D2 domain, a
close homolog to torsinA, has a pore loop with a conserved GYVG sequence [2]. The
structure-based alignment of torsinA to ClpB’s D2 domain (see Figure 1-2) [7] indicates
a region in torsinA that could correspond to this pore loop. While torsinA does not
contain the typical GYVG sequence, it does contain a sequence with conserved residues
including a tyrosine (Y147) that could function similarly to the key tyrosine in ClpB
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(residues 147-155, boxed, Figure 5-1). I made triple alanine mutations across this
sequence (which were termed pore loop mutants 1a, 1b, and 1c, see Figure 5-2A) and
assessed their affect on torsinA behavior.
The three pore loop mutants all moved to the NE with lower frequency in
response to LULL1 (Figure 5-2B-F) and were ineffectual at displacing Sun2 (Figure 53A-E). These mutations did not, however, abolish binding to LULL1 (Figure 5-3F). It thus
appears that these mutations specifically affect torsinA’s targeting to and activity in the
NE, without affecting interaction with cofactor proteins. Individual point mutations in the
pore loop region will clarify which residue(s) are required for normal function. If this
sequence does in fact contain a pore loop, it might be possible to crosslink the pore loop
to NE-localized substrates using a modified amino acid, as was previously done with
ClpB [2].

Mutation to a conserved arginine in renders torsinA inactive at the NE
An additional feature that I noticed in torsinA’s AAA+ domain was the presence of
an absolutely conserved arginine residue in helix 5 at residue 288; this arginine and the
following glycine are conserved from H sapiens torsinA to the C elegans OOC-5
homolog (Figure 5-1, arrow). Arginine residues in AAA domains have been implicated in
cross-subunit interactions with nucleotide, which stabilizes oligomers [3], as well as
interacting with substrate [4]. I mutated this residue to an alanine and assessed the
effect of this mutation on torsinA. I find that this mutant redistributes to the NE with
approximately normal frequency in LULL1-myc expressing cells (Figure 5-4B’, C).
However, torsinA-R288A does not displace the NE resident protein Sun2 from the NE
(Figure 5-4E,F). This loss of activity at the NE occurs without an effect on torsinA’s
ability to bind to LULL1 (Figure 5-4G) or hexamerize (Figure 5-4H). These findings make

177

a role for R288 in ATP binding or oligomerization unlikely, and may be most consistent
with R288 being a substrate-interacting residue.
Intriguingly, a recent case study described a mutation of this arginine to a
glutamine (R288Q) in a case of hereditary dystonia [5]. We also made this substitution
and assessed its effects. It appears that the R288Q substitution also allows torsinA to
move into the NE (Figure 5-5B’,C), but is unable to displace Sun2 from the NE (Figure 55E,F), as seen with the alanine substitution. This phenotype is similar to what we
previously observed for the more common dystonia-causing ∆GAG mutation: ∆GAG torsinA can move into the NE in response to LULL1, but is much less efficient at
displacing Sun2 once there (Chapter 2). Thus, we have identified a similar cellular
phenotype arising from two disease-related mutations. These data further strengthen the
model that torsinA-related disease arises from loss of function or dysfunction of torsinA
at the NE.
While these two disease-associated mutants similarly affect torsinA’s function in
cellular assays, there may be important distinctions between them. The ∆GAG mutation
has been shown to weaken the interaction of torsinA with LAP1 and LULL1 [6], whereas
the R288Q mutation probably does not have this effect (not shown, but see IP of R288A
with LULL1 in Figure 5-4G). The available data on the ∆GAG mutation are suggestive of
this mutation destabilizing the protein. The deleted residue is predicted to fall within an
alpha helix directly preceding the ATP-interacting Sensor II motif [7, 8]. A single alanine
or glutamine substitution in helix 5 (in the case of the R288A/R288Q mutations), on the
other hand, is less likely to perturb secondary structure. It is attractive to speculate that
this highly conserved arginine may be involved in substrate interaction. Since mutations
to R288 allow movement to the NE but not displacement of Sun2, one possibility is that
these mutations could stabilize interaction with Sun2 and/or other NE substrates.
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Characterization of cells individually depleted of LULL1, LAP1, and torsinA
As described in Chapter 2, I found that depletion of LULL1 prevented enrichment
of ∆GAG-torsinA-mGFP in the NE. This finding, combined with the fact that LULL1 overexpression causes dramatic relocalization of torsinA to the NE, suggests that LULL1
levels directly regulate the extent of torsinA enrichment at and activity in the NE. NE
resident proteins including Sun2, nesprin3, and nesprin2-Giant are displaced in cells coexpressing exogenous torsinA and LULL1. I therefore further analyzed the localization of
these and other NE resident proteins in LULL1 knockdown cell lines. U2OS or LULL1
shRNA 2088 cells were stained for antibodies to Sun1, Sun2, nesprin2-Giant, nesprin3,
and LAP1 (Figure 5-6). Sun1 and nesprin3 levels appeared subtly increased at the NE in
LULL1 2088 cells compared to U2OS cells at the same exposure time (Figure 5-6A, D).
Occasional nuclei were observed in LULL1 2088 cells that were completely lacking in
Sun2 signal or lower in LAP1 signal (Figure 5-6B, E). Nesprin2-Giant appeared
unaffected (Figure 5-6C). The loss of Sun2 staining in some cells expressing LULL1
shRNA 2088 was quite dramatic, so I assessed the effect of LULL shRNAs 1269 and
1507 on Sun2 protein localization. Cells expressing these shRNAs also had diminished
Sun2 at the NE (Figure 5-7B,C). Additional controls will be required to confirm that these
alterations in LINC protein levels are directly related to LULL1 protein depletion.
Since NE-localized torsinA can alter the stability of NE resident proteins, I
analyzed NE resident proteins in cells depleted of torsinA. A representative Western blot
showing knockdown of torsinA in two clonal cell lines expressing hairpin 376 is shown in
Figure 5-8A. Somewhat surprisingly, Sun2 appeared grossly normal in most cells. In
cells stained with mAb414, I noted frequent nuclear pore complex (NPC)
disorganization. Normally, NPCs are abundant and relatively evenly distributed across
the NE surface. In torsinA knockdown cells, I noted many cells with blotches of NPC-free
NE, as well as occasional cells with very low levels of mAb414 staining, or having a pole
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of the nucleus completely lacking in NPC signal (Figure 5-8C, D, arrows). Since these
poles also lacked Sun2 staining (Figure 5-8C,D, arrows), it is possible that these are
regions where the NE and/or underlying lamina are perturbed.
I also obtained short interfering RNA (siRNA) against LAP1. A representative
Western blot of the level of LAP1 knockdown achieved is shown in Figure 5-10A. I
analyzed the effect of LAP1 knockdown on other NE resident proteins. Cells lacking
LAP1 had grossly normal levels and localization of Sun1, Sun2, nesprin2-Giant, and
nesprin3 (Figure 5-9B-E). Occasionally, cells lacking Sun2 staining at the NE could be
found, as was also noted with LULL1 knockdown (Figure 5-9C, asterisks). Endogenous
LULL1 also appeared grossly normal (Figure 5-9F).
TorsinA moves into the NE when LULL1 is coexpressed, but it is unclear what
anchors torsinA in that compartment. A likely candidate would be LAP1, as this protein
binds to torsinA [6] and is a stable [9] and abundant component of the NE. To test
whether LAP1 is required for anchoring torsinA at the NE, I transfected LAP1 siRNAs
into a cell line inducibly expressing LULL1-myc. Cells were transfected with siRNA,
incubated for 60 hours, and expression of LULL1-myc was induced with tetracycline.
TorsinA-mGFP was transiently transfected into the cells 6-8 hours later. Cells were fixed
and stained for microscopy after ~18 hours of LULL1-myc and torsinA-mGFP coexpression. Despite the efficient knockdown of LAP1 protein at the NE, torsinA-mGFP
remained targeted to the NE (Figure 5-10C-E). Treatment with the control RNAi (which
targets firefly luciferase) caused a partial but significant decrease in frequency of NE
localization (Figure 5-10B,F). This is somewhat surprising since other groups have
reported that LAP1 is required for localization of the “substrate trapped” E171Q-torsinA
mutant to the NE [10]. These data suggest that LAP1 and LULL1 independently
influence torsinA localization. The question of what retains wild type torsinA in the NE
thus remains unanswered.
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TorsinA and LULL1 are required for interphase assembly of nuclear pore complexes
In my initial characterization of cell lines stably expressing torsinA or LULL1
shRNAs, I noticed that many cells had disorganized or diminished nuclear pore complex
(NPC) populations (Figure 5-8 and not shown). Our laboratory previously described the
accumulation of E171Q-torsinA-mGFP in pore-depleted islands of the NE [11]. Since
NPCs are normally evenly distributed across the NE, this could indicate that membranes
containing mutant torsinA are not competent for NPC insertion. We decided to analyze
the relationship between the levels of torsinA and LULL1 and NPC homeostasis in more
detail. In metazoan cells, NPCs are assembled by two distinct mechanisms at different
stages of the cell cycle [12]. Post-mitotic NPC assembly involves the recruitment of
soluble and membrane-bound NPC components to naked chromatin, and is coupled to
the reassembly of the NE. NPC insertion into the NE continues after the NE has
reformed during interphase. This latter mode of insertion requires the controlled fusion of
the inner and outer nuclear membranes and is less well understood. A recent study
describes a simple assay, based on the observation that total NPC numbers roughly
double through the cell cycle [13], to assess the relative efficiency of postmitotic versus
interphase NPC assembly [14]. I used this assay in U2OS cells to determine whether
changes to torsinA or LULL1 protein levels have any effect on NPC number.
U2OS cells or cells stably expressing shRNAs to torsinA or LULL1 were
synchronized in mitosis by nocodazole treatment and shake-off of the rounded mitotic
cells. Nocodazole was washed out and the cells were replated on coverslips to allow the
cell cycle to resume. Samples were collected after 5 hours and 19 hours. The former
timepoint is predominated by cells in early G1; these cells have just completed division
and NE reassembly and have a number of NPCs that were inserted concomitantly with
NE assembly. The latter timepoint is populated by cells in late G2; these nuclei have

181

grown in surface area, DNA content, and NPC number through S phase. Coverslips from
each timepoint were stained with mAb414 to detect NPCs, and the total fluorescence
intensity of NPCs was quantified. When U2OS cells are subjected to this analysis, the
intensity and thus overall number of NPCs roughly doubles between early and late
stages of the cell cycle (Figure 5-11A,D). In cells depleted of torsinA or LULL1, however,
NPC doubling is impaired (Figure 5-11B-D). These data suggest that torsinA and LULL1
may be involved in insertion of new NPCs into the NE.
It was previously noted that overexpressed E171Q-torsinA anti-localizes with
NPCs in the NE [11]. I also assessed cells overexpressing wild type or E171Q-torsinAmGFP and found that overexpression of either form of torsinA had a dominant effect on
NPC insertion; no increase in NPC intensity was observed through the cell cycle in cells
expressing wild type or E171Q-torsinA-mGFP (Figure 5-11E-H). It could be that if too
much of torsinA’s enzymatic activity is present at the NE, it could have a deleterious
effect on the process of NPC insertion. Alternatively, it may be that overexpression of
any protein that localizes partially or specifically to the NE inhibits NPC insertion.
Important controls to assess the specificity of this phenomenon will include knockdown
and overexpression of a NE and/or ER resident protein that is not expected to have a
function in NPC insertion.

∆GAG torsinA can oligomerize
Using native gel electrophoresis, I determined that torsinA can assemble into an
oligomer that migrates at an approximately hexameric size (Chapter 2, Figure 2-3).
Inheritance of one allele carrying the ∆GAG mutation can lead to dystonia. One
explanation for the dominant inheritance of dystonia could be that disease-mutant and
wild-type torsinA can coassemble. I find that ∆GAG-torsinA is also detectable as a
hexamer on BN-PAGE (Figure 5-12A). Blue Native PAGE separation of samples
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expressing differently tagged ∆GAG and wild type torsinA isoforms could be performed
to determine whether coassembly of mixed oligomers occurs. If coassembly is detected,
this could suggest that the ∆GAG mutation contributes to disease pathogenesis by
“poisoning” oligomers of wild type torsinA. If coassembly is not detected, this outcome
could also contribute to our understanding of dystonia. Because oligomeric species of
each form of torsinA are clearly detectable on Blue Native PAGE (Figure 2-3 and Figure
5-12A), a negative result would indicate that hetero-oligomers do not form or are
significantly less stable than homo-oligomers.

TorsinA and TorsinB can hetero-oligomerize
TorsinA has three homologs in humans; it has been suggested that these
homologs could compensate for loss of torsinA function in disease, perhaps explaining
why mutation to a ubiquitously expressed enzyme could lead to an exclusively neuronal
phenotype. It is thus desirable to understand whether the other torsin homologs could be
expected to be active AAA ATPases. To that end, I used Blue Native PAGE to determine
whether these homologs are also stable oligomers. Myc-tagged torsinA, torsinB,
torsin2A, or torsin3A were expressed in U2OS cells and subjected to Blue Native PAGE
in the presence of 0.5% digitonin. Oligomeric species were detected for torsinA,
torsin2A, and torsin3A, while torsinB was detectable only as a monomer (Figure 5-12B).
A related question of interest is whether torsin family members can heterooligomerize together to create mixed oligomers. To answer this question, I transiently
transfected cells stably expressing torsinA-mGFP with myc-tagged torsinB, torsin2A, or
torsin3A. These samples were subjected to Blue Native PAGE in the presence of 0.5%
digitonin, and the torsinA-mGFP signal was examined for unique bands when homologs
were co-expressed. Only torsinB-myc expression caused the migration of a GFPreactive band of unique size (~140 kDa) (other combinations not shown) (Figure 5-12D).
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This band was also detected by myc antibody, indicating that the band is composed of
torsinA-mGFP and torsinB-myc molecules (Figure 5-12E). These data suggest that
torsinA and torsinB could coassemble in cells. TorsinA and torsinB are the most closely
related members of the torsin subfamily, with torsin2A and torsin3A being more distantly
related. Interestingly, torsinB is the only other torsin family member that shares the
double Glu residues, which are commonly mutated in DYT1 dystonia, with torsinA [15].
Further, recent work in mice indicates that torsinB is highly expressed along with torsinA
in all tissues except brain [16, 17]; if torsinB can compensate for and/or cooperate with
torsinA, this could explain how mutation to torsinA causes exclusively neuronal
dysfunction.
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Figure Legends

Figure 5-1. Multiple sequence alignment of torsin AAA+ domains, aligned to residues
71-332 of human torsinA. Completely conserved residues are highlighted in green,
conserved residues in yellow; conservative substitutions are highlighted in cyan, and
nonconservative substitutions in white. Predicted secondary structure elements, based
on the alignment to ClpB in [7], are indicated below the alignment. Key regions of the
sequence are boxed in red. An absolutely conserved arginine residue at position 288 is
indicated (arrow).

Figure 5-2. Mutations to a possible pore loop affect torsinA’s targeting to the NE. (A)
Alignment to residues 145-156 of human torsinA where a pore loop may lie (see red
boxed region in Figure 5-1). Three mutants were generated: pore loop 1a (147YKD149 
AAA), pore loop 1b (150QLQ152  AAA), pore loop 1c (153LWI155  AAA). (B-E)
Epifluorescence microscopy of torsinA-mGFP (B-B’), torsinA-PL1a-mGFP (C-C’),
torsinA-PL1b-mGFP (D-D’), torsinA-PL1c-mGFP (E-E’) alone (B,C,D,E) or in cells
coexpressing LULL1-myc (B’,C’,D’,E’). (F) Quantification of the fraction of torsinA-mGFP
and LULL1-myc coexpressing cells having torsinA in the NE. N>100 cells per condition. *
indicates significant difference from WT by unpaired t-test (p<0.05).

Figure 5-3. Mutations to a possible pore loop affect torsinA’s activity in the NE. (A-D)
Epifluorescence microscopy of cells coexpressing torsinA-mGFP (A), torsinA-PL1amGFP (B), torsinA-PL1b-mGFP (C), or torsinA-PL1c-mGFP (D) and LULL1-myc (not
pictured), costained for endogenous Sun2. Scale bars, 10 µm. (E) Quantification of the
fraction of GFP-expressing cells lacking detectable Sun2 in the NE. N>100 cells per
condition. ER-GFP was used as a control for effect of transfection on Sun2 protein
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levels. * indicates significant difference from WT by unpaired t-test (p<0.05). (F) Coimmunoprecipitation of the indicated myc-tagged torsinA constructs with endogenous
LULL1.

Figure 5-4. Effect of R288A mutation on torsinA function. (A-B’) Epifluorescence
microscopy of torsinA-mGFP (A-A’) or torsinA-R288A-mGFP (B-B’) alone (A,B) or in
cells coexpressing LULL1-myc (A’, B’). (C) Quantification of the fraction of torsinA-mGFP
and LULL1-myc coexpressing cells having torsinA in the NE. N>100 cells per condition.
(D-E) Epifluorescence microscopy of cells coexpressing torsinA-mGFP (D) or torsinAR288A-mGFP (E) and LULL1-myc (not pictured), costained for endogenous Sun2. Scale
bars, 10 µm. (F) Quantification of the fraction of GFP-expressing cells lacking detectable
Sun2 in the NE. N>100 cells per condition. ER-GFP was used as a control for effect of
transfection on Sun2 protein levels. * indicates significant difference from WT by
unpaired t-test (p<0.05). (G) Co-immunoprecipitation of the indicated myc-tagged torsinA
constructs with endogenous LULL1. (H) Clear Native PAGE of GFP-tagged torsinA in
the presence of 0.25% dodecylmaltoside detergent. (I) SDS-PAGE separation of the
samples shown in (H).

Figure 5-5. Effect of R288Q mutation on torsinA function. (A-B’) Epifluorescence
microscopy of torsinA-mGFP (A-A’) or torsinA-R288Q-mGFP (B-B’) alone (A,B) or in
cells coexpressing LULL1-myc (A’, B’). (C) Quantification of the fraction of torsinA-mGFP
and LULL1-myc coexpressing cells having torsinA in the NE. N>100 cells per condition.
(D-E) Epifluorescence microscopy of cells coexpressing torsinA-mGFP (D) or torsinAR288Q-mGFP (E) and LULL1-myc (not pictured), costained for endogenous Sun2. Scale
bars, 10 µm. (F) Quantification of the fraction of GFP-expressing cells lacking detectable
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Sun2 in the NE. N>100 cells per condition. ER-GFP was used as a control for effect of
transfection on Sun2 protein levels. * indicates significant difference from WT by
unpaired t-test (p<0.05).

Figure 5-6. Immunofluorescence of NE resident proteins in LULL1-depleted cells. U2OS
or LULL1 shRNA line 2088 cells were stained for endogenous Sun1 (A), Sun2 (B),
nesprin2-Giant (C), nesprin3 (D), and LAP1 (E) and imaged by epifluorescence
microscopy. Images were acquired at similar exposure times to compare relative levels
of these proteins between U2OS and LULL1-depleted cells. Nuclei lacking Sun2 staining
are indicated with asterisks. Scale bars, 10 µm.

Figure 5-7. Sun2 is decreased in a survey of LULL1-depleted cell lines. U2OS (A),
LULL1 shRNA line 1269 (B), LULL1 shRNA line 1507 (C), and LULL1 shRNA line 2088
(D) cells were stained for endogenous Sun2. Images were acquired at similar exposure
times to compare relative levels of Sun2 amongst the different cell lines. Sun2 protein
levels are reproducibly decreased in the three LULL1-depleted cell lines tested. Nuclei
lacking detectable Sun2 are indicated with asterisks. Scale bars, 10 µm.

Figure 5-8. Stable knockdown of torsinA causes NE and NPC disorganization. (A)
Representative Western blot of four puromycin-selected clonal lines stably expressing
either hairpin 376 or hairpin 1911. The two lines expressing hairpin 376 show efficient
knockdown of torsinA. (B-D) Epifluorescence microscopy of U2OS (B), torsinA shRNA
line 376 clone 8 (C), or torsinA shRNA line 376 clone 21 (D), stained with mAb414 to
visualize NPCs and Sun2. Instances of partial or complete NPC displacement are
indicated by arrows. Scale bars, 10 µm.
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Figure 5-9. Immunofluorescence of NE resident proteins in LAP1-depleted cells. (A)
Representative Western blot of U2OS cell lysates that had been transfected with the
indicated concentrations of LAP1 or control (to firefly luciferase) siRNA for ~90 hours. (BF) LAP1-depleted cells were stained for Sun1 (B), Sun2 (C), nesprin2-Giant (D),
nesprin3 (E), or LULL1 (F). Images were acquired at similar exposure times to compare
relative levels of the indicated proteins between treatment conditions. All proteins tested
appeared grossly normal, with rare displacement of Sun2 from the NE (asterisks). Scale
bars, 10 µm.

Figure 5-10. LAP1 depletion has no effect on the ability of torsinA to move into the NE in
response to LULL1. Cells stably expressing LULL1-myc were transfected with the
indicated concentrations of control (to firefly luciferase) or LAP1 siRNA. After 60 hours of
siRNA incubation, tetracycline was added to induce LULL1 expression; torsinA-mGFP
was transfected into the cells 8 hours later. Coverslips were collected and processed by
immunofluorescence after ~18 hours of torsinA expression. (A-E) Cells transfected with
the indicated concentrations of siRNA and expressing torsinA-mGFP were stained for
endogenous LAP1 and myc to detect LULL1 (not shown). (F) The fraction of doubly
expressing cells with torsinA in the NE was quantified for each condition (N>100 cells
per condition). * indicates significant difference from no RNAi and Sham transfection
controls by unpaired t-test (p<0.05).

Figure 5-11. Altering LULL1 and torsinA expression levels inhibits the insertion of NPCs
into the NE. (A-C) Epifluorescence microscopy of U2OS, torsinA shRNA line 376-8, or
LULL1 shRNA line 2088 were stained with mAb414 antibody 5 hours and 19 hours after
being released from cell cycle block. (D) Quantification of total mAb414 fluorescence
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intensity. N>50 cells per condition. (E-G) U2OS, torsinA-mGFP, or E171Q-torsinAmGFP stably expressing cells were processed as in A-C. (H) Quantification of total
mAb414 fluorescence intensity. N>50 cells per condition.

Figure 5-12. Blue Native PAGE separation of torsin family members. (A) Separation of
overexpressed untagged wild type or ∆GAG-torsinA on BN-PAGE in the presence of
0.25% dodecylmaltoside. (B) Separation of the indicated myc-tagged torsin family
members on Blue Native PAGE in the presence of 0.5% digitonin. TorsinA, torsin2A, and
torsin3A are detectable in various oligomeric species, but no oligomers of torsinB were
observed. (C) SDS-PAGE separation of the samples from (A). (D) The indicated myctagged constructs were transfected into cells stably expressing torsinA-mGFP and the
lysates were separated on Blue Native PAGE in the presence of digitonin. A unique
~140 kDa band is detected by GFP (D) and myc (E) antibodies in samples coexpressing
both torsinA-mGFP and torsinB-myc, suggesting that torsinA and torsinB can coassemble. No coassembly was observed with torsinA and torsin2A or torsin3A (not
shown).

191

Figure 5-1

Walker A

H sapien A GQHLAKKIILNAVFGFINNPKPKKPLTLSLHGWTGTGKNFVSKII AENIYE 130
C familiaris A GQHLAKKVILNAVSGFISNPKPKKPLTLSLHGWTGTGKNFVSKII AENIYE
M musculus A GQHLAKKVILNAVSGFLSNPKPKKPLTLSLHGWTGTGKNFASKII AENIYE
X tropicalis A GQHLAKKVILKGVTGFLRNKQPKKPLTLSFHGWTGTGKNYISQVL ARNIYP
H sapiens B GQHLATEVIFKALTGFRNNKNPKKPLTLSLHGWAGTGKNFVSQIV AENLHP
OOC-5 GQHLVKDVVVNSIKSHWYNENPRKPLVLSFHGYTGSGKNYVAEII ANNTFR
α1

β2

α0

pore loop?
H sapien A
C familiaris A
M musculus A
X tropicalis A
H sapiens B

Walker B

G GLNSDYVH LFVATLHFPHASNITLYKDQLQLWIRGNVSACARSIFIFDEMDKMHAG 190
G GLNSDYVH LFVATLHFPHASNITLYKDQLQLWIRSNVSACARSIFIFDEMDKMHAG
G GLNSDYVH LFVATLHFPHASNITQYKDQLQMWIRGNVSACARSIFIFDEMDKMHAG
Q GMESHFVH QFVATLHFPHANQVDKYKDQLQAWIKGNVSNCERSIFIFDEVDKMHPG
K GLKSNFVH LFVSTLHFPHEQKIKLYQDQLQKWIRGNVSACANSVFIFDEMDKLHPG
L GLRSTFVQ HIVATNDFPDKNKLEEYQVELRNRILTTVQKCQRSIFIFDEADKLPEQ
β2

α2

β3

Sensor I
H sapien A
C familiaris A
M musculus A
X tropicalis A
H sapiens B
OOC-5

LIDAIKPFLDYY DLVDGVSYQKAMFIFLSNAGAERITDVALDFWRSGKQRE DIKLK D 250
LIDAIKPFLDYY DHVDGVSYQKAIFIFLSNAGAERITDVALDFWRSGKQRE EIRLK D
LIDAIKPFLDYY DVVDEVSYQKAIFIFLSNAGAERITDVALDFWKSGKQRE EIKLR D
LIDSIKPFLDYY EQLEGVSYRKSIFIFLSNAGGEIISKLALDFWKNGKKRE DINLF E
IIDAIKPFLDYY EQVDGVSYRKAIFIFLSNAGGDLITKTALDFWRAGRKRE DIQLK D
LLGAIKPFLDYY STISGVDFRRSIFILLSNKGGGEIARITKEQYESGYPRE QLRLE A
β4

α3

H sapien A
C familiaris A
M musculus A
X tropicalis A
H sapiens B
OOC-5

IEHALSVSVFNNKNS GFWHSSLIDRNLIDYFVPFLPLEYKHLKMCIRVEMQ SRG---307
MEPALSVSAFNNKNS GFWHSSLIDRNLIDYFVPFLPLEYKHLKMCIRVEMQ SRG--MEPALAVSVFNNKNS GFWHSSLIDRNLIDYFVPFLPLEYKHLKMCIRVEMQ SRG--VERQLSLAAFNNKDS GFWHSSLIEKNLIDFFVPFLPLELKHVKMCVRAELR HRG--LEPVLSVGVFNNKHS GLWHSGLIDKNLIDYFIPFLPLEYRHVKMCVRAEMR ARG--FERELMNFSYNEK-G GLQMSELISNHLIDHFVPFLPLQREHVRSCVGAYLR KRGRGD
α4

β5

α5

E302/303
Sensor 2
H sapien A YEIDEDIVSRVAEEMTFF PKEERVFSDKGCKTVFTKLDYYYDD------- -------332
C familiaris A FDIDEDIVTKVADEMTFF PKEERVFSDKGCKTVFTKLDYYYD-------- ------M musculus A YEVDEDIISKVAEEMTFF PKEEKVFSDKGCKTVFTKLDYYLDD------- ------X tropicalis A YEVDEEIVTKVAKEMTYF PKDENVFSVRGCKVVSTKLEFYL--------- ------H sapiens B SAIDEDIVTRVAEEMTFF PRDEKIYSDKGCKTVQSRLDFH---------- ------OOC-5 LVSNVDFVERVLNSLQYF PESSKAFSSSGCKRVDAKTDLEMAKIRPLLSS VHFDDEL
β6

α6

α7

192

15
5

A

14
7

Figure 5-2

H sapiens Torsin A TLYKDQLQLWIR
M musculus Torsin A TQYKDQLQMWIR
X tropicalis Torsin A DKYKDQLQAWIK
H sapiens Torsin B KLYQDQLQKWIR
C elegans OOC-5 EEYQVELRNRIL
Pore loop 1a (PL1a)...LAAAQL...
...DAAALW...
Pore loop 1b (PL1b)
...QAAAIR...
Pore loop 1c (PL1c)

B

B’

torsinA-mGFP

C

torsinA-mGFP

C’

LULL1-myc

merge

PL1a-mGFP

PL1a-mGFP

LULL1-myc

merge

D

D’

PL1b-mGFP

E

PL1b-mGFP

E’

LULL1-myc

merge

PL1c-mGFP

PL1c-mGFP

LULL1-myc

merge

F

193

1c
PL

1b
PL

PL
1a

W

T

*

Figure 5-3
A

torsinA-mGFP

Sun2

merge

PL1a-mGFP

Sun2

merge

PL1b-mGFP

Sun2

merge

PL1c-mGFP

Sun2

merge

B

C

D

EE

E1

71
Q
E1
71
Q
E1
+
71 PL
1a
Q
+
E1
71 PL
1b
Q
+
PL
1c

F

TorA-myc
LULL1 (IP)

1c
PL

PL
1b

PL

1a

*

194

Figure 5-4

C

A

A’

torsinA-mGFP

torsinA-mGFP

B

B’

R288A-mGFP

R288A-mGFP

LULL1-myc

merge

LULL1-myc

merge

F

torsinA-mGFP

Sun2

merge

Sun2

merge

fraction GFP-positive cells lacking Sun2

D

E1

torsinA-myc
LULL1 (IP)

669 kDa
440 kDa
232 kDa
140 kDa

I

195

28
R

ild

ty

pe

H
w

G

71
E1 Q
71
w Qild R
ty 288
pe A

R288A-mGFP

8A

E

*

Figure 5-5

torsinA-mGFP

B

B’

R288Q-mGFP

R288Q-mGFP

LULL1-myc

merge

LULL1-myc

merge

R

28
8Q

torsinA-mGFP

C

TA

A’

W

A

Sun2

merge

E

R288Q-mGFP

D
196

*

TA
-G
FP
R
28
8Q

merge

ER

Sun2

W

torsinA-mGFP

fraction GFP-positive cells lacking Sun2

F

D

Figure 5-6

U2OS

LULL shRNA (2088)

Sun1

A

1700 ms

1700 ms

1700 ms

1700 ms

B
Sun2

*

1800 ms

*

3000 ms

2300 ms

1800 ms

2300 ms

2100 ms

2400 ms

4000 ms

3600 ms

3600 ms

nesp2G

C

2100 ms

nesprin3

D

4100 ms

LAP1

E

*
2700 ms

6400 ms

4000 ms

197

4500 ms

*

hairpin 2088

hairpin 1507
hairpin 1269

U2OS

Figure 5-7

Sun2

*

DAPI

A

B
*

*

*

C
*

*

D
*

*

198

hairpin 376 clone 21

hairpin 376 clone 8
U2OS

37
68
37
621
19
11
-2
19
11
-8

Figure 5-8
A

TorsinA

α-tubulin

B

mAb414

C
mAb414
Sun2
Sun2
DAPI

D

199
merge

10

A

nM
20 LA
nM P1
50 LA
nM P1
20 LA
nM P1
ct
rl

Figure 5-9

-

-

75 kDa
LAP1

50 kDa
37 kDa
25 kDa

α-tubulin
20 nM LAP1 siRNA

20 nM control siRNA

Sun1

B

Sun2

C
*

*
*

Nesprin2G

D

Nesprin3

E

LULL1

F

200

50 nM LAP1 siRNA

20 nM LAP1 siRNA

10 nM LAP1 siRNA

20 nM control siRNA

no siRNA

Figure 5-10

A
TorA-mGFP
AP-LAP1
F

*

B

C

D

E

201

Figure 5-11
5h (G1)

19h (G2)

5h (G1)

19h (G2)

D

U2OS

A

TorA shRNA

B

LULL shRNA

C

E
U2OS

H

E171Q-torA-mGFP

TorA-mGFP

F

G

202

To
r

kDa

ΔG

A

A
To GrA

A.

B.
kDa

669
440

669

669

440

440

232

232

232

140

140

To
rA
-m
y
To
rB c
-m
yc
To
r2
-m
To yc
r3
-m
yc

Figure 5-12

140

66

66

66

C.
50
37

D.
kDa

+
-

E.

+
+

kDa

669

669

440

440

232

232

*

140

-

+
+

*

140

66

66
WB: GFP

WB: myc

203

TorsinA-mGFP
TorsinB-myc

Chapter 6

Summary and Discussion

204

Summary of the thesis
AAA+ ATPase enzymes couple ATP hydrolysis to the exertion of conformational
change on a substrate. TorsinA is one of the few AAA+ ATPases that reside within the
lumen of the mammalian endoplasmic reticulum (ER), where it performs an essential
function. As an AAA+ ATPase, torsinA is expected to modulate the folded state of
protein substrate(s). Determining the cellular function of this enzyme is the broad goal of
this thesis.
The work presented here demonstrates that torsinA may be targeted specifically
to the NE, where other studies have suggested it may function. TorsinA is dynamically
targeted from ER to NE upon coexpression with LULL1; this is concomitant with
displacement of NE resident transmembrane proteins including Sun2, nesprin-2, and
nesprin-3. Because Sun and nesprin proteins cooperate to anchor the nucleus to the
cytoskeleton, these effects suggest a role for torsinA in modulating nuclear positioning.
The dystonia-causative ΔGAG mutant can also be enriched in the NE by LULL1, but is
extremely inefficient at displacing Sun2. These findings identify a possible activity of
torsinA at the NE as well as a mechanism for regulating this activity via LULL1, and
suggest that activity at the NE is perturbed by the disease-causative ΔGAG mutation
(Chapter 2). We also find that a rare second dystonia-causative mutation, R288Q, has a
similar cellular phenotype to ΔGAG (Chapter 5), strengthening the argument that
dysfunction of torsinA at the NE causes disease.
By analyzing the features of torsinA required for response to LULL1, we
determined that an N-terminal hydrophobic domain (NTD) is required for NE targeting
(Chapter 2). Surprisingly, deletion of this domain also abolishes retention of torsinA
within the ER. I demonstrate that the NTD mediates stable monotopic association with
the lumenal leaflet of the ER, which in turn controls ER retention (Chapter 3). It has been
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shown that TMDs from some ER resident proteins control targeting by selective
partitioning among different domains of the membrane bilayer. I propose that this lipidbased sorting mechanism extends to monotopic membrane proteins, and identify a
group of proteins that may share torsinA’s topology and ER retention mechanism, This
group includes the pharmacologically important prostaglandin synthetic enzyme COX1
(Chapter 3). This study has several exciting implications. Firstly, it identifies a previously
unknown way for lumenal membrane proteins to escape “bulk flow” secretion out of the
ER without the intervention of recycling receptors or vesicular coat proteins. Secondly,
many monotopic membrane domains have been shown to sense membrane curvature;
torsinA’s NTD could preferentially partition into relatively flat membranes, and thus
contribute to torsinA’s targeting to the NE by LULL1. Finally, homology models suggest
that the NTD could place torsinA’s central catalytic pore proximal to the membrane,
which could have consequences for engagement with transmembrane protein
substrates.
Returning to the interaction between torsinA and LULL1, I identify nonoverlapping regions of LULL1 that are responsible for torsinA binding and torsinA retargeting to the NE. Specifically, a conserved helix at the extreme C terminus of LULL1
mediates its interaction with torsinA, while residues at the extreme N terminus of LULL1
must be present in order for torsinA to be effectively targeted to the NE. Importantly, the
N terminus of LULL1 is cytosolic, while the C-terminal torsinA-binding domain is lumenal,
raising the intriguing possibility that control of torsinA localization involves
communication between the cytosol and the ER lumen (Chapter 4). Separately,
conserved cysteines in LULL1’s lumenal domain must be present in order for LULL1 to
re-target torsinA, which might suggest that regulation of torsinA by LULL1 involves a
redox component.
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The work in this thesis provides new insights into aspects of torsinA’s cellular
function and dysfunction in disease, as well as the sorting mechanisms that lumenal
membrane proteins, including torsinA, use to achieve ER localization.
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Discussion
Understanding torsinA’s dysfunction in dystonia
Deletion of one of a pair of glutamic acids (E302/303) is the most common
causative mutation in early onset torsion dystonia [1]. The ∆GAG mutation cannot
rescue the lethality of torsinA knockout [2], lacks the ability to displace NE resident
proteins in a cellular assay [3] (Chapter 2), and weakens binding to LAP1 and LULL1 [4],
supporting the hypothesis that the mutant lacks the enzyme’s normal function. However,
the ∆GAG mutation causes mislocalization to the NE [5, 6], overexpressed ∆GAGtorsinA inhibits flux through the secretory pathway [7], and ∆GAG-torsinA can also
assemble into a hexamer (Chapter 5), suggesting a means for a toxic gain of function.
Unfortunately, mice heterozygous (∆GAG/+) for the DYT1 mutation, which should model
the human disease state, do not exhibit outward signs of disease or inward signs of
pathology [2], which has proven a roadblock to studying the disease. Brain imaging
studies of human subjects have made some headway in identifying changes to brain
circuitry in the disease state [8, 9], and these differences were recently confirmed to also
exist in the mouse model [10]. A key consideration in understanding torsinA function
may be the developmental window in which torsinA is required. ∆GAG/∆GAG mice
gestate normally, but die shortly after birth; nuclear envelope membrane deformations
become more pronounced as neurons mature [2]. One possibility may be that torsinA
functions in the NE during or at the conclusion of neuronal migration. Continued analysis
of the physiological, cell biological, and biochemical effects of this mutation will be
needed to determine how and when it affects normal enzyme function and causes
disease.
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Is torsinA a functioning AAA+ ATPase?
Work in this thesis and contemporaneous work by other groups supports the
possibility of torsinA being an active AAA+ ATPase enzyme. We determined that in
cellular extracts, torsinA assembles into oligomers of approximately hexameric size
(Chapter 2), which is typical of Class II AAA+s. Purified OOC-5 (the C elegans homolog)
becomes more thermostable in the presence of nucleotide, which likely means that
torsinA at least binds to ATP [11]. Weak hydrolysis of ATP has been reported with the
purified AAA+ domain of human torsinA, although this fragment was monomeric [12].
Further, various mutations to the catalytic domain have been shown by our laboratory
and others to affect torsinA’s behavior in vivo [4-6, 13]. We have determined that torsinA
associates with membranes via a hydrophobic N terminal domain (Chapter 3). Deletion
of this domain affects cellular readouts of torsinA activity (Chapter 2), and it may also be
that this domain (and an associated membrane) must be present for optimal ATPase
activity of torsinA. A future goal should be to determine conditions for isolation of an
active oligomer with ATPase activity that can be reproducibly observed; it would then be
possible to determine whether this activity is impaired by dystonia-causative mutations
or modulated by the NTD, LAP1, LULL1, or putative substrate proteins such as the Suns
and nesprins.

Functional significance of torsinA’s effects on LINC complex proteins
We have established that torsinA moves into the NE and displaces select NE
resident proteins when induced to move there by LULL1. These proteins are
components of the linker of nucleoskeleton and cytoskeleton (LINC) complex, which
functions in nuclear positioning by tethering the nuclear lamina to the cytoskeleton [14,
15]. Correct LINC complex function is required for establishment of cell polarity and
subsequent cellular migration; these proteins are thus important for proper development
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of the brain [16] and other tissues [17, 18]. Data in model organisms [19] and in cellular
assays [20] support the idea that torsinA has a role in nuclear movement. However,
antibody limitations prevent us from determining whether endogenous torsinA enriches
in the NE in response to increased LULL1 expression. Depletion of endogenous torsinA
by RNAi did not seem to affect LINC complex protein levels or localization in our hands
(Chapter 5) although nesprin-3 displacement has been reported in torsinA -/- fibroblasts
[20] and depletion of the cofactor LULL1 did cause mislocalization of Sun2 (Chapter 5).
The displacement of LINC complex proteins from the NE is admittedly an indirect
readout of torsinA’s putative activity. We know that torsinA causes the displacement of
Sun2, nesprin2, and nesprin3 from the NE when it is concentrated there. However, we
know little about the molecular changes taking place to these proteins and their binding
partners at the NE. It may be that these three proteins show this change in localization
because torsinA has dissolved the interaction(s) responsible for retaining them at the
NE. If torsinA is disassembling intact LINC complexes, this could then allow the nucleus
to move or rotate within the cell. It is important to note that similar conformational
changes could be happening to other proteins that could affect their oligomeric state or
interaction with partners without causing their displacement from the NE. We do not yet
have a full picture of torsinA’s activity on NE structure and components.
Preliminary data (Chapter 5) indicate that torsinA may play a role in interphase
NPC insertion, a process that every cycling cell participates in [21]. Our laboratory
previously reported that overexpressed E171Q-torsinA concentrates in pore-depleted
regions of the NE, inducing ultrastructural deformations including NE thinning and
bubbling [6]. The idea of a molecular machine such as an ATPase participating in
membrane deformation to allow NPC insertion is intuitively attractive. Intriguingly, very
recent (unpublished) work indicates that Sun1, which is known to associate more
intimately with NPCs than Sun2 [22], is involved in this process as well (Talamas et al, in
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press). We found that torsinA does not displace Sun1 from the NE (Chapter 2), but it is
possible that torsinA could modulate Sun1 in other ways. For instance, it is known that
Sun1 and Sun2 hetero-oligomerize via their lumenal coiled-coil domains [23], although it
is not clear how formation of these oligomers relates to participation in LINC complexes.
To gain greater resolution of torsinA’s activity on the LINC proteins, it will be necessary
to reconstitute the interaction of torsinA with individual LINC proteins and intact LINC
complexes.

The significance of torsinA’s interactions with LAP1 and LULL1
LAP1 and LULL1 bind to torsinA in an ATP-dependent fashion [4, 24], and
LULL1 co-assembles into an oligomer with ATP-trapped E171Q-torsinA (Chapter 4).
Similarly to other AAA+ ATPases with divergent Walker-A motifs [25, 26], it could be that
interaction with cofactors stimulates torsinA’s ATPase activity. This interaction would
then be a means of regulating torsinA’s enzymatic activity on substrate protein(s).
The consequences of torsinA’s interaction with LULL1 have been a major focus
of the work presented here. LULL1’s ability to promote accumulation of torsinA in the NE
has parallels to the ability of other AAA+ cofactors to direct enzymes to their targets [27].
The activating signal could involve the transmission of a conformational change from
LULL1 to torsinA; alternatively, other domains of LULL1 could serve as a platform for
interaction of torsinA with NE resident binding partners. Control of this signal could be
achieved by controlling LULL1 expression level or addition of activating/inhibitory
modifications to LULL1, to name a few possibilities. Analysis of the features of the
LULL1-torsinA interaction and identification of any additional cellular factors that promote
torsinA activation will continue to further our understanding of regulation of torsinA by
LULL1.
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Less is understood about the importance of LAP1 to torsinA function. LAP1 is an
abundant component of the inner nuclear membrane that directly interacts with the
nuclear lamina [28]. Mutations that trap torsinA on ATP (so-called ‘substrate traps’) also
cause torsinA to accumulate in the NE [6], and this relies on the presence of LAP1 in the
NE [29]. However, interaction of torsinA with LAP1 at the NE does not promote
displacement of LINC proteins as seen with LULL1 [3](Chapter 2). Depletion of LAP1 in
mice is perinatally lethal, and causes ultrastructural abnormalities at the NE that bear
similarity to the phenotype observed in neurons lacking torsinA [30]. Depletion of LAP1
in cells did not significantly affect LINC complex protein localization or LULL1-dependent
torsinA targeting (Chapter 5). It may be that LULL1 and LAP1 promote distinct functions
of torsinA at the NE. Separately, it is possible that LAP1 has torsinA-independent
functions the nuclear periphery.
LAP1 function has not been studied extensively; however, it was noted that LAP1
is found in membrane vesicles associated with the mitotic spindle during mitosis [31].
More recently, it was demonstrated in an RNAi screen that ablation of LAP1 results in a
mitotic delay [32]. This delay was determined to arise from failures in mitotic spindle
establishment. Somewhat surprisingly, torsinA did not exhibit a related phenotype in this
screen. Such a finding could indicate an independent function for LAP1, or could
suggest that a redundant enzyme compensates when torsinA is knocked down.
Regardless, a potential role of LAP1 in mitotic spindle formation could be an exciting
area for future exploration.

Do torsinA and torsinB have overlapping functions?
TorsinA and TorsinB are the most closely related torsin family members, having
~70% homology between the human sequences [33]. TorsinB can interact with LAP1 to
some extent [29, 30], so it is possible that LAP1 and/or LULL1 might also influence
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torsinB activity. TorsinA-null mice have distorted NEs exclusively in neurons; knockout of
torsinB in fibroblasts from these mice caused the emergence of these ultrastructural
defects [30]. Combined with the fact that torsinA and B are coexpressed in most tissues,
but only torsinA is expressed in neurons, these data suggest that torsinB may
compensate for torsinA loss in non-neuronal tissues [30]. If this is the case, this may
help to explain the contradiction between the relatively mild effects of depleting torsinA in
most cells and the basic cellular functions ascribed to the enzyme. Dual depletion of
torsinA and torsinB may reveal more dramatic effects on NE structure and function.
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Appendix I

Generation of affinity-purified LAP1 and LULL1 antibodies
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In order to study the roles of LAP1 and LULL1 proteins in regulating torsinA
function, it is desirable to have a method of detecting the endogenous proteins. We
chose to generate antibodies to human LAP1 and LULL1, using the divergent
extralumenal domains of these two proteins as antigens.
A glutathione-S-transferase (GST) epitope tag was affixed to the N terminus of
the protein domains for affinity purification. Plasmids encoding GST-tagged LAP1 or
LULL1 residues 1-217 were transformed into E. coli BL21-CodonPlus(DE3)-RIL cells
(Stratagene) and grown on agar plates. The resulting colonies were used to inoculate 2
x 500 mL flasks of TB media. Cultures were grown at 37°C until density reached an
OD600 of ~0.8. Cultures were then cooled to room temperature, induced with 0.5 mM
IPTG, and grown an additional 3 hours at room temperature. The cultures were collected
by centrifugation and lysed in buffer containing 100 mM HEPES pH 7.4, 300 mM NaCl,
5% glycerol, 1 mM EDTA, 1 mM DTT, and 1 mM PMSF by 3 x 30-second pulses of
sonication on ice. Triton-X-100 detergent was then added to 1% final concentration and
samples were solubilized for 30 minutes at 4°C. Soluble material was harvested by
centrifugation at 12,000 rpm for 10 minutes at 4°C. Glutathione-conjugated Sepharose
beads (GE Healthcare) were equilibrated in lysis buffer, then incubated with the
supernatant for 1 hour at 4°C. The mixture was then centrifuged at 1000 rpm for 5
minutes at 4°C to separate unbound material. The resin was washed with lysis buffer
supplemented with Triton-X-100 detergent, then incubated in lysis buffer supplemented
with 50 mM glutathione to elute protein. Elutions were collected by centrifugation at 1000
rpm. Analysis of the eluates by SDS-PAGE and Coomassie stain demonstrates that the
GST fusion proteins were purified to homogeneity (Figure A-1). GST-LAP1 1-217 did not
elute efficiently from the glutathione resin; protein was released by boiling the resin in
SDS-PAGE sample buffer. Several milligrams of purified protein were then run on a
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preparative SDS-PAGE gel, and the fixed and Coomassie-stained gel slices were sent to
Sigma Genosys for rabbit immunization and serum production.
The crude sera were reactive to overexpressed and endogenous protein (Figure
A-2) as well as to GST (not shown). The sera were depleted of GST-reactive antibodies
by incubation with GST protein, and subsequently affinity purified on immobilized GSTLAP 1-217 or LULL 1-217. Affinity purification increased antibody specificity and ability to
detect endogenous protein. For an example of detection of LULL1 by Western blot with
affinity-purified serum, see Figure 2-3. See Figure A-3 for an example of specific
detection of LAP1 with affinity-purified serum. LAP1 is spliced into up to three distinct
proteins- LAP1A, LAP1B, and LAP1C; the variable sequences are found in the
nucleoplasmic domain, which was used as the antigen for antibody production. The
affinity-purified LAP1 serum variably recognizes one to three bands of distinct molecular
weight in U2OS cells.
The ability of the affinity purified sera to detect LAP1 and LULL1 by
immunofluorescence was also tested. U2OS cells expressing LULL1-myc or LAP1mGFP were fixed for 10 minutes in 4% paraformaldehyde, followed by permeabilization
for 10 minutes in 0.2% Triton-X-100, blocking for 30 minutes in 2% goat serum, and
incubation with the indicated antibodies. The affinity purified antibody signals were
comparable to the epitope tag signals (Figure A-4A, A-4B). In U2OS cells, which express
sufficient endogenous LAP1 and LULL1 to be detected reliably on a Western blot (see
above), immunofluorescence signals in the expected cellular compartments are
observed. LULL1 is detected in the NE and ER; the signal appears better preserved in
cells that were permeabilized with 0.1% saponin (Figure A-4C) than in cells
permeabilized with 0.2% Triton-X-100 (Figure A-4D). LAP1, conversely, is detected
clearly at the NE in cells permeabilized with 0.2% Triton-X-100 (Figure A-4F), and less
so in cells permeabilized with 0.1% saponin (Figure A-4E). This detection only after
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incubation with more stringent detergent may reflect the fact that the LAP1 epitope lies
within the domain known to associate with the nuclear lamina.
Finally, the ability of the sera to immunoprecipitate endogenous LAP1 and LULL1
was assessed. U2OS cell lysates from a 35 mm culture dish were incubated with two
microliters of affinity-purified anti-LAP1 or anti-LULL1 serum, followed by
immunoprecipitation of the protein:antibody complexes with Protein G-conjugated
Sepharose. As demonstrated in Figure A-5, the affinity purified sera also
immunoprecipitate endogenous LAP1 and LULL1 well.
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Figure Legends
Figure A-1. GST affinity purification of LAP1 and LULL1 extralumenal domains from E.
coli. (A) GST-LULL1 1-217 or (B) GST-LAP1 1-217 were expressed and purified from E.
coli by glutathione resin affinity purification. Aliquots of unbound material, glutathioneeluted material, and material remaining on glutathione resin were analyzed by SDSPAGE and Coomassie stain.

Figure A-2. Western blots with sera generated against LAP1 and LULL1. (A) Cell
lysates from cells expressing LULL1-myc were subjected to Western blot with
preimmune serum at 1:1000 dilution or anti-GST-LULL1 1-217 serum at 1:1000 dilution.
LULL1-myc is detected by serum raised to the LULL1 1-217 antigen but not by
preimmune serum. (B) Cell lysates from cells transfected (+) or not (-) with LAP1-myc
were subjected to Western blot with anti-GST-LAP1 1-217 serum at 1:500 dilution.
LAP1-myc and a slightly smaller band that could be endogenous LAP1 are detected by
the serum. Nonspecific lower molecular weight bands are also apparent.

Figure A-3. Affinity purified serum to human LAP1 specifically detects endogenous
LAP1 in U2OS cells. A specific ~60 kDa band corresponds to human LAP1 and is
detected in untreated or control siRNA-treated cells, but is absent in cells treated with
10-50 nM of LAP1 siRNA.

Figure A-4. Immunofluorescent detection of LAP1 and LULL1 with affinity purified sera.
(A) Cells stably expressing LULL1-myc were costained with myc and AP-LULL1
antibodies at 1:500 dilution; myc and AP-LULL1 signals coincide. (B) Cells transiently
expressing LAP1-mGFP were stained with AP-LAP1 antibody at 1:100 dilution. AP-LAP1
recognizes LAP1-mGFP and more dimly, endogenous LAP1 in nearby cells. (C-F) After
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fixing, U2OS cells were permeabilized with the indicated detergents for 10 minutes,
followed by blocking in goat serum and incubation with (C-D) AP-LULL at 1:100 dilution
or (E-F) AP-LAP1 at 1:100 dilution.

Figure A-5. Affinity purified antibodies immunoprecipitate endogenous LULL1 and
LAP1. (A-B) U2OS cell lysates from 35 mm dishes were incubated with two microliters of
the indicated antibodies, followed by immunoprecipitation of the protein:antibody
complexes with Protein G-conjugated Sepharose beads. Immunoprecipitated material
was detected by Western blot with the same antibodies. The relative positions of the
immunoprecipitated protein and the cross-reacting antibody chains (IgG) are indicated
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Name of plasmid
Lenti LULL1 shRNA 1269
Lenti LULL1 shRNA 1507
Lenti LULL1 shRNA 1697
Lenti LULL1 shRNA 1895
Lenti LULL1 shRNA 2088
pcDNA4 LULL1-myc
pcDNA4 LULL1-myc 1-439
pcDNA4 LULL1-myc 1-373
pcDNA4 LULL1-myc 1-217
pGEX LULL1 1-217
pcDNA4 LULL1-myc 1-241
pShooter LULL1-myc 373-470
pShooter LULL1-myc 241-470
pcDNA4 LULL1-myc 207-470
pcDNA4 LULL1-myc 101-470
pcDNA4 LULL1-myc 51-470
eGFPN1 LULL1-GFP
TagRFPN1 LULL1-RFP
TagRFPC1 RFP-LULL1
pmCherryN1 LULL1-mCherry
pcDNA4 LULL1-myc S70D
pcDNA4 LULL1-myc S70A
pcDNA4 LULL1-myc S72D
pcDNA4 LULL1-myc S72A
pcDNA4 LULL1-myc C310S
pcDNA4 LULL1-myc C382S
pcDNA4 LULL1-myc C468S
pcDNA4 LULL1-myc C310/382S
pcDNA4 LULL1-myc C382/468S
pcDNA4 LULL1-myc C310/468S
pcDNA4 LULL1-myc 3 x C/S
pcDNA4 LULL1-myc KKAA
pcDNA4 LULL1-myc RRAA 178/179

Key word
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1

expression
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
bacterial
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian

antibiotics
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Kan
Kan
Kan
Kan
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp

original
DNA source
TRC1
TRC1
TRC1
TRC1
TRC1
cloned by SD
cloned by ABV
cloned by ABV
cloned by SD
cloned by SD
cloned by SD
cloned by ABV
cloned by SD
cloned by ABV
cloned by ABV
cloned by ABV
cloned by SD
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV

Primers
(Fwd/Rev)
N/A
N/A
N/A
N/A
N/A
N/A
PHA 717/PHB 123
PHA 717/PHB 168
N/A
N/A
N/A
PHB 190/PHB 191
N/A
PHB 189/PHB 718
PHB 252/PHB 718
PHB 271/PHB 718
N/A
N/A
PHB 272/PHB 273
N/A
PHB 348/PHB 349
PHB 350/PHB 351
PHB 352/PHB 353
PHB 354/PHB 355
PHB 39/PHB 40
PHB 41/PHB 42
PHB 43/PHB 44
see above
see above
see above
see above
PHB 153/PHB 154
PHB 149/PHB 150

Restriction
enzyme (5'/3') backbone vector
N/A
pLKO
N/A
pLKO
N/A
pLKO
N/A
pLKO
N/A
pLKO
N/A
pcDNA4/TO/MycHisB
EcoRI, HindIII pcDNA4/TO/MycHisB
EcoRI, HindIII pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pGEX 4T
N/A
pcDNA4/TO/MycHisB
SalI, NotI
pCMV/myc/ER
N/A
pCMV/myc/ER
EcoRI, HindIII pcDNA4/TO/MycHisB
EcoRI, HindIII pcDNA4/TO/MycHisB
EcoRI, HindIII pcDNA4/TO/MycHisB
N/A
eGFP-N1
HindIII, EcoRI Tag-RFP-N1
HindIII, EcoRI Tag-RFP-C1
HindIII, EcoRI pmCherry-N1
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
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Name of plasmid
pcDNA4 LULL1-myc RRAA 179/180
pcDNA4 LULL1-myc T307A
pcDNA4 LULL1-myc T307S
pcDNA4 LULL1-myc D441A
pcDNA4 LULL1-myc S444A
pcDNA4 LULL1-myc L446R
pcDNA4 LULL1-myc R449A
pcDNA4 LULL1-myc I450R
pcDNA4 LULL1-myc L453R
pcDNA4 LAP1-myc 1-367
pcDNA4 LAP1-myc 1-240
pcDNA4 LAP1-myc 1-217
pcDNA4 LAP1-myc 367-462
Lenti torsinA shRNA 376
Lenti torsinA shRNA 442
Lenti torsinA shRNA 529
Lenti torsinA shRNA 819
Lenti torsinA shRNA 1911
eGFPN1 torsinA mGFP
pcDNA4 torsinA-myc
eYFPN1 torsinA-YFP
eCFPN1 torsinA-CFP
eGFPN1 torsinA/d26-43-mGFP
pcDNA4 torsinA/d26-43-mGFP
eGFPN1 torsinA pore loop 1-mGFP
eGFPN1 torsinA pore loop 2-mGFP
eGFPN1 torsinA pore loop 3-mGFP
eGFPN1 torsinA R260A-mGFP
eGFPN1 torsinA R288A-mGFP
eGFPN1 torsinA N143Q-mGFP
eGFPN1 torsinA N158Q-mGFP
eGFPN1 torsinA-dGAG mGFP
eGFPN1 torsinA LALALA mGFP
eGFPN1 torsinA ALA/RRR mGFP

Key word
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LULL1
LAP1
LAP1
LAP1
LAP1
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA

expression
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian

antibiotics
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Amp
Kan
Amp
Kan
Kan
Kan
Amp
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan

original
DNA source
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by SD
cloned by SD
cloned by ABV
TRC1
TRC1
TRC1
TRC1
TRC1
cloned by TN
cloned by TN
cloned by TN
cloned by TN
cloned by TN
cloned by TN
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by TN
cloned by ABV
cloned by ABV

Primers
(Fwd/Rev)
PHB 151/PHB 152
PHB 356/PHB 357
PHB 369/PHB 370
PHB 293/PHB 294
PHb 377/PHB 378
PHB 297/PHB 298
PHB 295/PHB 296
PHB 299/PHB 300
PHB 379/PHB 380
PHA 721/PHB 167
N/A
N/A
PHB 226/PHB 227
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
PHB 216/PHB 217
PHB 218/PHB 219
PHB 220/PHB 221
PHB 222/PHB 223
PHB 224/PHB 225
PHB 236/PHB 237
PHB 238/PHB 239
N/A
PHB 207/PHB 208
PHB 179/PHB 180

Restriction
enzyme (5'/3') backbone vector
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
EcoRI, HindIII pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
N/A
pcDNA4/TO/MycHisB
SalI, NotI
pcDNA4/TO/MycHisB
N/A
pLKO
N/A
pLKO
N/A
pLKO
N/A
pLKO
N/A
pLKO
N/A
eGFP-N1
N/A
pcDNA4/TO/MycHisB
N/A
eYFP-N1
N/A
eCFP-N1
N/A
eGFP-N1
N/A
pcDNA4/TO/MycHisB
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
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Name of plasmid
eGFPN1 torsinA Ala insert mGFP
eGFPN1 torsinA L28R mGFP
eGFPN1 torsinA A29R mGFP
eGFPN1 torsinA L30R mGFP
eGFPN1 torsinA L31R mGFP
eGFPN1 His-torsinA-mGFP
eGFPN1 torsinA D216A mGFP
eGFPN1 torsinA F221A mGFP
eGFPN1 torsinA 1-43 LALALA mGFP
eGFPN1 torsinA 1-43 S25L/G27L mGFP
eGFPN1 torsinA 1-43 S25L/G27L/G32L mGFP
eGFPN1 torsinA 1-43 5 x Leu mGFP
pHO2d 1-43-mGFP
pHO2d 1-67-mGFP
eGFPN1 1-67 LALALA mGFP
eGFPN1 1-67 S25L/G27L mGFP
eGFPN1 1-67 3 x Leu mGFP
eGFPN1 1-67 5 x Leu mGFP
pMAL-c MBP-21-43
pMAL-c MBP-21-67
Lep-torsinA forward
Lep-torsinA reverse
eGFPN1 E171Q-torsinA-mGFP
pcDNA4 E171Q/d26-43-torsinA-mGFP
eGFPN1 E171Q/pore loop 1-torsinA-mGFP
eGFPN1 E171Q/pore loop 2-torsinA-mGFP
eGFPN1 E171Q/pore loop 3-torsinA-mGFP
eGFPN1 E171Q/R260A-torsinA-myc
eGFPN1 E171Q/R288A-torsinA-myc
pcDNA4 E171Q/N143Q-torsinA-myc
pcDNA4 E171Q/N158Q-torsinA-myc
eGFPN1 E171Q/I24R-torsinA-mGFP
eGFPN1 E171Q/L26R-torsinA-mGFP
eGFPN1 E171Q/L30R-torsinA-mGFP

Key word
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA

expression
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
bacterial
bacterial
mammalian
mammalian
mammalian
mammalian
bacterial
bacterial
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian

antibiotics
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Amp
Amp
Kan
Kan
Kan
Kan
Amp
Amp
Amp
Amp
Kan
Kan
Kan
Kan
Kan
Amp
Amp
Amp
Amp
Kan
Kan
Kan

original
DNA source
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by TN
cloned by TN
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV

Primers
(Fwd/Rev)
PHB 177/PHB 178
PHB 301/PHB 302
PHB 305/PHB 306
PHB 257/PHB 258
PHB 303/PHB 304
PHB 281/PHB 282
PHB 381/PHB 382
PHB 383/PHB 384
PHB 207/PHB 208
PHB 244/PHB 245
PHB 246/PHB 247
PHB 250/PHB 251
PHB 228/PHB 240
PHB 228/PHB 241
PHB 207/PHB 208
PHB 244/PHB 245
PHB 246/PHB 247
PHB 250/PHB 251

PHB 283-286
PHB 309-312
N/A
N/A
PHB 216/PHB 217
PHB 218/PHB 219
PHB 220/PHB 221
PHB 222/PHB 223
PHB 224/PHB 225
PHB 236/PHB 237
PHB 238/PHB 239
PHB 261/PHB 262
PHB 263/PHB 264
PHB 257/PHB 258

Restriction
enzyme (5'/3') backbone vector
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
SalI, BamHI pHO2d
SalI, BamHI pHO2d
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
EcoRI, BamHI pMal-c
EcoRI, BamHI pMal-c
SpeI, KpnI
pGEM1
SpeI, KpnI
pGEM1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
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Name of plasmid
eGFPN1 E171Q/L30A-torsinA-mGFP
eGFPN1 E171Q/V33N-torsinA-mGFP
eGFPN1 E171Q/V33Q-torsinA-mGFP
eGFPN1 E171Q/L34R-torsinA-mGFP
eGFPN1 E171Q/L34A-torsinA-mGFP
eGFPN1 E171Q/I38R-torsinA-mGFP
eGFPN1 E171Q ALA/RRR torsinA-mGFP
eGFPN1 E171Q Ala insert torsinA-mGFP
ER-GFP
ER-RFP
ER-Tomato
Lys-SS-GFP
eGFPN1 FP17-GFP
FP17-Venus
eGFPN1 FP22-GFP
FP22-Venus
eGFPN1 VSVG-ts045-GFP
Cathepsin-D-myc
Sec13-HA
NPY-GFP
NogoA-GFP
R7BP-GFP
Cdc25c S216A-GFP
DHHC2-GFP
SNAP25b-GFP
Lep 19A
Lep 18A/1L
Lep 13A/6L
Lep 12A/7L
CFP-alpha 1-spectrin
YFP-alpha 2-spectrin
pShooter Sun1L-myc
pShooter Sun2L-myc
pShooter Sun2 TM+myc

Key word
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
torsinA
ER
ER
ER
lysosome
ER
ER
ER
ER
VSVG
lysosome
COPII
ER
ER
PM
PM
PM
PM
model TM
model TM
model TM
model TM
cytoskeleton
cytoskeleton
LINC
LINC
LINC

expression
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
Stuart Kornfeld

original
DNA source
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
cloned by ABV
Erik Snapp
Erik Snapp
Erik Snapp
Erik Snapp
Nica Borgese
Nica Borgese
Nica Borgese
Nica Borgese
antibiotics
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Kan
Amp

Didier Hodzic
Didier Hodzic
Didier Hodzic

Ken Blumer
H. Piwnica-Worms
Maurine Linder
Maurine Linder
Gunnar Von Heijne
Gunnar Von Heijne
Gunnar Von Heijne
Gunnar Von Heijne

Kan
Kan
Kan
Kan
Kan
Kan
Amp
Amp
Amp
Amp
Kan
Kan
Amp
Amp
Amp

Primers
(Fwd/Rev)
PHB 181/PHB 182
PHB 287/PHB 288
PHB 307/PHB 308
PHB 183/PHB 184
PHB 192/PHB 193
PHB 185/PHB 186
PHB 179/PHB 180
PHB 177/PHB 178
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Restriction
enzyme (5'/3') backbone vector
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
pcDNA3.1
N/A
pcDNA3.1
N/A
pcDNA3.1
N/A
pcDNA3.1
N/A
pcDNA3.1
N/A
pcDNA3.1
N/A
pcDNA3.1
N/A
pcDNA3.1
N/A
eGFP-N1
N/A
pcDNA3.1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
pGEM1
N/A
pGEM1
N/A
pGEM1
N/A
pGEM1
N/A
N/A
N/A
pCMV/myc/ER
N/A
pCMV/myc/ER
N/A
pCMV/myc/ER
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Name of plasmid
Sun2 TM+HA
Sun2 dlumen
Sun2-GFP
pShooter Sun3L-myc
KASH1-GFP
eGFPC1 nesprin1-GFP
eGFPC1 nesprin1-GFP delta C term
KASH2-GFP
KASH2ext-GFP
eGFPC1 nesprin2-GFP delta C term
eGFPC1 nesprin3-GFP
Klarsicht-GFP
PGHS1
PGHS2
pcDNA3 torsinA
pcDNA3 dGAG-torsinA
pCMV VSVG env
p8.2 dR
pRRL GFP
COX1-GFP
COX2-GFP
erlin1-GFP
erlin2-GFP

Key word
LINC
LINC
LINC
LINC
LINC
LINC
LINC
LINC
LINC
LINC
LINC
LINC
COX-1
COX-2
torsinA
torsinA
virus
virus
virus
COX-1
COX-2
erlin
erlin

expression
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian
mammalian

mammalian
mammalian
mammalian
mammalian

original
Primers
antibiotics DNA source
(Fwd/Rev)
Didier Hodzic
N/A
Didier Hodzic
N/A
Kan
Didier Hodzic
N/A
Amp
Didier Hodzic
N/A
Kan
Didier Hodzic
N/A
Kan
Didier Hodzic
N/A
Kan
Didier Hodzic
N/A
Kan
Didier Hodzic
N/A
Kan
Didier Hodzic
N/A
Kan
Didier Hodzic
N/A
Kan
Didier Hodzic
N/A
Kan
Didier Hodzic
N/A
Amp
Richard Kulmacz N/A
Amp
Richard Kulmacz N/A
Amp
cloned by TN
N/A
Amp
cloned by TN
N/A
Sheila Stewart
N/A
Sheila Stewart
N/A
Sheila Stewart
N/A
cloned by ABV
N/A
cloned by ABV
N/A
Richard WojcikiewiczN/A
Richard WojcikiewiczN/A
Kan
Kan
Kan
Kan

Restriction
enzyme (5'/3') backbone vector
N/A
pCMV/myc/ER
N/A
N/A
N/A
pCMV/myc/ER
N/A
eGFP-C1
N/A
eGFP-C1
N/A
eGFP-C1
N/A
eGFP-C1
N/A
eGFP-C1
N/A
eGFP-C1
N/A
eGFP-C1
N/A
N/A
pSG5
N/A
pSG5
N/A
pcDNA3.1
N/A
pcDNA3.1
N/A
N/A
N/A
pRRL
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
N/A
eGFP-N1
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